FALSE2025Q10000098362December 31.6667xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:puretkr:segmenttkr:reporting_unittkr:covenantiso4217:EURtkr:employee00000983622025-01-012025-03-3100000983622025-03-3100000983622024-01-012024-03-3100000983622024-12-310000098362tkr:PreferredStockClassIIMember2025-03-310000098362tkr:PreferredStockClassIMember2024-12-310000098362tkr:PreferredStockClassIIMember2024-12-310000098362tkr:PreferredStockClassIMember2025-03-3100000983622023-12-3100000983622024-03-310000098362country:UStkr:EngineeredBearingsMember2025-01-012025-03-310000098362country:UStkr:IndustrialMotionMember2025-01-012025-03-310000098362country:US2025-01-012025-03-310000098362country:UStkr:EngineeredBearingsMember2024-01-012024-03-310000098362country:UStkr:IndustrialMotionMember2024-01-012024-03-310000098362country:US2024-01-012024-03-310000098362tkr:CanadaMexicoAndSouthAmericaMembertkr:EngineeredBearingsMember2025-01-012025-03-310000098362tkr:CanadaMexicoAndSouthAmericaMembertkr:IndustrialMotionMember2025-01-012025-03-310000098362tkr:CanadaMexicoAndSouthAmericaMember2025-01-012025-03-310000098362tkr:CanadaMexicoAndSouthAmericaMembertkr:EngineeredBearingsMember2024-01-012024-03-310000098362tkr:CanadaMexicoAndSouthAmericaMembertkr:IndustrialMotionMember2024-01-012024-03-310000098362tkr:CanadaMexicoAndSouthAmericaMember2024-01-012024-03-310000098362us-gaap:EMEAMembertkr:EngineeredBearingsMember2025-01-012025-03-310000098362us-gaap:EMEAMembertkr:IndustrialMotionMember2025-01-012025-03-310000098362us-gaap:EMEAMember2025-01-012025-03-310000098362us-gaap:EMEAMembertkr:EngineeredBearingsMember2024-01-012024-03-310000098362us-gaap:EMEAMembertkr:IndustrialMotionMember2024-01-012024-03-310000098362us-gaap:EMEAMember2024-01-012024-03-310000098362srt:AsiaPacificMembertkr:EngineeredBearingsMember2025-01-012025-03-310000098362srt:AsiaPacificMembertkr:IndustrialMotionMember2025-01-012025-03-310000098362srt:AsiaPacificMember2025-01-012025-03-310000098362srt:AsiaPacificMembertkr:EngineeredBearingsMember2024-01-012024-03-310000098362srt:AsiaPacificMembertkr:IndustrialMotionMember2024-01-012024-03-310000098362srt:AsiaPacificMember2024-01-012024-03-310000098362tkr:EngineeredBearingsMember2025-01-012025-03-310000098362tkr:IndustrialMotionMember2025-01-012025-03-310000098362tkr:EngineeredBearingsMember2024-01-012024-03-310000098362tkr:IndustrialMotionMember2024-01-012024-03-310000098362us-gaap:SalesChannelDirectlyToConsumerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310000098362us-gaap:SalesChannelDirectlyToConsumerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000098362us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310000098362us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000098362us-gaap:CustomerConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310000098362us-gaap:CustomerConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000098362tkr:U.S.GovernmentMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310000098362tkr:U.S.GovernmentMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-3100000983622024-01-012024-12-310000098362us-gaap:OperatingSegmentsMembertkr:EngineeredBearingsMember2025-01-012025-03-310000098362us-gaap:OperatingSegmentsMembertkr:IndustrialMotionMember2025-01-012025-03-310000098362us-gaap:CorporateNonSegmentMember2025-01-012025-03-310000098362us-gaap:OperatingSegmentsMembertkr:EngineeredBearingsMember2024-01-012024-03-310000098362us-gaap:OperatingSegmentsMembertkr:IndustrialMotionMember2024-01-012024-03-310000098362us-gaap:CorporateNonSegmentMember2024-01-012024-03-310000098362us-gaap:OperatingSegmentsMembertkr:EngineeredBearingsMember2025-03-310000098362us-gaap:OperatingSegmentsMembertkr:EngineeredBearingsMember2024-12-310000098362us-gaap:OperatingSegmentsMembertkr:IndustrialMotionMember2025-03-310000098362us-gaap:OperatingSegmentsMembertkr:IndustrialMotionMember2024-12-310000098362us-gaap:CorporateNonSegmentMember2025-03-310000098362us-gaap:CorporateNonSegmentMember2024-12-310000098362tkr:EngineeredBearingsMember2024-12-310000098362tkr:IndustrialMotionMember2024-12-310000098362tkr:EngineeredBearingsMember2025-03-310000098362tkr:IndustrialMotionMember2025-03-310000098362us-gaap:CustomerRelationshipsMember2025-03-310000098362us-gaap:CustomerRelationshipsMember2024-12-310000098362us-gaap:TechnologyBasedIntangibleAssetsMember2025-03-310000098362us-gaap:TechnologyBasedIntangibleAssetsMember2024-12-310000098362us-gaap:TrademarksMember2025-03-310000098362us-gaap:TrademarksMember2024-12-310000098362us-gaap:ComputerSoftwareIntangibleAssetMember2025-03-310000098362us-gaap:ComputerSoftwareIntangibleAssetMember2024-12-310000098362us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember2025-03-310000098362us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember2024-12-310000098362us-gaap:TradeNamesMember2025-03-310000098362us-gaap:TradeNamesMember2024-12-310000098362tkr:FAAAirAgencyCertificatesMember2025-03-310000098362tkr:FAAAirAgencyCertificatesMember2024-12-310000098362tkr:ForeignSubsidiaryMember2025-03-310000098362tkr:ForeignSubsidiaryMember2024-12-310000098362tkr:LineOfCreditAccountsReceivableSecuritizationMember2025-03-310000098362tkr:LineOfCreditAccountsReceivableSecuritizationMember2024-12-310000098362tkr:EuroSeniorUnsecuredNotes2.02Member2024-12-310000098362tkr:EuroSeniorUnsecuredNotes2.02Member2025-03-310000098362tkr:TermLoanVariableRateMaturing2027Member2025-03-310000098362tkr:TermLoanVariableRateMaturing2027Member2024-12-310000098362tkr:SeriesMediumTermNoteMembersrt:MinimumMember2025-03-310000098362tkr:SeriesMediumTermNoteMembersrt:MinimumMember2024-12-310000098362tkr:SeriesMediumTermNoteMembersrt:MaximumMember2025-03-310000098362tkr:SeriesMediumTermNoteMembersrt:MaximumMember2024-12-310000098362tkr:SeriesMediumTermNoteMember2025-03-310000098362tkr:SeriesMediumTermNoteMember2024-12-310000098362tkr:SeniorUnsecuredNotes4.5Member2024-12-310000098362tkr:SeniorUnsecuredNotes4.5Member2025-03-310000098362tkr:SeniorUnsecuredNotes20324.125Member2024-12-310000098362tkr:SeniorUnsecuredNotes20324.125Member2025-03-310000098362tkr:EuroSeniorUnsecuredNotes20344.125Member2024-12-310000098362tkr:EuroSeniorUnsecuredNotes20344.125Member2025-03-310000098362tkr:FixedRateBankLoanBEKAMember2025-03-310000098362tkr:FixedRateBankLoanBEKAMember2024-12-310000098362tkr:OtherLongTermDebtMember2025-03-310000098362tkr:OtherLongTermDebtMember2024-12-310000098362tkr:SeniorCreditFacilityVariableRateMember2022-12-050000098362tkr:TermLoanVariableRateMaturing2027Memberus-gaap:UnsecuredDebtMemberus-gaap:LineOfCreditMember2022-12-050000098362tkr:SeniorCreditFacilityVariableRateMember2025-03-310000098362tkr:SeniorUnsecuredNotes20344.125Member2024-05-230000098362tkr:SeniorUnsecuredNotes20243.875Member2024-05-230000098362tkr:TimkenIndiaLimitedMemberus-gaap:PendingLitigationMembertkr:GovernmentVsTimkenIndiaLimitedMember2024-06-112024-06-110000098362tkr:StatedCapitalMember2024-12-310000098362us-gaap:OtherAdditionalCapitalMember2024-12-310000098362us-gaap:RetainedEarningsUnappropriatedMember2024-12-310000098362us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000098362us-gaap:TreasuryStockCommonMember2024-12-310000098362us-gaap:NoncontrollingInterestMember2024-12-310000098362us-gaap:RetainedEarningsUnappropriatedMember2025-01-012025-03-310000098362us-gaap:NoncontrollingInterestMember2025-01-012025-03-310000098362us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000098362us-gaap:OtherAdditionalCapitalMember2025-01-012025-03-310000098362us-gaap:TreasuryStockCommonMember2025-01-012025-03-310000098362tkr:StatedCapitalMember2025-03-310000098362us-gaap:OtherAdditionalCapitalMember2025-03-310000098362us-gaap:RetainedEarningsUnappropriatedMember2025-03-310000098362us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310000098362us-gaap:TreasuryStockCommonMember2025-03-310000098362us-gaap:NoncontrollingInterestMember2025-03-310000098362tkr:StatedCapitalMember2023-12-310000098362us-gaap:OtherAdditionalCapitalMember2023-12-310000098362us-gaap:RetainedEarningsUnappropriatedMember2023-12-310000098362us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000098362us-gaap:TreasuryStockCommonMember2023-12-310000098362us-gaap:NoncontrollingInterestMember2023-12-310000098362us-gaap:RetainedEarningsUnappropriatedMember2024-01-012024-03-310000098362us-gaap:NoncontrollingInterestMember2024-01-012024-03-310000098362us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000098362us-gaap:OtherAdditionalCapitalMember2024-01-012024-03-310000098362us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000098362tkr:StatedCapitalMember2024-03-310000098362us-gaap:OtherAdditionalCapitalMember2024-03-310000098362us-gaap:RetainedEarningsUnappropriatedMember2024-03-310000098362us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000098362us-gaap:TreasuryStockCommonMember2024-03-310000098362us-gaap:NoncontrollingInterestMember2024-03-310000098362us-gaap:EmployeeSeveranceMemberus-gaap:CorporateNonSegmentMembertkr:PresidentAndChiefExecutiveOfficerMember2025-01-012025-03-310000098362tkr:HiddeniteNorthCarolinaMemberus-gaap:FacilityClosingMembertkr:EngineeredBearingsMember2025-02-202025-02-200000098362tkr:HiddeniteNorthCarolinaMemberus-gaap:FacilityClosingMembersrt:MinimumMembertkr:EngineeredBearingsMember2025-02-200000098362tkr:HiddeniteNorthCarolinaMemberus-gaap:FacilityClosingMembersrt:MaximumMembertkr:EngineeredBearingsMember2025-02-200000098362tkr:HiddeniteNorthCarolinaMemberus-gaap:FacilityClosingMembertkr:EngineeredBearingsMember2025-01-012025-03-310000098362tkr:SpringfieldMissouriMemberus-gaap:EmployeeSeveranceMembertkr:IndustrialMotionMember2024-12-062024-12-060000098362tkr:FortScottKansasMemberus-gaap:FacilityClosingMembertkr:EngineeredBearingsMember2023-11-302023-11-300000098362tkr:FortScottKansasMemberus-gaap:FacilityClosingMembersrt:MinimumMembertkr:IndustrialMotionMember2023-11-300000098362tkr:FortScottKansasMemberus-gaap:FacilityClosingMembersrt:MaximumMembertkr:IndustrialMotionMember2023-11-300000098362tkr:FortScottKansasMemberus-gaap:FacilityClosingMembertkr:IndustrialMotionMember2025-01-012025-03-310000098362tkr:FortScottKansasMemberus-gaap:FacilityClosingMembertkr:IndustrialMotionMember2024-01-012024-03-310000098362us-gaap:OtherCurrentLiabilitiesMember2025-03-310000098362us-gaap:OtherNoncurrentLiabilitiesMember2025-03-310000098362us-gaap:PensionPlansDefinedBenefitMember2025-01-012025-03-310000098362country:USus-gaap:PensionPlansDefinedBenefitMember2025-01-012025-03-310000098362country:USus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-03-310000098362us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-01-012025-03-310000098362us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-03-310000098362us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-03-310000098362us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2025-01-012025-03-310000098362us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-03-310000098362us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310000098362us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310000098362us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-310000098362us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-03-310000098362us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-03-310000098362us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-01-012025-03-310000098362us-gaap:AccumulatedTranslationAdjustmentMember2025-03-310000098362us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-03-310000098362us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-03-310000098362us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000098362us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000098362us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000098362us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310000098362us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-03-310000098362us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-03-310000098362us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000098362us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-310000098362us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310000098362us-gaap:FairValueInputsLevel12And3Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310000098362us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310000098362us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310000098362us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310000098362us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310000098362us-gaap:FairValueMeasurementsRecurringMember2025-03-310000098362us-gaap:FairValueInputsLevel12And3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000098362us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000098362us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000098362us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000098362us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000098362us-gaap:FairValueMeasurementsRecurringMember2024-12-310000098362tkr:A2034NotesMemberus-gaap:NetInvestmentHedgingMember2025-01-012025-03-310000098362tkr:A2027NotesMemberus-gaap:NetInvestmentHedgingMember2020-09-150000098362tkr:A2027NotesMember2020-09-152020-09-150000098362tkr:A2027NotesMemberus-gaap:NetInvestmentHedgingMember2025-01-012025-03-310000098362us-gaap:DesignatedAsHedgingInstrumentMember2025-03-310000098362us-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000098362us-gaap:DesignatedAsHedgingInstrumentMember2025-01-012025-03-310000098362us-gaap:NondesignatedMember2025-03-310000098362us-gaap:NondesignatedMember2024-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
|
|
|
|
|
|
| ☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2025
OR
|
|
|
|
|
|
| ☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number: 1-1169
THE TIMKEN COMPANY
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
| Ohio |
|
34-0577130 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
| 4500 Mount Pleasant Street NW |
|
|
| North Canton |
Ohio |
|
44720-5450 |
| (Address of principal executive offices) |
|
(Zip Code) |
234.262.3000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
|
|
Common Shares, without par value |
|
TKR |
|
The New York Stock Exchange |
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Large accelerated filer |
|
☒ |
|
Accelerated filer |
☐ |
|
|
|
|
|
|
| Non-accelerated filer |
|
☐ |
|
Smaller reporting company |
☐ |
|
|
|
|
|
|
|
|
|
|
Emerging growth company |
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
Indicate the number of shares outstanding of each of the issuer's classes of common shares, as of the latest practicable date.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class |
|
Outstanding at March 31, 2025 |
|
|
Common Shares, without par value |
|
69,963,042 shares |
|
THE TIMKEN COMPANY
INDEX TO FORM 10-Q REPORT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PAGE |
| I. |
|
|
|
|
Item 1. |
|
|
|
Item 2. |
|
|
|
Item 3. |
|
|
|
Item 4. |
|
|
| II. |
|
|
|
|
Item 1. |
|
|
|
Item1A. |
|
|
|
Item 2. |
|
|
|
Item 5. |
|
|
|
Item 6. |
|
|
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
THE TIMKEN COMPANY AND SUBSIDIARIES
Consolidated Statements of Income
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
|
| |
2025 |
|
2024 |
|
|
|
|
| (Dollars in millions, except per share data) |
|
|
|
|
|
|
|
| Net sales |
$ |
1,140.3 |
|
|
$ |
1,190.3 |
|
|
|
|
|
| Cost of products sold |
781.6 |
|
|
792.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Selling, general and administrative expenses |
184.8 |
|
|
190.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amortization of intangible assets |
19.0 |
|
|
20.0 |
|
|
|
|
|
| Impairment and restructuring charges |
10.9 |
|
|
2.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating Income |
144.0 |
|
|
184.6 |
|
|
|
|
|
| Interest expense |
(26.5) |
|
|
(32.2) |
|
|
|
|
|
| Interest income |
2.3 |
|
|
2.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-service pension and other postretirement expense |
(1.2) |
|
|
(1.0) |
|
|
|
|
|
| Other expense, net |
(0.3) |
|
|
(0.9) |
|
|
|
|
|
| Income Before Income Taxes |
118.3 |
|
|
153.3 |
|
|
|
|
|
| Provision for income taxes |
26.9 |
|
|
42.7 |
|
|
|
|
|
| Net Income |
91.4 |
|
|
110.6 |
|
|
|
|
|
| Less: Net income attributable to noncontrolling interest |
13.1 |
|
|
7.1 |
|
|
|
|
|
| Net Income Attributable to The Timken Company |
$ |
78.3 |
|
|
$ |
103.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income per Common Share Attributable to The Timken Company Common Shareholders |
|
|
|
|
|
|
|
| Basic earnings per share |
$ |
1.12 |
|
|
$ |
1.47 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diluted earnings per share |
$ |
1.11 |
|
|
$ |
1.46 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying Notes to the Consolidated Financial Statements.
Consolidated Statements of Comprehensive Income
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
|
| |
2025 |
|
2024 |
|
|
|
|
| (Dollars in millions) |
|
|
|
|
|
|
|
| Net Income |
$ |
91.4 |
|
|
$ |
110.6 |
|
|
|
|
|
| Other comprehensive income (loss), net of tax: |
|
|
|
|
|
|
|
| Foreign currency translation adjustments |
67.1 |
|
|
(50.7) |
|
|
|
|
|
| Pension and postretirement liability adjustments |
(1.6) |
|
|
(1.5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value of derivative financial instruments |
(2.1) |
|
|
1.1 |
|
|
|
|
|
| Other comprehensive income (loss), net of tax |
63.4 |
|
|
(51.1) |
|
|
|
|
|
| Comprehensive income, net of tax |
154.8 |
|
|
59.5 |
|
|
|
|
|
| Less: comprehensive income attributable to noncontrolling interest |
13.7 |
|
|
6.7 |
|
|
|
|
|
| Comprehensive income attributable to The Timken Company |
$ |
141.1 |
|
|
$ |
52.8 |
|
|
|
|
|
See accompanying Notes to the Consolidated Financial Statements.
Consolidated Balance Sheets
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited) |
|
|
| (Dollars in millions) |
March 31, 2025 |
|
December 31, 2024 |
| ASSETS |
|
|
|
| Current Assets |
|
|
|
| Cash and cash equivalents |
$ |
376.1 |
|
|
$ |
373.2 |
|
| Restricted cash |
0.4 |
|
|
0.4 |
|
| Accounts receivable, net |
744.6 |
|
|
664.6 |
|
| Unbilled receivables |
159.0 |
|
|
140.8 |
|
| Inventories, net |
1,196.4 |
|
|
1,195.6 |
|
| Deferred charges and prepaid expenses |
50.8 |
|
|
39.5 |
|
| Other current assets |
89.5 |
|
|
102.8 |
|
|
|
|
|
| Total Current Assets |
2,616.8 |
|
|
2,516.9 |
|
| Property, Plant and Equipment, net |
1,317.7 |
|
|
1,306.9 |
|
| Other Assets |
|
|
|
| Goodwill |
1,417.0 |
|
|
1,383.3 |
|
| Other intangible assets, net |
1,011.7 |
|
|
1,006.5 |
|
| Operating lease assets |
135.4 |
|
|
130.6 |
|
|
|
|
|
|
|
|
|
| Deferred income taxes |
42.8 |
|
|
41.0 |
|
| Other non-current assets |
29.0 |
|
|
25.8 |
|
|
|
|
|
| Total Other Assets |
2,635.9 |
|
|
2,587.2 |
|
| Total Assets |
$ |
6,570.4 |
|
|
$ |
6,411.0 |
|
| LIABILITIES AND EQUITY |
|
|
|
| Current Liabilities |
|
|
|
|
|
|
|
|
|
|
|
| Accounts payable, trade |
$ |
338.5 |
|
|
$ |
321.7 |
|
| Short-term debt, including current portion of long-term debt |
21.7 |
|
|
13.0 |
|
| Salaries, wages and benefits |
126.1 |
|
|
142.2 |
|
| Income taxes payable |
26.0 |
|
|
24.4 |
|
|
|
|
|
| Other current liabilities |
319.4 |
|
|
319.2 |
|
|
|
|
|
| Total Current Liabilities |
831.7 |
|
|
820.5 |
|
| Non-Current Liabilities |
|
|
|
| Long-term debt |
2,105.4 |
|
|
2,049.7 |
|
| Accrued pension benefits |
142.5 |
|
|
157.7 |
|
| Accrued postretirement benefits |
29.7 |
|
|
29.8 |
|
| Long-term operating lease liabilities |
88.8 |
|
|
84.0 |
|
| Deferred income taxes |
172.2 |
|
|
175.0 |
|
| Other non-current liabilities |
111.1 |
|
|
110.2 |
|
|
|
|
|
| Total Non-Current Liabilities |
2,649.7 |
|
|
2,606.4 |
|
| Shareholders’ Equity |
|
|
|
| Class I and II Serial Preferred Stock, without par value: |
|
|
|
Authorized – 10,000,000 shares each class, none issued |
— |
|
|
— |
|
| Common shares, without par value: |
|
|
|
Authorized – 200,000,000 shares |
|
|
|
|
Issued (including shares in treasury) (2025 – 79,549,446 shares;
2024 – 79,173,667 shares)
|
|
|
|
| Stated capital |
40.7 |
|
|
40.7 |
|
| Other paid-in capital |
1,277.1 |
|
|
1,269.3 |
|
| Retained earnings |
2,542.0 |
|
|
2,488.8 |
|
| Accumulated other comprehensive loss |
(238.9) |
|
|
(301.7) |
|
Treasury shares at cost (2025 – 9,586,404 shares; 2024 – 9,174,863 shares) |
(703.2) |
|
|
(670.6) |
|
| Total Shareholders’ Equity |
2,917.7 |
|
|
2,826.5 |
|
| Noncontrolling Interest |
171.3 |
|
|
157.6 |
|
| Total Equity |
3,089.0 |
|
|
2,984.1 |
|
| Total Liabilities and Equity |
$ |
6,570.4 |
|
|
$ |
6,411.0 |
|
See accompanying Notes to the Consolidated Financial Statements.
Consolidated Statements of Cash Flows
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
| |
2025 |
|
2024 |
| (Dollars in millions) |
|
|
|
| CASH PROVIDED (USED) |
|
|
|
| Operating Activities |
|
|
|
| Net income |
$ |
91.4 |
|
|
$ |
110.6 |
|
| Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
| Depreciation and amortization |
55.1 |
|
|
55.3 |
|
|
|
|
|
| (Gain) loss on sale of assets |
(1.0) |
|
|
0.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deferred income tax benefit |
— |
|
|
(4.3) |
|
| Stock-based compensation expense |
7.5 |
|
|
4.5 |
|
| Pension and other postretirement expense |
1.8 |
|
|
1.6 |
|
| Pension and other postretirement benefit contributions and payments |
(23.8) |
|
|
(12.2) |
|
|
|
|
|
|
|
|
|
| Changes in operating assets and liabilities: |
|
|
|
| Accounts receivable |
(70.8) |
|
|
(106.1) |
|
| Unbilled receivables |
(18.2) |
|
|
9.5 |
|
| Inventories |
15.3 |
|
|
(11.1) |
|
| Accounts payable, trade |
20.2 |
|
|
20.7 |
|
| Other accrued expenses |
(16.0) |
|
|
(31.2) |
|
| Income taxes |
3.5 |
|
|
24.8 |
|
| Other, net |
(6.4) |
|
|
(12.9) |
|
|
|
|
|
|
|
|
|
| Net Cash Provided by Operating Activities |
58.6 |
|
|
49.3 |
|
| Investing Activities |
|
|
|
| Capital expenditures |
(35.2) |
|
|
(44.1) |
|
|
|
|
|
| Proceeds from disposal of property, plant and equipment |
1.9 |
|
|
— |
|
|
|
|
|
| Investments in short-term marketable securities, net |
0.8 |
|
|
19.7 |
|
| Other, net |
— |
|
|
(0.1) |
|
|
|
|
|
|
|
|
|
| Net Cash Used in Investing Activities |
(32.5) |
|
|
(24.5) |
|
| Financing Activities |
|
|
|
| Cash dividends paid to shareholders |
(25.1) |
|
|
(24.5) |
|
| Purchase of treasury shares |
(23.1) |
|
|
— |
|
| Proceeds from exercise of stock options |
0.3 |
|
|
2.0 |
|
| Payments related to tax withholding for stock-based compensation |
(9.5) |
|
|
(8.9) |
|
| Borrowings on accounts receivable facility |
57.0 |
|
|
30.0 |
|
| Payments on accounts receivable facility |
(27.0) |
|
|
(22.0) |
|
| Proceeds from long-term debt |
— |
|
|
203.3 |
|
| Payments on long-term debt |
(1.2) |
|
|
(196.9) |
|
|
|
|
|
| Short-term debt activity, net |
(2.0) |
|
|
2.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net Cash Used in Financing Activities |
(30.6) |
|
|
(15.0) |
|
| Effect of exchange rate changes on cash |
7.4 |
|
|
(6.8) |
|
| Increase in Cash, Cash Equivalents and Restricted Cash |
2.9 |
|
|
3.0 |
|
| Cash, cash equivalents and restricted cash at beginning of year |
373.6 |
|
|
419.3 |
|
| Cash, Cash Equivalents and Restricted Cash at End of Period |
$ |
376.5 |
|
|
$ |
422.3 |
|
See accompanying Notes to the Consolidated Financial Statements.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(Dollars in millions, except per share data)
Note 1 - Basis of Presentation
The accompanying Consolidated Financial Statements (unaudited) for The Timken Company (the "Company" or "Timken") have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and notes required by the accounting principles generally accepted in the United States ("U.S. GAAP") for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) and disclosures considered necessary for a fair presentation have been included. For further information, refer to the Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
Note 2 - Significant Accounting Policies
The Company's significant accounting policies are detailed in "Note 1 - Significant Accounting Policies" of the Annual Report on Form 10-K for the year ended December 31, 2024.
Recent Accounting Pronouncements:
New Accounting Guidance Issued and Not Yet Adopted:
In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03, Income Statement—Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40). ASU 2024-03 requires that a public entity disclose the detailed information about types of expense. Specifically, a public entity would disclose the amounts of (a) purchases of inventory, (b) employee compensation, (c) depreciation and (d) intangible asset amortization included in each relevant expense caption. A relevant expense caption is an expense caption presented on the face of the income statement within continuing operations that contains any of the expense categories listed in (a)–(d). In addition, a public entity should include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements. A public entity would also disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively and disclose the total amounts of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses. For public entities, the new guidance is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The new guidance should be applied either prospectively to financial statements issued after the effective date of ASU 2024-03 or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of the new guidance.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 40). ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this update require that public entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. The amendments require that all entities disclose on an annual basis the amount of income taxes paid disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. For public entities, the new guidance is effective for annual periods beginning after December 15, 2024. The Company is preparing to adopt the new disclosure requirements beginning with its Annual Report on Form 10-K for the year ended December 31, 2025.
Note 3 - Revenue
The following table presents details deemed relevant to the users of the financial statements about total revenue for the three months ended March 31, 2025 and 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
Three Months Ended |
|
March 31, 2025 |
March 31, 2024 |
|
Engineered Bearings |
Industrial Motion |
Total |
Engineered Bearings |
Industrial Motion |
Total |
| United States |
$ |
311.5 |
|
$ |
202.3 |
|
$ |
513.8 |
|
$ |
335.1 |
|
$ |
192.7 |
|
$ |
527.8 |
|
Americas excluding the United States |
88.2 |
|
21.2 |
|
109.4 |
|
94.7 |
|
24.6 |
|
119.3 |
|
| Europe / Middle East / Africa |
139.6 |
|
129.7 |
|
269.3 |
|
169.5 |
|
142.6 |
|
312.1 |
|
|
|
|
|
|
|
|
| Asia-Pacific |
221.4 |
|
26.4 |
|
247.8 |
|
203.2 |
|
27.9 |
|
231.1 |
|
| Net sales |
$ |
760.7 |
|
$ |
379.6 |
|
$ |
1,140.3 |
|
$ |
802.5 |
|
$ |
387.8 |
|
$ |
1,190.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
When reviewing revenue by sales channel, the Company separates net sales to original equipment manufacturers ("OEMs") from sales to distributors and end users. The following table presents the approximate percent of revenue by sales channel for the three months ended March 31, 2025 and 2024:
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
Three Months Ended |
| Revenue by sales channel |
March 31, 2025 |
March 31, 2024 |
| Original equipment manufacturers |
60% |
60% |
| Distribution/direct to end users |
40% |
40% |
In addition to disaggregating revenue by segment, geography and by sales channel as shown above, the Company believes information about the timing of transfer of goods or services and type of customer is also relevant. During the three months ended March 31, 2025 and March 31, 2024, approximately 9% and 7%, respectively, of total net sales were recognized over-time because of the continuous transfer of control to the customer, with the remainder recognized as of a point in time. Finally, business with the United States ("U.S.") government or its contractors represented approximately 7% and 6% of total net sales during the three months ended March 31, 2025 and March 31, 2024, respectively.
Note 3 - Revenue (continued)
Remaining Performance Obligations:
Remaining performance obligations represent the transaction price of orders meeting the definition of a contract for which work has not been performed and excludes unexercised contract options. Performance obligations having a duration of more than one year are concentrated in contracts for certain products and services provided to the U.S. government or its contractors. The aggregate amount of the transaction price allocated to remaining performance obligations for such contracts with a duration of more than one year was approximately $154 million at March 31, 2025.
Unbilled Receivables:
The following table contains a rollforward of unbilled receivables for the three months ended March 31, 2025 and the twelve months ended December 31, 2024:
|
|
|
|
|
|
|
|
|
|
March 31, 2025 |
December 31, 2024 |
| Beginning balance, January 1 |
$ |
140.8 |
|
$ |
144.5 |
|
| Additional unbilled revenue recognized |
89.0 |
|
380.5 |
|
| Less: amounts billed to customers |
(70.8) |
|
(384.2) |
|
|
|
|
|
|
|
| Ending balance |
$ |
159.0 |
|
$ |
140.8 |
|
There were no impairment losses recorded on unbilled receivables for the three months ended March 31, 2025 and the twelve months ended December 31, 2024.
Deferred Revenue:
The following table contains a rollforward of deferred revenue for the three months ended March 31, 2025 and the twelve months ended December 31, 2024:
|
|
|
|
|
|
|
|
|
|
March 31, 2025 |
December 31, 2024 |
| Beginning balance, January 1 |
$ |
41.4 |
|
$ |
45.4 |
|
| Acquisitions |
— |
|
0.7 |
|
| Revenue received or billed in advance of recognition |
34.4 |
|
153.0 |
|
| Less: revenue recognized |
(43.1) |
|
(157.7) |
|
| Ending balance |
$ |
32.7 |
|
$ |
41.4 |
|
Note 4 - Segment Information
The Company operates under two reportable segments: (1) Engineered Bearings and (2) Industrial Motion. The Company's Chief Operating Decision Maker ("CODM") is the President and Chief Executive Officer ("CEO"). The primary measurement used by the CODM to measure the financial performance of each segment is adjusted EBITDA. The Company's CODM evaluates financial performance and allocates resources based on return on capital and profitable growth. The CODM considers actual and budgeted results provided on a regular basis for both segment's profit measures when making decisions about allocating capital and personnel to the segments.
The following tables provide segment financial information and a reconciliation of segment results to consolidated results for the three months ended March 31, 2025:
|
|
|
|
|
|
|
|
|
|
|
|
|
Engineered Bearings |
Industrial Motion |
Total |
| Net sales |
$ |
760.7 |
|
$ |
379.6 |
|
$ |
1,140.3 |
|
Cost of products sold (1) |
(523.3) |
|
(256.6) |
|
|
Selling, general and administrative expenses (2) |
(102.5) |
|
(68.0) |
|
|
Other segment items (3) |
0.7 |
|
— |
|
|
Depreciation and amortization (4) |
23.6 |
|
12.1 |
|
|
| Adjusted EBITDA for reportable segments |
$ |
159.2 |
|
$ |
67.1 |
|
$ |
226.3 |
|
|
|
|
|
| Unallocated corporate expense |
|
|
(18.2) |
|
| Impairment, restructuring and reorganization charges |
|
|
(3.1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gain on sale of certain assets |
|
|
1.2 |
|
| CEO succession expenses |
|
|
(8.6) |
|
|
|
|
|
| Depreciation and amortization |
|
|
(55.1) |
|
| Interest expense |
|
|
(26.5) |
|
| Interest income |
|
|
2.3 |
|
| Income before income taxes |
|
|
$ |
118.3 |
|
For the three months ended March 31, 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
Engineered Bearings |
Industrial Motion |
Total |
| Net sales |
$ |
802.5 |
|
$ |
387.8 |
|
$ |
1,190.3 |
|
Cost of products sold (1) |
(540.8) |
|
(245.5) |
|
|
Selling, general and administrative expenses (2) |
(105.9) |
|
(70.9) |
|
|
Other segment items (3) |
1.8 |
|
(0.1) |
|
|
Depreciation and amortization (4) |
23.8 |
|
10.8 |
|
|
| Adjusted EBITDA for reportable segments |
$ |
181.4 |
|
$ |
82.1 |
|
$ |
263.5 |
|
|
|
|
|
| Unallocated corporate expense |
|
|
(17.1) |
|
| Impairment, restructuring and reorganization charges |
|
|
(4.4) |
|
|
|
|
|
| Acquisition-related charges |
|
|
(4.7) |
|
|
|
|
|
| Gain on sale of certain assets |
|
|
0.7 |
|
|
|
|
|
|
|
|
|
| Depreciation and amortization |
|
|
(55.3) |
|
| Interest expense |
|
|
(32.2) |
|
| Interest income |
|
|
2.8 |
|
| Income before income taxes |
|
|
$ |
153.3 |
|
(1) Cost of products sold exclude acquisition-related and reorganization charges.
(2) Selling, general, and administrative expenses exclude acquisition-related charges and CEO succession expenses.
(3) Other segments items is Other (expense) income, net and exclude gain on sale of certain assets.
(4) Depreciation and amortization excludes acquisition intangible amortization and depreciation recognized in reorganization charges, if any.
Note 4 - Segment Information (continued)
The following tables provides additional segment financial information:
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2025 |
|
December 31, 2024 |
| Assets by Segment: |
|
|
|
| Engineered Bearings |
$ |
3,236.5 |
|
|
$ |
3,126.1 |
|
| Industrial Motion |
2,878.0 |
|
|
2,822.6 |
|
Corporate (5) |
455.9 |
|
|
462.3 |
|
| |
$ |
6,570.4 |
|
|
$ |
6,411.0 |
|
(5) Corporate assets include corporate buildings and cash and cash equivalents.
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2025 |
|
2024 |
| Capital expenditures: |
|
|
|
| Engineered Bearings |
$ |
24.9 |
|
|
$ |
34.5 |
|
| Industrial Motion |
10.2 |
|
|
9.4 |
|
| Corporate |
0.1 |
|
|
0.2 |
|
| |
$ |
35.2 |
|
|
$ |
44.1 |
|
| Depreciation and amortization: |
|
|
|
| Engineered Bearings |
$ |
26.6 |
|
|
$ |
26.7 |
|
| Industrial Motion |
28.3 |
|
|
28.2 |
|
| Corporate |
0.2 |
|
|
0.4 |
|
| |
$ |
55.1 |
|
|
$ |
55.3 |
|
Note 5 - Income Taxes
The Company's provision for income taxes in interim periods is computed by applying the estimated annual effective tax rates to income or loss before income taxes for the period. In addition, non-recurring or discrete items are recorded during the period(s) in which they occur.
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
|
| |
2025 |
2024 |
|
|
|
| Provision for income taxes |
$ |
26.9 |
|
$ |
42.7 |
|
|
|
|
| Effective tax rate |
22.7 |
% |
27.9 |
% |
|
|
|
Income tax expense for the three months ended March 31, 2025 was calculated using forecasted multi-jurisdictional annual effective tax rates to determine a blended annual effective tax rate. The effective tax rate differs from the U.S. federal statutory rate of 21% due to the actual and projected mix of earnings in non-U.S. jurisdictions with relatively higher tax rates, U.S. state and local income taxes, and other permanent differences (net).
The effective tax rate of 22.7% for the three months ended March 31, 2025 was lower than the effective tax rate for the three months ended March 31, 2024 primarily due to the net favorable impact of discrete items versus the year ago period. The favorable discrete items in the current period primarily related to the reversal of accruals for uncertain tax positions to account for the expiration of statue of limitations in jurisdictions outside the United States.
Note 6 - Earnings Per Share
The following table sets forth the reconciliation of the numerator and the denominator of basic earnings per share and diluted earnings per share for the three months ended March 31, 2025 and 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2025 |
|
2024 |
|
|
|
|
| Numerator: |
|
|
|
|
|
|
|
| Net income attributable to The Timken Company |
$ |
78.3 |
|
|
$ |
103.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Denominator: |
|
|
|
|
|
|
|
| Weighted average number of shares outstanding - basic |
70,024,836 |
|
|
70,266,660 |
|
|
|
|
|
| Effect of dilutive securities: |
|
|
|
|
|
|
|
Stock options and awards - based on the treasury stock method |
489,101 |
|
|
613,355 |
|
|
|
|
|
Weighted average number of shares outstanding assuming dilution of stock options and awards |
70,513,937 |
|
|
70,880,015 |
|
|
|
|
|
| Basic earnings per share |
$ |
1.12 |
|
|
$ |
1.47 |
|
|
|
|
|
| Diluted earnings per share |
$ |
1.11 |
|
|
$ |
1.46 |
|
|
|
|
|
The dilutive effect of performance-based restricted stock units is taken into account once they have met minimum performance thresholds. The dilutive effect of stock options includes all outstanding stock options except stock options that are considered antidilutive. Stock options are antidilutive when the exercise price exceeds the average market price of the Company’s common shares during the periods presented. There were no antidilutive stock options outstanding during the three months ended March 31, 2025 and 2024.
Note 7 - Inventories
The components of inventories at March 31, 2025 and December 31, 2024 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2025 |
|
December 31, 2024 |
| Manufacturing supplies |
$ |
44.2 |
|
|
$ |
42.8 |
|
| Raw materials |
132.3 |
|
|
155.2 |
|
| Work in process |
489.3 |
|
|
476.0 |
|
| Finished products |
608.6 |
|
|
595.0 |
|
| Subtotal |
1,274.4 |
|
|
1,269.0 |
|
| Allowance for obsolete and surplus inventory |
(78.0) |
|
|
(73.4) |
|
| Total inventories, net |
$ |
1,196.4 |
|
|
$ |
1,195.6 |
|
Inventories are valued at net realizable value, with approximately 60% valued on the first-in, first-out ("FIFO") method and the remaining 40% valued on the last-in, first-out ("LIFO") method. The majority of the Company's U.S. inventories are valued on the LIFO method. The Company's non-U.S. inventories are valued on the FIFO method.
The LIFO reserve as of March 31, 2025 and December 31, 2024 was $256.2 million and $257.2 million, respectively. An actual valuation of the inventory under the LIFO method can be made only at the end of each year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on current inventory levels and costs. Because these calculations are subject to many factors beyond management’s control, annual results may differ from interim results as they are subject to the final year-end LIFO inventory valuation.
Note 8 - Goodwill and Other Intangible Assets
The Company tests goodwill and indefinite-lived intangible assets for impairment at least annually, performing its annual impairment test as of October 1st. Goodwill and indefinite-lived intangible assets are also reviewed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.
The Company reviews goodwill for impairment at the reporting unit level. The Engineered Bearings segment has one reporting unit and the Industrial Motion segment has six reporting units.
The changes in the carrying amount of goodwill for the three months ended March 31, 2025 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Engineered Bearings |
Industrial Motion |
|
Total |
| Beginning balance, January 1 |
$ |
692.0 |
|
$ |
691.3 |
|
|
$ |
1,383.3 |
|
|
|
|
|
|
|
|
|
|
|
| Foreign currency translation adjustments and other changes |
4.4 |
|
29.3 |
|
|
33.7 |
|
| Ending balance |
$ |
696.4 |
|
$ |
720.6 |
|
|
$ |
1,417.0 |
|
The following table displays intangible assets as of March 31, 2025 and December 31, 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Balance at March 31, 2025 |
Balance at December 31, 2024 |
|
Gross Carrying Amount |
Accumulated Amortization |
Net Carrying Amount |
Gross Carrying Amount |
Accumulated Amortization |
Net Carrying Amount |
Intangible assets subject to amortization: |
|
|
|
|
|
|
| Customer relationships |
$ |
821.5 |
|
$ |
(274.8) |
|
$ |
546.7 |
|
$ |
805.7 |
|
$ |
(262.9) |
|
$ |
542.8 |
|
| Technology and know-how |
377.0 |
|
(128.7) |
|
248.3 |
|
369.6 |
|
(120.4) |
|
249.2 |
|
| Trade names |
110.5 |
|
(18.5) |
|
92.0 |
|
107.5 |
|
(16.9) |
|
90.6 |
|
| Capitalized software |
304.6 |
|
(278.5) |
|
26.1 |
|
302.8 |
|
(276.1) |
|
26.7 |
|
| Other |
10.1 |
|
(9.0) |
|
1.1 |
|
11.0 |
|
(9.8) |
|
1.2 |
|
|
$ |
1,623.7 |
|
$ |
(709.5) |
|
$ |
914.2 |
|
$ |
1,596.6 |
|
$ |
(686.1) |
|
$ |
910.5 |
|
| Intangible assets not subject to amortization: |
|
|
|
|
|
|
| Trade names |
$ |
88.8 |
|
|
$ |
88.8 |
|
$ |
87.3 |
|
|
$ |
87.3 |
|
| FAA air agency certificates |
8.7 |
|
|
8.7 |
|
8.7 |
|
|
8.7 |
|
|
$ |
97.5 |
|
|
$ |
97.5 |
|
$ |
96.0 |
|
|
$ |
96.0 |
|
| Total intangible assets |
$ |
1,721.2 |
|
$ |
(709.5) |
|
$ |
1,011.7 |
|
$ |
1,692.6 |
|
$ |
(686.1) |
|
$ |
1,006.5 |
|
Amortization expense for intangible assets was $21.0 million and $21.6 million for the three months ended March 31, 2025 and 2024, respectively. Amortization expense for intangible assets is projected to be approximately $84 million in 2025; $82 million in 2026; $79 million in 2027; $76 million in 2028; and $74 million in 2029.
Note 9 - Other Current Liabilities
The following table displays other current liabilities as of March 31, 2025 and December 31, 2024:
|
|
|
|
|
|
|
|
|
|
March 31, 2025 |
December 31, 2024 |
| Sales rebates |
$ |
57.1 |
|
$ |
69.2 |
|
| Interest |
37.2 |
|
25.3 |
|
| Deferred revenue |
32.7 |
|
41.4 |
|
| Operating lease liabilities |
32.4 |
|
32.0 |
|
| Taxes other than income and payroll taxes |
20.8 |
|
25.8 |
|
| Product warranty |
18.3 |
|
18.0 |
|
| Freight and duties |
16.9 |
|
14.3 |
|
| Unprocessed invoices |
16.4 |
|
15.1 |
|
| Professional fees |
13.1 |
|
11.5 |
|
| Restructuring |
10.7 |
|
3.7 |
|
| Current derivative liability |
10.0 |
|
10.4 |
|
| Other |
53.8 |
|
52.5 |
|
| Total other current liabilities |
$ |
319.4 |
|
$ |
319.2 |
|
Note 10 - Financing Arrangements
Short-term debt at March 31, 2025 and December 31, 2024 was as follows:
|
|
|
|
|
|
|
|
|
|
March 31, 2025 |
December 31, 2024 |
|
|
|
Borrowings under lines of credit for certain of the Company’s foreign subsidiaries with various banks with interest rates ranging from 3.01% to 3.46% at March 31, 2025 and 3.36% to 3.95% at December 31, 2024 |
$ |
7.4 |
|
$ |
8.7 |
|
| Short-term debt |
$ |
7.4 |
|
$ |
8.7 |
|
Lines of credit for certain of the Company's foreign subsidiaries provide for short-term borrowings. Most of these lines of credit are uncommitted. At March 31, 2025, the Company’s foreign subsidiaries had borrowings outstanding of $7.4 million and bank guarantees of $0.3 million.
Long-term debt at March 31, 2025 and December 31, 2024 was as follows:
|
|
|
|
|
|
|
|
|
|
March 31, 2025 |
December 31, 2024 |
|
|
|
|
Variable-rate Accounts Receivable Facility with an interest rate of 5.31%
at March 31, 2025
|
$ |
30.0 |
|
$ |
— |
|
|
|
|
|
Fixed-rate Euro Senior Unsecured Notes(1), maturing on September 7, 2027,
with an interest rate of 2.02%
|
162.2 |
|
155.3 |
|
|
Variable-rate Term Loan(1), maturing on December 5, 2027, with an interest rate
of 5.55% at March 31, 2025 and 5.58% at December 31, 2024
|
369.6 |
|
369.6 |
|
|
Fixed-rate Medium-Term Notes, Series A(1), maturing at various dates through
May 2028, with interest rates ranging from 6.74% to 7.76%
|
154.9 |
|
154.8 |
|
|
Fixed-rate Senior Unsecured Notes(1), maturing on December 15, 2028, with
an interest rate of 4.50%
|
398.2 |
|
398.1 |
|
|
Fixed-rate Senior Unsecured Notes(1), maturing on April 1, 2032, with an
interest rate of 4.13%
|
345.5 |
|
345.1 |
|
|
Fixed-rate Euro Senior Unsecured Notes(1), maturing on May 23, 2034, with an
interest rate of 4.13%
|
638.0 |
|
609.7 |
|
|
Fixed-rate Euro Bank Loan, maturing on June 30, 2033, with an
interest rate of 2.15%
|
10.8 |
|
10.6 |
|
|
|
|
| Other |
10.5 |
|
10.8 |
|
| Total debt |
$ |
2,119.7 |
|
$ |
2,054.0 |
|
| Less: current maturities |
14.3 |
|
4.3 |
|
| Long-term debt |
$ |
2,105.4 |
|
$ |
2,049.7 |
|
(1) Net of discounts and fees
Note 10 - Financing Arrangements (continued)
The Company has a $100 million Amended and Restated Asset Securitization Agreement (the "Accounts Receivable Facility"), which matures on November 30, 2026. Under the terms of the Accounts Receivable Facility, the Company sells, on an ongoing basis, certain domestic trade receivables to Timken Receivables Corporation, a wholly-owned consolidated subsidiary that, in turn, uses the trade receivables to secure borrowings that are funded through a vehicle that issues commercial paper in the short-term market. Borrowings under the Accounts Receivable Facility may be limited by certain borrowing base limitations; however, availability under the Accounts Receivable Facility was not reduced by any such borrowing base limitations at March 31, 2025. As of March 31, 2025, there was $30.0 million of outstanding borrowings under the Accounts Receivable Facility, which reduced the availability under this facility to $70.0 million. The cost of this facility, which is the prevailing commercial paper rate plus facility fees, is considered a financing cost and is included in interest expense in the Consolidated Statements of Income.
On December 5, 2022, the Company entered into the Fifth Amended and Restated Credit Agreement ("Credit Agreement"), which is comprised of a $750 million unsecured revolving credit facility ("Senior Credit Facility") and a $400 million unsecured term loan facility ("2027 Term Loan") that each mature on December 5, 2027. The interest rates under the Credit Agreement are based on Secured Overnight Financing Rate ("SOFR"). At March 31, 2025, the Company had no outstanding borrowings under the Senior Credit Facility. The Credit Agreement has two financial covenants: a consolidated net leverage ratio and a consolidated interest coverage ratio.
On May 23, 2024, the Company issued fixed-rate Euro senior unsecured notes ("2034 Notes") in the aggregate principal amount of €600 million with an interest rate of 4.13%, maturing on May 23, 2034. Proceeds from the 2034 Notes were used for the redemption of the Company's outstanding fixed-rate unsecured senior notes in the aggregate principal amount of $350 million that were due to mature on September 1, 2024 ("2024 Notes"), as well as the repayment of other debt outstanding at the time of issuance.
At March 31, 2025, the Company was in full compliance with all applicable covenants on its outstanding debt.
In the ordinary course of business, the Company utilizes standby letters of credit issued by financial institutions to guarantee certain obligations, most of which relate to certain insurance contracts and indirect taxes. At March 31, 2025, outstanding letters of credit totaled $57.2 million, most with expiration dates within 12 months.
The maturities of long-term debt (including $8.6 million of finance leases) subsequent to March 31, 2025 are as follows:
|
|
|
|
|
|
| Year |
|
| 2025 |
$ |
3.9 |
|
| 2026 |
84.2 |
|
| 2027 |
520.6 |
|
| 2028 |
522.5 |
|
| 2029 |
2.0 |
|
| 2030 |
1.5 |
|
| Thereafter |
1,002.8 |
|
The table above excludes $17.8 million of unamortized discounts and fees that are netted against long-term debt at March 31, 2025.
Note 11 - Supply Chain Financing
The Company offers a supplier finance program with different financial institutions where suppliers may receive early payment from the financial institutions on invoices issued to the Company. The Company and each financial institution entered into arrangements whereby the Company pays the financial institution per the terms of any supplier invoice paid early under the program and pays an annual fee for the supplier finance platform subscription and related support. The Company or the financial institutions may terminate participation in the program with 90 days’ written notice. The supplier finance programs are unsecured and are not guaranteed by the Company. The financial institutions enter into separate arrangements with suppliers directly to participate in the program. The Company does not determine the terms or conditions of such arrangements or participate in the transactions between the suppliers and the financial institutions. The supplier invoice terms under the program typically require payment in full within 90 days of the invoice date.
The following table is a rollforward of the outstanding obligations for the Company’s supplier finance program for the three months ended March 31, 2025 and twelve months ended December 31, 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2025 |
|
December 31, 2024 |
|
|
| Confirmed obligations outstanding, January 1 |
$ |
16.7 |
|
|
$ |
21.3 |
|
|
|
| Invoices confirmed |
21.5 |
|
|
105.0 |
|
|
|
| Confirmed invoices paid |
(20.8) |
|
|
(109.6) |
|
|
|
| Confirmed obligations outstanding, ending balance |
$ |
17.4 |
|
|
$ |
16.7 |
|
|
|
The obligations outstanding at March 31, 2025 and December 31, 2024 were included in accounts payable, trade on the Consolidated Balance Sheets.
Note 12 - Contingencies
The Company is responsible for environmental remediation at various manufacturing facilities presently or formerly operated by the Company. In addition, the Company, through one of its subsidiaries, has currently been identified as a potentially responsible party for investigation and remediation under the Comprehensive Environmental Response, Compensation and Liability Act, known as the Superfund, or similar state laws with respect to one site. Claims for investigation and remediation have been asserted against numerous other unrelated entities, which are believed to be financially solvent and are expected to fulfill their proportionate share of the obligation.
On December 28, 2004, the United States Environmental Protection Agency (“USEPA”) sent Lovejoy, LLC ("Lovejoy") a Special Notice Letter that identified Lovejoy as a potentially responsible party, together with at least 12 unrelated parties, at the Ellsworth Industrial Park Site, Downers Grove, DuPage County, Illinois (the “Site”). The Company acquired Lovejoy in 2016. Lovejoy’s Downers Grove property is situated within the Ellsworth Industrial Complex. The USEPA and the Illinois Environmental Protection Agency (“IEPA”) allege there have been one or more releases or threatened releases of hazardous substances, including, but not limited to, a release or threatened release on or from Lovejoy's property at the Site. The relief sought by the USEPA and IEPA includes further investigation and potential remediation of the Site and reimbursement of response costs. Lovejoy’s allocated share of past and future costs related to the Site, including for investigation and/or remediation, could be significant. All previously pending property damage and personal injury lawsuits against Lovejoy related to the Site were settled or dismissed prior to our acquisition of Lovejoy.
In addition, governmental authorities in the United States and the European Union are increasingly focused on regulating per- and polyfluoroalkyl substances (“PFAS”). PFAS regulations are applicable to portions of the Company's products, and conditions may develop, arise or be discovered that create potentially significant environmental compliance or remediation liabilities at certain of its facilities.
The Company had total environmental accruals of $4.8 million for various known environmental matters that are probable and reasonably estimable at March 31, 2025 and December 31, 2024, which includes the Lovejoy matter described above. These accruals were recorded based upon the best estimate of costs to be incurred considering the progress made in determining the magnitude of remediation costs, the timing and extent of remedial actions required by governmental authorities and the amount of the Company’s liability in proportion to other responsible parties. The ultimate resolution of these matters could result in actual costs that exceed amounts accrued.
Note 12 - Contingencies (continued)
Legal Matter:
On June 11, 2024, the Company's majority-owned subsidiary, Timken India Limited ("TIL"), received a government order claiming damages (penalties and interest) totaling approximately $12 million. The order relates to the closure of TIL’s retirement trust for employees and subsequent transfer of trust assets to the government-administered Employees’ Provident Fund Organization ("EFPO"). The order alleges that the surrender of trust assets did not follow applicable EFPO timing guidelines. TIL believes it fully complied with EFPO requirements and guidelines under the circumstances. TIL is disputing the merits of the order and has filed an appeal with the high court in India having jurisdiction over the matter. Management believes that relief will be provided to TIL once the matter is fully adjudicated; accordingly, no liability has been recorded. While no assurance can be given as to the ultimate outcome of this matter, the Company does not believe that the final resolution will have a material effect on the Company's consolidated financial position or liquidity; however, the effect of any future outcome may be material to the results of operations of any particular period in which costs, if any, are recognized.
Product Warranties:
In addition to the contingencies above, the Company provides limited warranties on certain of its products. The balances at the end of each respective period represent the best estimates of costs for existing and future claims for products that are still under warranty. The balances as of March 31, 2025 and December 31, 2024 primarily related to accruals for products sold into the automotive and wind energy sectors. Accrual estimates are based on actual claims and expected trends that continue to mature. In addition, the Company continues to evaluate other claims raised by certain customers with respect to the performance of bearings sold into the wind energy and automotive sectors. Management believes that the outcome of these claims will not have a material effect on the Company's consolidated financial position; however, the effect of a change in our assessment may be material to the results of operations of any particular period in which such change occurs.
The following is a rollforward of the consolidated product warranty accrual for the three months ended March 31, 2025 and twelve months ended December 31, 2024:
|
|
|
|
|
|
|
|
|
|
|
March 31, 2025 |
December 31, 2024 |
|
| Beginning balance, January 1 |
$ |
18.0 |
|
$ |
15.2 |
|
|
| Expense |
1.7 |
|
9.4 |
|
|
| Payments |
(1.4) |
|
(6.6) |
|
|
| Ending balance |
$ |
18.3 |
|
$ |
18.0 |
|
|
The product warranty accrual at March 31, 2025 and December 31, 2024 was included in other current liabilities on the Consolidated Balance Sheets.
Note 13 - Equity
The following tables present the changes in the components of equity for the three months ended March 31, 2025 and 2024, respectively:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
The Timken Company Shareholders |
|
| |
Total |
Stated Capital |
Other Paid-In Capital |
Retained Earnings |
Accumulated Other Comprehensive Loss |
Treasury Stock |
Non controlling Interest |
| Balance at December 31, 2024 |
$ |
2,984.1 |
|
$ |
40.7 |
|
$ |
1,269.3 |
|
$ |
2,488.8 |
|
$ |
(301.7) |
|
$ |
(670.6) |
|
$ |
157.6 |
|
| Net income |
91.4 |
|
|
|
78.3 |
|
|
|
13.1 |
|
| Foreign currency translation adjustment |
67.1 |
|
|
|
|
66.5 |
|
|
0.6 |
|
|
Pension and other postretirement liability
adjustments (net of income tax benefit
of $0.5 million)
|
(1.6) |
|
|
|
|
(1.6) |
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of derivative financial instruments, net of reclassifications |
(2.1) |
|
|
|
|
(2.1) |
|
|
|
|
|
|
|
|
|
|
|
Dividends - $0.34 per share |
(25.1) |
|
|
|
(25.1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock-based compensation expense |
7.5 |
|
|
7.5 |
|
|
|
|
|
| Stock purchased at fair market value |
(23.1) |
|
|
|
|
|
(23.1) |
|
|
| Stock option exercise activity |
0.3 |
|
|
0.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments related to tax withholding for stock-based compensation |
(9.5) |
|
|
|
|
|
(9.5) |
|
|
| Balance at March 31, 2025 |
$ |
3,089.0 |
|
$ |
40.7 |
|
$ |
1,277.1 |
|
$ |
2,542.0 |
|
$ |
(238.9) |
|
$ |
(703.2) |
|
$ |
171.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
The Timken Company Shareholders |
|
| |
Total |
Stated Capital |
Other Paid-In Capital |
Retained Earnings |
Accumulated Other Comprehensive Loss |
Treasury Stock |
Non controlling Interest |
| Balance at December 31, 2023 |
$ |
2,702.4 |
|
$ |
40.7 |
|
$ |
1,076.5 |
|
$ |
2,232.2 |
|
$ |
(146.9) |
|
$ |
(620.1) |
|
$ |
120.0 |
|
| Net income |
110.6 |
|
|
|
103.5 |
|
|
|
7.1 |
|
| Foreign currency translation adjustment |
(50.7) |
|
|
|
|
(50.3) |
|
|
(0.4) |
|
|
Pension and other postretirement liability
adjustments (net of income tax benefit of
$0.5 million)
|
(1.5) |
|
|
|
|
(1.5) |
|
|
|
Change in fair value of derivative financial instruments, net of reclassifications |
1.1 |
|
|
|
|
1.1 |
|
|
|
|
|
|
|
|
|
|
|
Dividends - $0.33 per share |
(24.5) |
|
|
|
(24.5) |
|
|
|
|
|
|
|
|
|
|
|
|
| Stock-based compensation expense |
4.5 |
|
|
4.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock option exercise activity |
2.0 |
|
|
2.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments related to tax withholding for stock-based compensation |
(8.9) |
|
|
|
|
|
(8.9) |
|
|
| Balance at March 31, 2024 |
$ |
2,735.0 |
|
$ |
40.7 |
|
$ |
1,083.0 |
|
$ |
2,311.2 |
|
$ |
(197.6) |
|
$ |
(629.0) |
|
$ |
126.7 |
|
Note 14 - Impairment and Restructuring Charges
Impairment and restructuring charges by segment are comprised of the following:
For the three months ended March 31, 2025:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Engineered Bearings |
Industrial Motion |
Unallocated Corporate |
Total |
|
|
|
|
|
| Severance and related benefit costs |
$ |
0.6 |
|
$ |
0.7 |
|
$ |
9.4 |
|
$ |
10.7 |
|
| Exit costs |
— |
|
0.2 |
|
— |
|
0.2 |
|
| Total |
$ |
0.6 |
|
$ |
0.9 |
|
$ |
9.4 |
|
$ |
10.9 |
|
For the three months ended March 31, 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Engineered Bearings |
Industrial Motion |
Unallocated Corporate |
Total |
|
|
|
|
|
| Severance and related benefit costs |
$ |
0.7 |
|
$ |
1.3 |
|
$ |
— |
|
$ |
2.0 |
|
| Exit costs |
0.3 |
|
— |
|
— |
|
0.3 |
|
| Total |
$ |
1.0 |
|
$ |
1.3 |
|
$ |
— |
|
$ |
2.3 |
|
The following discussion explains the more significant impairment and restructuring charges recorded for the periods presented; however, it is not intended to reflect a comprehensive discussion of all amounts included in the tables above.
Corporate:
On March 31, 2025, Timken announced that the Company and Tarak B. Mehta, the President and CEO of the Company, had mutually agreed that Mr. Mehta would depart from the Company, including resigning as a member of the Company’s Board of Directors (the "Board"), effective immediately. The Company also announced that the Board had appointed Richard G. Kyle as the interim President and CEO of the Company, effective immediately. Mr. Kyle serves as a member of the Board and previously acted as Advisor to the CEO of the Company from September 2024 until his retirement in February 2025 after having previously served as President and CEO of the Company from 2014 to 2024. During the three months ended March 31, 2025, the Company recorded severance expense of $9.3 million, plus related taxes, for Mr. Mehta's settlement arrangement and release of claims. Approximately two-thirds of this amount is expected to be paid in 2025, with the remaining amounts paid in 2026 and 2027.
Engineered Bearings:
On February 20, 2025, the Company announced the closure of its bearing manufacturing plant in Hiddenite, North Carolina. This plant was part of the American Roller Bearing Company acquisition completed on January 31, 2023. The Company will transfer its operations to other bearing manufacturing facilities in the United States. The closure of this facility is expected to be completed during the first half of 2026 and is expected to affect approximately 60 employees. The Company expects to incur approximately $5 million to $7 million of pretax costs in total related to this closure. During the three months ended March 31, 2025, the Company recorded severance and related benefits of $0.5 million related to this closure. The Company has incurred cumulative pretax costs related to this closure of $1.9 million as of March 31, 2025, including rationalization costs recorded in cost of products sold.
Note 14 - Impairment and Restructuring Charges (continued)
Industrial Motion:
On December 6, 2024, the Company announced a reduction in force for its belts manufacturing facility in Springfield, Missouri. The reorganization of this facility is expected to affect approximately 100 employees and be completed during the first half of 2026. On November 30, 2023, the Company announced the closure of its belts manufacturing facility in Fort Scott, Kansas. The Company expects to transfer its operations to other belts manufacturing facilities. The closure of this facility is expected to be completed during the second half of 2025 and is expected to affect approximately 60 employees. The Company expects to incur approximately $12 million to $14 million of pretax costs in total related to the closure of the Fort Scott facility and the reorganization of the Springfield facility. During the three months ended March 31, 2025 and 2024, the Company recorded severance and related benefit costs of $0.4 million and $0.8 million, respectively, related to these actions. The Company has incurred cumulative pretax costs related to these actions of $7.6 million as of March 31, 2025, including rationalization costs recorded in cost of products sold.
Consolidated Restructuring Accrual:
The following is a rollforward of the consolidated restructuring accrual for the three months ended March 31, 2025 and twelve months ended December 31, 2024:
|
|
|
|
|
|
|
|
|
|
|
March 31, 2025 |
December 31, 2024 |
|
| Beginning balance, January 1 |
$ |
3.7 |
|
$ |
5.8 |
|
|
| Expense |
10.9 |
|
9.9 |
|
|
| Payments |
(1.9) |
|
(12.0) |
|
|
| Ending balance |
$ |
12.7 |
|
$ |
3.7 |
|
|
On the Consolidated Balance Sheet, $10.7 million of the restructuring accrual at March 31, 2025 was included in other current liabilities, with the remaining $2.0 million included in other non-current liabilities. The restructuring accrual at December 31, 2024 was included in other current liabilities on the Consolidated Balance Sheet.
Note 15 - Retirement Benefit Plans
The following table sets forth the net periodic benefit cost for the Company’s defined benefit pension plans. The amounts for the three months ended March 31, 2025 are based on calculations prepared by the Company's actuaries and represent the Company’s best estimate of that period’s proportionate share of the amounts to be recorded for the year ending December 31, 2025.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Plans |
International Plans |
Total |
| |
Three Months Ended March 31, |
Three Months Ended March 31, |
Three Months Ended March 31, |
| |
2025 |
2024 |
2025 |
2024 |
2025 |
2024 |
| Components of net periodic benefit cost (credit): |
|
|
|
|
|
|
| Service cost |
$ |
0.2 |
|
$ |
0.1 |
|
$ |
0.4 |
|
$ |
0.5 |
|
$ |
0.6 |
|
$ |
0.6 |
|
| Interest cost |
4.3 |
|
4.3 |
|
2.7 |
|
2.5 |
|
7.0 |
|
6.8 |
|
| Expected return on plan assets |
(2.1) |
|
(1.9) |
|
(2.2) |
|
(2.4) |
|
(4.3) |
|
(4.3) |
|
| Amortization of prior service cost |
— |
|
— |
|
0.1 |
|
0.1 |
|
0.1 |
|
0.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net periodic benefit cost |
$ |
2.4 |
|
$ |
2.5 |
|
$ |
1.0 |
|
$ |
0.7 |
|
$ |
3.4 |
|
$ |
3.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 16 - Other Postretirement Benefit Plans
The following table sets forth the net periodic benefit cost for the Company’s other postretirement benefit plans. The amounts for the three months ended March 31, 2025 are based on calculations prepared by the Company's actuaries and represent the Company’s best estimate of that period’s proportionate share of the amounts to be recorded for the year ending December 31, 2025.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
Three Months Ended March 31, |
| |
|
|
|
|
2025 |
|
2024 |
| Net periodic benefit credit: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest cost |
|
|
|
|
0.5 |
|
|
0.5 |
|
|
|
|
|
|
|
|
|
| Amortization of prior service credit |
|
|
|
|
(2.1) |
|
|
(2.1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net periodic benefit credit |
|
|
|
|
$ |
(1.6) |
|
|
$ |
(1.6) |
|
Note 17 - Accumulated Other Comprehensive Income (Loss)
The following tables present details about components of accumulated other comprehensive (loss) income for the three months ended March 31, 2025 and 2024, respectively:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustments |
Pension and other postretirement liability adjustments |
|
Change in fair value of derivative financial instruments |
Total |
| Balance at December 31, 2024 |
$ |
(344.6) |
|
$ |
38.7 |
|
|
$ |
4.2 |
|
$ |
(301.7) |
|
|
|
|
|
|
|
Other comprehensive income (loss) before reclassifications and income taxes |
59.8 |
|
(0.1) |
|
|
(1.8) |
|
57.9 |
|
Amounts reclassified from accumulated other comprehensive loss before income taxes |
— |
|
(2.0) |
|
|
(1.2) |
|
(3.2) |
|
| Income tax benefit |
7.3 |
|
0.5 |
|
|
0.9 |
|
8.7 |
|
Net current period other comprehensive income (loss), net of income taxes |
67.1 |
|
(1.6) |
|
|
(2.1) |
|
63.4 |
|
| Noncontrolling interest |
(0.6) |
|
— |
|
|
— |
|
(0.6) |
|
Net current period other comprehensive income (loss), net of income taxes and noncontrolling interest |
66.5 |
|
(1.6) |
|
|
(2.1) |
|
62.8 |
|
| Balance at March 31, 2025 |
$ |
(278.1) |
|
$ |
37.1 |
|
|
$ |
2.1 |
|
$ |
(238.9) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustments |
Pension and other postretirement liability adjustments |
|
Change in fair value of derivative financial instruments |
Total |
| Balance at December 31, 2023 |
$ |
(193.8) |
|
$ |
44.7 |
|
|
$ |
2.2 |
|
$ |
(146.9) |
|
|
|
|
|
|
|
Other comprehensive (loss) income before reclassifications and income taxes |
(50.7) |
|
— |
|
|
1.7 |
|
(49.0) |
|
Amounts reclassified from accumulated other comprehensive (loss) income before income taxes |
— |
|
(2.0) |
|
|
(0.2) |
|
(2.2) |
|
| Income tax benefit (expense) |
— |
|
0.5 |
|
|
(0.4) |
|
0.1 |
|
Net current period other comprehensive (loss) income, net of income taxes |
(50.7) |
|
(1.5) |
|
|
1.1 |
|
(51.1) |
|
| Noncontrolling interest |
0.4 |
|
— |
|
|
— |
|
0.4 |
|
Net current period other comprehensive (loss) income, net of income taxes and noncontrolling interest |
(50.3) |
|
(1.5) |
|
|
1.1 |
|
(50.7) |
|
| Balance at March 31, 2024 |
$ |
(244.1) |
|
$ |
43.2 |
|
|
$ |
3.3 |
|
$ |
(197.6) |
|
|
|
|
|
|
|
Foreign currency translation adjustments at March 31, 2025 and December 31, 2024 included cumulative gains of $4.1 million and $27.1 million, respectively, net of deferred taxes, related to net investment hedges. Refer to Note 19 - Derivative Instruments and Hedging Activities for additional information on the net investment hedges.
Other comprehensive (loss) income before reclassifications and income taxes includes the effect of foreign currency.
Note 18 - Fair Value
Fair value is defined as the price that would be expected to be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The FASB provides accounting rules that classify the inputs used to measure fair value into the following hierarchy:
Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2 – Unadjusted quoted prices in active markets for similar assets or liabilities, or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability.
Level 3 – Unobservable inputs for the asset or liability.
The following tables present the fair value hierarchy for those financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2025 and December 31, 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
March 31, 2025 |
| |
Total |
Level 1 |
Level 2 |
Level 3 |
| Assets: |
|
|
|
|
| Cash and cash equivalents |
$ |
342.8 |
|
$ |
340.8 |
|
$ |
2.0 |
|
$ |
— |
|
| Cash and cash equivalents measured at net asset value |
33.3 |
|
|
|
|
| Restricted cash |
0.4 |
|
0.4 |
|
— |
|
— |
|
| Short-term investments |
15.2 |
|
— |
|
15.2 |
|
— |
|
|
|
|
|
|
|
|
|
|
|
| Foreign currency forward contracts |
2.3 |
|
— |
|
2.3 |
|
— |
|
| Total assets |
$ |
394.0 |
|
$ |
341.2 |
|
$ |
19.5 |
|
$ |
— |
|
| Liabilities: |
|
|
|
|
| Foreign currency forward contracts |
$ |
10.0 |
|
$ |
— |
|
$ |
10.0 |
|
$ |
— |
|
|
|
|
|
|
| Total liabilities |
$ |
10.0 |
|
$ |
— |
|
$ |
10.0 |
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
December 31, 2024 |
| |
Total |
Level 1 |
Level 2 |
Level 3 |
| Assets: |
|
|
|
|
| Cash and cash equivalents |
$ |
343.1 |
|
$ |
341.8 |
|
$ |
1.3 |
|
$ |
— |
|
| Cash and cash equivalents measured at net asset value |
30.1 |
|
|
|
|
| Restricted cash |
0.4 |
|
0.4 |
|
— |
|
— |
|
| Short-term investments |
15.9 |
|
— |
|
15.9 |
|
— |
|
|
|
|
|
|
| Foreign currency forward contracts |
4.9 |
|
— |
|
4.9 |
|
— |
|
| Total assets |
$ |
394.4 |
|
$ |
342.2 |
|
$ |
22.1 |
|
$ |
— |
|
| Liabilities: |
|
|
|
|
| Foreign currency forward contracts |
$ |
10.4 |
|
$ |
— |
|
$ |
10.4 |
|
$ |
— |
|
| Total liabilities |
$ |
10.4 |
|
$ |
— |
|
$ |
10.4 |
|
$ |
— |
|
Cash and cash equivalents include highly liquid investments with maturities of 90 days or less when purchased that are valued at redemption value. Short-term investments are investments with maturities between 91 days and one year, and generally are valued at amortized cost, which approximates fair value. A portion of the cash and cash equivalents and short-term investments are valued based on net asset value. The Company uses publicly available foreign currency forward and spot rates to measure the fair value of its foreign currency forward contracts.
Note 18 - Fair Value (continued)
In addition, the Company remeasures certain assets at fair value, using Level 3 inputs, as a result of the occurrence of triggering events such as purchase accounting for acquisitions or goodwill impairment.
No material assets were measured at fair value on a nonrecurring basis during the three months ended March 31, 2025 and 2024.
Financial Instruments:
The Company’s financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, trade accounts payable, short-term borrowings and long-term debt. Due to their short-term nature, the carrying value of cash and cash equivalents, short-term investments, accounts receivable, trade accounts payable and short-term borrowings are a reasonable estimate of their fair value. Due to the nature of fair value calculations for variable-rate debt, the carrying value of the Company's long-term variable-rate debt is a reasonable estimate of its fair value. The fair value of the Company’s long-term fixed-rate debt, based on Level 2 inputs (quoted market prices), was $1,692.4 million and $1,659.2 million at March 31, 2025 and December 31, 2024, respectively. The carrying value of this debt was $1,711.4 million and $1,675.6 million at March 31, 2025 and December 31, 2024, respectively. The difference between fair value and carrying value primarily reflects the net impact of changes in prevailing interest rates and credit spreads since the fixed-rate debt was issued.
The Company does not believe it has significant concentrations of risk associated with the counterparties to its financial instruments.
Note 19 - Derivative Instruments and Hedging Activities
The Company is exposed to certain risks relating to its ongoing business operations. The primary risks managed by using derivative instruments are foreign currency exchange rate risk and interest rate risk. Forward contracts on various foreign currencies are entered into in order to manage the foreign currency exchange rate risk associated with certain of the Company's commitments denominated in foreign currencies. From time to time, interest rate swaps are used to manage interest rate risk associated with the Company’s fixed and floating-rate borrowings.
The Company designates certain foreign currency forward contracts as cash flow hedges of forecasted revenues and certain interest rate hedges as cash flow hedges of fixed-rate borrowings.
On May 23, 2024, the Company designated its 2034 Notes as a hedge against its net investment in one of its European subsidiaries. The objective of the hedge transaction is to protect the net investment in the foreign operations against changes in the exchange rate between the U.S. dollar and the Euro. The net impact for the three months ended March 31, 2025 was a loss of $27.7 million recorded to accumulated other comprehensive (loss) income.
On September 15, 2020, the Company designated €54.5 million of its €150.0 million fixed-rate senior unsecured notes, maturing on September 7, 2027, as a hedge against its net investment in one of its European subsidiaries. The objective of the hedge transaction is to protect the net investment in the foreign operations against changes in the exchange rate between the U.S. dollar and the Euro. The net impact for the three months ended March 31, 2025 was a loss of $2.5 million recorded to accumulated other comprehensive (loss) income.
The Company does not purchase or hold any derivative financial instruments for trading purposes. As of March 31, 2025 and December 31, 2024, the Company had $422.6 million and $471.6 million, respectively, of outstanding foreign currency forward contracts at notional value. Refer to Note 18 - Fair Value for the fair value disclosure of derivative financial instruments.
Cash Flow Hedging Strategy:
For certain derivative instruments that are designated and qualify as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk), the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period or periods during which the hedged transaction affects earnings.
To protect against a reduction in the value of forecasted foreign currency cash flows resulting from export sales, the Company has instituted a foreign currency cash flow hedging program. The Company hedges portions of its forecasted cash flows denominated in certain foreign currencies with forward contracts. When the dollar strengthens significantly against these foreign currencies, the decline in the present value of future foreign currency revenue is offset by gains in the fair value of the forward contracts designated as hedges. Conversely, when the dollar weakens, the increase in the present value of future foreign currency cash flows is offset by losses in the fair value of the forward contracts. As of March 31, 2025 and December 31, 2024, the Company had $66.2 million and $63.0 million, respectively, of outstanding foreign currency forward contracts at notional value that were classified as cash flow hedges.
The maximum length of time over which the Company hedges its exposure to the variability in future cash flows for forecast transactions is generally eighteen months or less.
Note 19 - Derivative Instruments and Hedging Activities (continued)
Purpose for Derivative Instruments not designated as Hedging Instruments:
For derivative instruments that are not designated as hedging instruments, the instruments are typically forward contracts. In general, the practice is to reduce volatility by selectively hedging transaction exposures including intercompany loans, accounts payable and accounts receivable. Intercompany loans between entities with different functional currencies typically are hedged with a forward contract at the inception of the loan with a maturity date corresponding to the maturity of the loan. The revaluation of these contracts, as well as the revaluation of the underlying balance sheet items, is recorded directly to the income statement so the adjustment generally offsets the revaluation of the underlying balance sheet items to protect cash payments and reduce income statement volatility.
As of March 31, 2025 and December 31, 2024, the Company had $356.4 million and $408.6 million, respectively, of outstanding foreign currency forward contracts at notional value that were not designated as hedging instruments. The following table presents the impact of derivative instruments not designated as hedging instruments for the three months ended March 31, 2025 and 2024, respectively, and the related location within the Consolidated Statements of Income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount of gain or (loss) recognized in income |
|
|
|
Three Months Ended March 31, |
|
| Derivatives not designated as hedging instruments: |
Location of gain or (loss) recognized in income |
2025 |
2024 |
|
|
|
|
|
|
|
|
| Foreign currency forward contracts |
Other expense, net |
$ |
(1.1) |
|
$ |
(6.1) |
|
|
|
|
|
|
|
|
|
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(Dollars in millions, except per share data)
OVERVIEW
Introduction:
The Timken Company designs and manufactures a growing portfolio of engineered bearings and industrial motion products, and related services. With more than a century of knowledge and innovation, the Company continuously improves the reliability and efficiency of global machinery and equipment to move the world forward. The Company’s growing product and services portfolio features many strong industrial brands, such as Timken®, GGB®, Philadelphia Gear®, Cone Drive®, Rollon®, Nadella®, Diamond®, Drives®, Groeneveld®, BEKA®, Des-Case®, Lovejoy® and Lagersmit®. Timken employs approximately 19,000 people globally in 45 countries. The Company operates under two reportable segments: (1) Engineered Bearings and (2) Industrial Motion. The following further describes these business segments:
•Timken’s Engineered Bearings segment features a broad range of product designs serving original equipment manufacturers (OEMs) and end-users worldwide. Timken is a leading authority on tapered roller bearings and leverages its position by applying engineering know-how and technology across its entire bearing portfolio, which includes tapered, spherical and cylindrical roller bearings; plain bearings, metal-polymer bearings and rod end bearings; thrust and specialty ball bearings; and housed or mounted bearings. The Engineered Bearings portfolio features the Timken®, GGB® and Fafnir® brands and serves customers across global industries, including wind energy, agriculture, construction, food and beverage, metals and mining, automotive and truck, aerospace, rail and more.
•Timken’s Industrial Motion segment includes a diverse and growing portfolio of engineered products, including industrial drives, automatic lubrication systems, linear motion products and systems, chains, belts, couplings, filtration systems, seals, and industrial clutches and brakes that keep systems running efficiently. Industrial Motion also includes industrial drivetrain services, which return equipment to like-new condition. The Industrial Motion portfolio features many strong brands, including Philadelphia Gear®, Cone Drive®, Spinea®, Rollon®, Nadella®, Groeneveld®, BEKA®, Des-Case®, Diamond®, Drives®, Timken® Belts, Lovejoy®, PT Tech®, Lagersmit® and CGI. Industrial Motion products are used across a broad range of industries, including solar energy, automation, construction, agriculture and turf, passenger rail, marine, aerospace, packaging and logistics, medical and more.
Timken creates value by understanding customer needs and applying its know-how to serve a broad range of customers in attractive markets and industries across the globe. The Company’s business strengths include its product technology, end-market diversity, geographic reach and aftermarket mix. Timken collaborates with OEMs to improve equipment efficiency with its engineered products and captures subsequent equipment replacement cycles by selling largely through independent channels in the aftermarket. Timken focuses its international efforts and footprint in regions of the world where strong macroeconomic factors such as urbanization, infrastructure development, industrialization and sustainability create demand for its products and services.
The Company's strategy has three primary elements:
Profitable Growth. The Company intends to expand into new and existing markets by leveraging its collective knowledge of materials science, friction management and power transmission to create value for Timken customers. Using a highly collaborative technical selling approach, the Company places particular emphasis on creating unique solutions for challenging and/or demanding applications. The Company intends to grow in attractive market sectors around the world, emphasizing those spaces that are highly fragmented, demand high service and value the reliability and efficiency offered by Timken products. The Company also targets applications that offer significant aftermarket demand, thereby providing product and services revenue throughout the equipment’s lifetime.
Operational Excellence. Timken operates with a relentless drive for exceptional results and a passion for superior execution. The Company embraces a continuous improvement culture that is charged with increasing efficiency, lowering costs, eliminating waste, increasing cash flow, driving organizational advancement and agility, and building greater brand equity to fuel growth. This requires the Company’s ongoing commitment to attract, retain and develop the best talent across the world.
Capital Deployment to Drive Shareholder Value. The Company is focused on providing the highest returns for shareholders through its capital allocation framework, which includes: (1) investing in the core business through capital expenditures, research and development and initiatives to drive profitable organic growth; (2) pursuing strategic acquisitions to broaden its portfolio and capabilities across diverse markets, with a focus on engineered bearings, industrial motion products and related services; (3) returning capital to shareholders through dividends and share repurchases; and (4) maintaining a strong balance sheet and sufficient liquidity. As part of this framework, the Company may also restructure, reposition or divest underperforming product lines or assets.
Overview:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
|
| |
2025 |
2024 |
$ Change |
% Change |
| Net sales |
$ |
1,140.3 |
|
$ |
1,190.3 |
|
$ |
(50.0) |
|
(4.2 |
%) |
| Net income |
91.4 |
|
110.6 |
|
(19.2) |
|
(17.4 |
%) |
|
|
|
|
|
| Net income attributable to noncontrolling interest |
13.1 |
|
7.1 |
|
6.0 |
|
84.5 |
% |
| Net income attributable to The Timken Company |
$ |
78.3 |
|
$ |
103.5 |
|
$ |
(25.2) |
|
(24.3 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diluted earnings per share |
$ |
1.11 |
|
$ |
1.46 |
|
$ |
(0.35) |
|
(24.0 |
%) |
| Average number of shares – diluted |
70,513,937 |
|
70,880,015 |
|
— |
|
(0.5 |
%) |
Net sales decreased for the three months ended March 31, 2025 compared with the three months ended March 31, 2024. The decrease was primarily driven by lower end-market demand in both segments, as well as the unfavorable impact of foreign currency exchange rate changes, partially offset by the benefit of acquisitions.
Net income decreased for the three months ended March 31, 2025 compared with the three months ended March 31, 2024 primarily due to the impact of lower volume, higher manufacturing costs, higher impairment and restructuring charges, unfavorable price/mix and the unfavorable impact of foreign currency exchange rate changes, partially offset by lower tax expense and the benefit of acquisitions.
Outlook:
In early 2025, the United States government announced the imposition of import tariffs on all countries. The baseline reciprocal tariff is 10%, with higher tariffs imposed on certain countries like China, Mexico and Canada, and sectors like steel, aluminum and automotive. The Company is taking steps to mitigate the increased costs from incremental tariffs through pricing, surcharges and other actions. Timken is also monitoring the impact that tariffs could have on global economic demand. The Company currently expects that tariffs and the related macroeconomic effects will adversely impact operating income in 2025.
As a result, the Company expects 2025 full-year revenues to be down in total compared to 2024, primarily driven by lower demand related to international trade volatility and the impact of unfavorable foreign currency exchange rates, partially offset by favorable pricing and the benefit of acquisitions completed during 2024. The Company's earnings are expected to be down in 2025 compared with 2024, primarily due to the impact of lower organic sales volume, higher tariffs and unfavorable foreign currency exchange rate changes, offset partially by lower operating costs and the favorable impact of acquisitions.
The Company expects to generate a higher amount of cash from operating activities in 2025 compared to 2024, driven by improved working capital performance, a lower level of capital expenditures, and lower cash taxes. The Company expects capital expenditures in 2025 to be in the range of 3.5% of sales.
THE STATEMENT OF INCOME
Operating Income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2025 |
2024 |
$ Change |
Change |
| Net sales |
$ |
1,140.3 |
|
$ |
1,190.3 |
|
$ |
(50.0) |
|
(4.2%) |
| Cost of products sold |
781.6 |
|
792.7 |
|
(11.1) |
|
(1.4%) |
| Selling, general and administrative expenses |
184.8 |
|
190.7 |
|
(5.9) |
|
(3.1%) |
| Amortization of intangible assets |
19.0 |
|
20.0 |
|
(1.0) |
|
(5.0%) |
| Impairment and restructuring charges |
10.9 |
|
2.3 |
|
8.6 |
|
373.9% |
|
|
|
|
|
| Operating income |
$ |
144.0 |
|
$ |
184.6 |
|
(40.6) |
|
(22.0%) |
| Operating income % to net sales |
12.6 |
% |
15.5 |
% |
|
(290) |
bps |
Net sales decreased for the three months ended March 31, 2025 compared with the three months ended March 31, 2024. The decrease was driven by lower organic revenue of $37 million and the unfavorable impact of foreign currency exchange rate changes of $25 million, partially offset by the favorable impact of acquisitions of $12 million.
Operating income decreased for the three months ended March 31, 2025 compared with the three months ended March 31, 2024, primarily due to the impact of lower volume, higher manufacturing costs, higher impairment and restructuring charges, unfavorable price/mix and the unfavorable impact of foreign currency exchange rate changes, partially offset by the benefit of acquisitions.
•Cost of products sold decreased for the three months ended March 31, 2025 compared with the three months ended March 31, 2024, due to the impact of foreign currency exchange rate changes of $18 million and the impact of lower volume of $12 million, partially offset by higher manufacturing costs of $12 million and the incremental cost of goods sold from acquisitions of $4 million.
•Selling, general and administrative ("SG&A") expenses decreased for the three months ended March 31, 2025 compared with the three months ended March 31, 2024, primarily due to the favorable impact of foreign currency exchange rates and reduced discretionary spending to align with the lower demand levels.
•Impairment and restructuring charges were higher for the three months ended March 31, 2025 compared with the three months ended March 31, 2024, primarily due to severance related to the CEO transition during the three months ended March 31, 2025.
Interest Income and Expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
|
| |
2025 |
2024 |
$ Change |
% Change |
| Interest expense |
$ |
(26.5) |
|
$ |
(32.2) |
|
$ |
5.7 |
|
(17.7 |
%) |
| Interest income |
2.3 |
|
2.8 |
|
$ |
(0.5) |
|
(17.9 |
%) |
| Interest expense, net |
$ |
(24.2) |
|
$ |
(29.4) |
|
$ |
5.2 |
|
(17.7 |
%) |
|
|
|
|
|
The decrease in interest expense for the three months ended March 31, 2025 compared with the three months ended March 31, 2024 was primarily due to lower average debt levels.
Other Income (Expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
| |
2025 |
2024 |
$ Change |
% Change |
| Non-service pension and other postretirement expense |
$ |
(1.2) |
|
$ |
(1.0) |
|
$ |
(0.2) |
|
20.0 |
% |
| Other expense, net |
(0.3) |
|
(0.9) |
|
0.6 |
|
(66.7 |
%) |
| Total other expense, net |
$ |
(1.5) |
|
$ |
(1.9) |
|
$ |
0.4 |
|
(21.1 |
%) |
|
|
|
|
|
|
|
|
|
|
Income Tax Expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
|
| |
2025 |
2024 |
$ Change |
Change |
| Provision for income taxes |
$ |
26.9 |
|
$ |
42.7 |
|
$ |
(15.8) |
|
(37.0 |
%) |
| Effective tax rate |
22.7 |
% |
27.9 |
% |
|
(520) |
bps |
Income tax expense decreased $15.8 million for the three months ended March 31, 2025 compared with the three months ended March 31, 2024 due to lower pre-tax earnings and the net favorable impact of discrete items in comparison to the year ago period. The favorable discrete items in the current period primarily related to the reversal of accruals for uncertain tax positions to account for the expiration of statutes of limitation in jurisdictions outside the United States.
Refer to Note 5 - Income Taxes in the Notes to the Consolidated Financial Statements for more information on the computation of the income tax expense in interim periods.
BUSINESS SEGMENTS
The Company's reportable segments are product-based business groups that serve customers in diverse industrial markets. The primary measurement used by management to measure the financial performance of each segment is adjusted EBITDA. Refer to Note 4 - Segment Information in the Notes to the Consolidated Financial Statements for the reconciliation of adjusted EBITDA by segment to consolidated income before income taxes.
The presentation of segment results below includes a reconciliation of the changes in net sales for each segment reported in accordance with U.S. GAAP to net sales adjusted to remove the effects of the acquisitions completed in 2024 and foreign currency exchange rate changes. The effects of acquisitions and foreign currency exchange rate changes on net sales are removed to allow investors and the Company to meaningfully evaluate the percentage change in net sales on a comparable basis from period to period.
The following item highlights the Company's acquisition completed in 2024:
•The Company acquired CGI, Inc. ("CGI") during the third quarter of 2024. Results for CGI are reported in the Industrial Motion segment.
Engineered Bearings Segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
|
| |
2025 |
2024 |
$ Change |
Change |
| Net sales |
$ |
760.7 |
|
$ |
802.5 |
|
$ |
(41.8) |
|
(5.2 |
%) |
| Cost of products sold |
(523.3) |
|
(540.8) |
|
17.5 |
|
(3.2 |
%) |
| Selling, general and administrative expenses |
(102.5) |
|
(105.9) |
|
3.4 |
|
(3.2 |
%) |
| Other segment items |
0.7 |
|
1.8 |
|
(1.1) |
|
(61.1 |
%) |
| Depreciation and amortization |
23.6 |
|
23.8 |
|
(0.2) |
|
(0.8 |
%) |
| Adjusted EBITDA |
$ |
159.2 |
|
$ |
181.4 |
|
$ |
(22.2) |
|
(12.2 |
%) |
| Adjusted EBITDA margin |
20.9 |
% |
22.6 |
% |
|
(170) |
bps |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
|
| |
2025 |
2024 |
$ Change |
% Change |
| Net sales |
$ |
760.7 |
|
$ |
802.5 |
|
$ |
(41.8) |
|
(5.2 |
%) |
|
|
|
|
|
|
|
|
|
|
| Less: Currency |
(19.4) |
|
— |
|
(19.4) |
|
NM |
| Net sales, excluding the impact of currency |
$ |
780.1 |
|
$ |
802.5 |
|
$ |
(22.4) |
|
(2.8 |
%) |
The Engineered Bearings segment's net sales, excluding the effects of foreign currency exchange rate changes, decreased $22.4 million or 2.8% in the three months ended March 31, 2025 compared with the three months ended March 31, 2024. The decrease was primarily driven by lower demand across most market sectors, with auto/truck and heavy industries sectors posting the largest declines, partially offset by higher renewable energy demand.
Adjusted EBITDA for the Engineered Bearings segment decreased for the three months ended March 31, 2025 by $22.2 million or 12.2% compared with the three months ended March 31, 2024, primarily due to the impact of lower volume, unfavorable price/mix and unfavorable foreign currency exchange rate changes.
•Cost of products sold decreased for the three months ended March 31, 2025 compared with the three months ended March 31, 2024 due to the impact of foreign currency exchange rate changes of $14 million and the impact of lower volume of $7 million.
•SG&A expenses decreased for the three months ended March 31, 2025 compared with the three months ended March 31, 2024 driven primarily by the favorable impact of foreign currency exchange rate changes and reduced discretionary spending.
Industrial Motion Segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
|
| |
2025 |
2024 |
$ Change |
Change |
| Net sales |
$ |
379.6 |
|
$ |
387.8 |
|
$ |
(8.2) |
|
(2.1 |
%) |
| Cost of products sold |
(256.6) |
|
(245.5) |
|
(11.1) |
|
4.5 |
% |
| Selling, general and administrative expenses |
(68.0) |
|
(70.9) |
|
2.9 |
|
(4.1 |
%) |
| Other segment items |
— |
|
(0.1) |
|
0.1 |
|
(100.0 |
%) |
| Depreciation and amortization |
12.1 |
|
10.8 |
|
1.3 |
|
12.0 |
% |
| Adjusted EBITDA |
$ |
67.1 |
|
$ |
82.1 |
|
$ |
(15.0) |
|
(18.3 |
%) |
| Adjusted EBITDA margin |
17.7 |
% |
21.2 |
% |
|
(350) |
bps |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
|
| |
2025 |
2024 |
$ Change |
% Change |
| Net sales |
$ |
379.6 |
|
$ |
387.8 |
|
$ |
(8.2) |
|
(2.1 |
%) |
| Less: Acquisitions |
12.3 |
|
— |
|
12.3 |
|
NM |
|
|
|
|
|
| Currency |
(5.7) |
|
— |
|
(5.7) |
|
NM |
Net sales, excluding the impact of acquisitions and currency |
$ |
373.0 |
|
$ |
387.8 |
|
$ |
(14.8) |
|
(3.8 |
%) |
The Industrial Motion segment's net sales, excluding the effects of acquisitions and foreign currency exchange rate changes, decreased $14.8 million or 3.8% in the three months ended March 31, 2025 compared with the three months ended March 31, 2024. The decrease reflects lower demand across most platforms, with industrial services and lubrication systems experiencing the largest declines, partially offset by growth in the drive systems platform.
Adjusted EBITDA decreased $15.0 million or 18.3% for the three months ended March 31, 2025 compared with the three months ended March 31, 2024 primarily due to the impact of lower volume and higher manufacturing costs, partially offset by the benefit of acquisitions and lower SG&A expenses.
•Cost of products sold increased for the three months ended March 31, 2025 compared with the three months ended March 31, 2024 due to the impact of higher manufacturing costs of $10 million and the incremental cost of goods sold from acquisitions of $8 million, partially offset by the impact of lower volume of $5 million.
•SG&A expenses decreased for the three months ended March 31, 2025 compared with the three months ended March 31, 2024 due to reduced discretionary spending, partially offset by the incremental SG&A expense from acquisitions.
Unallocated Corporate
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
|
| |
2025 |
2024 |
$ Change |
Change |
| Unallocated corporate expense |
$ |
(18.2) |
|
$ |
(17.1) |
|
$ |
(1.1) |
|
6.4 |
% |
| Unallocated corporate expense % to net sales |
(1.6 |
%) |
(1.4 |
%) |
|
(20) |
bps |
Unallocated corporate expense increased for the three months ended March 31, 2025 compared with the three months ended March 31, 2024 primarily due to an increase in compensation expense.
CASH FLOW
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
| |
2025 |
2024 |
$ Change |
|
|
|
|
|
|
|
|
| Net cash provided by operating activities |
$ |
58.6 |
|
$ |
49.3 |
|
$ |
9.3 |
|
|
|
|
|
|
|
|
|
| Net cash used in investing activities |
(32.5) |
|
(24.5) |
|
(8.0) |
|
|
|
|
|
|
|
|
|
| Net cash used in financing activities |
(30.6) |
|
(15.0) |
|
(15.6) |
|
| Effect of exchange rate changes on cash |
7.4 |
|
(6.8) |
|
14.2 |
|
Increase in cash and cash equivalents and restricted cash |
$ |
2.9 |
|
$ |
3.0 |
|
$ |
(0.1) |
|
Operating Activities:
The increase in net cash provided by operating activities for the first three months of 2025 compared with the first three months of 2024 was due to the favorable impact of working capital items of $48.7 million, partially offset by a decrease in net income of $19.2 million and lower accrued income taxes of $16 million. Refer to the tables below for additional detail of the impact of each line item on net cash provided by operating activities.
The following table displays the impact of working capital items on cash during the first three months of 2025 and 2024:
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
| |
2025 |
2024 |
$ Change |
| Cash (used in) provided by: |
|
|
|
| Accounts receivable |
$ |
(70.8) |
|
$ |
(106.1) |
|
$ |
35.3 |
|
| Unbilled receivables |
(18.2) |
|
9.5 |
|
(27.7) |
|
| Inventories |
15.3 |
|
(11.1) |
|
26.4 |
|
| Trade accounts payable |
20.2 |
|
20.7 |
|
(0.5) |
|
| Other accrued expenses |
(16.0) |
|
(31.2) |
|
15.2 |
|
| Cash used in working capital items |
$ |
(69.5) |
|
$ |
(118.2) |
|
$ |
48.7 |
|
The following table displays the impact of income taxes on cash during the first three months of 2025 and 2024:
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended March 31, |
|
| |
2025 |
2024 |
$ Change |
| Accrued income tax expense |
$ |
26.9 |
|
$ |
42.7 |
|
$ |
(15.8) |
|
| Income tax payments |
(23.4) |
|
(19.3) |
|
(4.1) |
|
| Other items |
— |
|
(2.9) |
|
2.9 |
|
| Change in income taxes |
$ |
3.5 |
|
$ |
20.5 |
|
$ |
(17.0) |
|
Investing Activities:
The increase in net cash used in investing activities for the first three months of 2025 compared with the first three months of 2024 was due to a decrease in cash from the net liquidation of short-term marketable securities of $18.9 million, partially offset by lower capital expenditures of $8.9 million.
Financing Activities:
The change in net cash used in financing activities for the first three months of 2025 compared with the first three months of 2024 was due to an increase in the purchase of treasury shares of $23.1 million, partially offset by a decrease in net borrowings of $10.4 million.
LIQUIDITY AND CAPITAL RESOURCES
Reconciliation of total debt to net debt and the ratio of net debt to capital:
Net Debt:
|
|
|
|
|
|
|
|
|
|
March 31, 2025 |
December 31, 2024 |
| Short-term debt, including current portion of long-term debt |
$ |
21.7 |
|
$ |
13.0 |
|
|
|
|
| Long-term debt |
2,105.4 |
|
2,049.7 |
|
| Total debt |
$ |
2,127.1 |
|
$ |
2,062.7 |
|
| Less: Cash and cash equivalents |
376.1 |
|
373.2 |
|
| Net debt |
$ |
1,751.0 |
|
$ |
1,689.5 |
|
Ratio of Net Debt to Capital:
|
|
|
|
|
|
|
|
|
|
March 31, 2025 |
December 31, 2024 |
| Net debt |
$ |
1,751.0 |
|
$ |
1,689.5 |
|
| Total equity |
3,089.0 |
|
2,984.1 |
|
| Net debt plus total equity (capital) |
$ |
4,840.0 |
|
$ |
4,673.6 |
|
| Ratio of net debt to capital |
36.2 |
% |
36.1 |
% |
The Company presents net debt because it believes net debt is more representative of the Company's financial position than total debt due to the amount of cash and cash equivalents held by the Company and the ability to utilize such cash and cash equivalents to reduce debt if needed.
At March 31, 2025, the Company had strong liquidity with $376.1 million of cash and cash equivalents on the Consolidated Balance Sheet, as well as $820.0 million available under committed credit lines. Of the $376.1 million of cash and cash equivalents, $355.1 million resided in jurisdictions outside the United States. Repatriation of non-U.S. cash could be subject to taxes and some portion may be subject to governmental restrictions. Part of the Company's strategy is to grow in attractive market sectors, many of which are outside the United States. This strategy includes making investments in facilities, equipment and potential new acquisitions. The Company plans to fund these investments, as well as meet working capital requirements, with cash and cash equivalents and unused lines of credit within the geographic location of these investments where feasible.
On December 5, 2022, the Company entered into the Credit Agreement, which is comprised of a $750.0 million Senior Credit Facility and a $400.0 million 2027 Term Loan that each mature on December 5, 2027. The interest rates under the Credit Agreement are based on SOFR. At March 31, 2025, the Company had no outstanding borrowings under the Senior Credit Facility. The Credit Agreement has two defined financial covenants: a consolidated net leverage ratio and a consolidated interest coverage ratio. The maximum consolidated net leverage ratio permitted under the Senior Credit Facility is 3.5 to 1.0. As of March 31, 2025, the Company's consolidated net leverage ratio was 2.17 to 1.0. The minimum consolidated interest coverage ratio permitted under the Senior Credit Facility is 3.0 to 1.0. As of March 31, 2025, the Company's consolidated interest coverage ratio was 7.70 to 1.0.
The interest rate under the Senior Credit Facility is variable with a spread based on the Company's debt rating. The average rate on outstanding Euro borrowings was 3.76% over the quarter ending March 31, 2025. There were no U.S. dollar borrowings during the quarter. In addition, the Company pays a facility fee based on the applicable rate, which is variable with a spread based on the Company's debt rating, multiplied by the aggregate commitments of all of the lenders under the Senior Credit Facility. As of March 31, 2025, the Company carried investment-grade credit ratings with both Moody's (Baa2) and S&P Global (BBB-).
The Company has a $100 million Accounts Receivable Facility, which matures on November 30, 2026. The Accounts Receivable Facility is subject to certain borrowing base limitations and is secured by certain domestic trade accounts receivable of the Company. The Accounts Receivable Facility had no borrowing base limitations at March 31, 2025. As of March 31, 2025, the Company had $30 million of outstanding borrowings under the Accounts Receivable Facility, which reduced the availability to $70 million.
Other sources of liquidity include uncommitted short-term lines of credit for certain of the Company's foreign subsidiaries, which currently provide for borrowings of up to $233.8 million. At March 31, 2025, the Company had borrowings outstanding of $7.4 million and bank guarantees of $0.3 million, which reduced the aggregate availability under these facilities to $226.1 million.
On May 23, 2024, the Company issued the 2034 Notes in the aggregate principal amount of €600 million with an interest rate of 4.13%, maturing on May 23, 2034. Proceeds from the 2034 Notes were used for the redemption of the 2024 Notes in the aggregate principal amount of $350 million that were due to mature on September 1, 2024, as well as the repayment of other debt outstanding at the time of the issuance.
At March 31, 2025, the Company was in full compliance with all applicable covenants on its outstanding debt.
The Company expects to generate a higher amount of cash from operating activities in 2025 compared to 2024, driven by improved working capital performance, a lower level of capital expenditures, and lower cash taxes. The Company expects capital expenditures in 2025 to be in the range of 3.5% of sales.
Financing Obligations and Other Commitments:
During the first three months of 2025, the Company made cash contributions and payments of $23.2 million to its global defined benefit pension plans and $0.6 million to its other postretirement benefit plans. In 2025, the Company expects to make contributions to its global defined benefit pension plans of approximately $36 million and to make payments of approximately $3 million to its other postretirement benefit plans. Excluding actuarial gains and losses, the Company expects higher pension and other postretirement benefits expense in 2025 compared to 2024 primarily due to lower expected returns on pension plan assets and higher interest expense.
The Company does not have any off-balance sheet arrangements with unconsolidated entities or other persons.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The Company's financial statements are prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. The Company reviews its critical accounting policies throughout the year. The Company has concluded that there have been no significant changes to its critical accounting policies or estimates, as described in its Annual Report on Form 10-K for the year ended December 31, 2024, during the three months ended March 31, 2025.
OTHER MATTERS
Foreign Currency:
Assets and liabilities of subsidiaries are translated at the rate of exchange in effect on the balance sheet date; income and expenses are translated at the average rates of exchange prevailing during the reporting period. Related translation adjustments are reflected as a separate component of accumulated other comprehensive loss. Foreign currency gains and losses resulting from transactions, and the related hedging activity, are included in the Consolidated Statements of Income.
For the three months ended March 31, 2025, the Company recorded positive foreign currency translation adjustments of $66.5 million that increased shareholders' equity, compared with negative foreign currency translation adjustments of $50.3 million that decreased shareholders' equity for the three months ended March 31, 2024. The foreign currency translation adjustments for the three months ended March 31, 2025 were impacted by the weakening of the U.S. dollar relative to other foreign currencies, including the Euro, the Romanian Leu, and the Brazilian Real.
Foreign currency exchange gains and losses, net of hedging activity, resulting from transactions included in the Company's operating results for the three months ended March 31, 2025 totaled $1.1 million of net gains, compared with $3.2 million of net losses during the three months ended March 31, 2024.
CEO Succession:
On September 5, 2024, the Company's Board appointed Tarak B. Mehta President and CEO of the Company and appointed Richard G. Kyle Advisor to the CEO. Mr. Mehta succeeded Mr. Kyle, who had served as Timken’s President and CEO since 2014. On March 31, 2025, Timken announced that the Company and Mr. Mehta had mutually agreed that Mr. Mehta would depart from the Company, including resigning as a member of the Company’s Board, effective immediately. The Company also announced that the Board had appointed Mr. Kyle as the interim President and CEO of the Company, effective immediately. During the three months ended March 31, 2025, the Company recorded severance of $9.3 million, plus related taxes, for Mr. Mehta's settlement arrangement and release of claims. Approximately two-thirds of this amount is expected to be paid in 2025, with the remaining amounts paid in 2026 and 2027.
NON-GAAP MEASURES
Supplemental Non-GAAP Measures:
In addition to results reported in accordance with U.S. GAAP, the Company provides information on non-GAAP financial measures. These non-GAAP financial measures include adjusted net income, adjusted earnings per share, adjusted EBITDA and adjusted EBITDA margins, ratio of net debt to adjusted EBITDA (for the trailing 12 months), net debt, ratio of net debt to capital, free cash flow and return on invested capital. This information is intended to supplement GAAP financial measures and is not intended to replace GAAP financial measures. Net debt and the ratio of net debt to capital is disclosed in the "Liquidity and Capital Resources" section of Management's Discussion and Analysis of Financial Condition and Results of Operations.
Adjusted Net Income and Adjusted EBITDA:
Adjusted net income and adjusted earnings per share represent net income attributable to The Timken Company and diluted earnings per share, respectively, adjusted for the amortization of intangible assets related to acquisitions, impairment, restructuring and reorganization charges, acquisition costs, including transaction costs and the amortization of the inventory step-up, property losses and recoveries, actuarial gains and losses associated with the remeasurement of the Company's defined benefit pension and other postretirement benefit plans, gains and losses on the sale of real estate, gains and losses on divestitures, the income tax impact of these adjustments, as well as other income tax discrete items, and other items from time to time that are not part of the Company's core operations. Management believes adjusted net income and adjusted earnings per share are useful to investors as they are representative of the Company's core operations and are used in the management of the business.
Adjusted EBITDA represents earnings before interest, taxes, depreciation and amortization, adjusted for items that are not part of the Company's core operations. These items include impairment, restructuring and reorganization charges, acquisition costs, including transaction costs and the amortization of the inventory step-up, property losses and recoveries, actuarial gains and losses associated with the remeasurement of the Company's defined benefit pension and other postretirement benefit plans, gains and losses on the sale of real estate, gains and losses on divestitures, and other items from time to time that are not part of the Company's core operations. Management believes adjusted EBITDA is useful to investors as it is representative of the Company's core operations and is used in the management of the business, including decisions concerning the allocation of resources and assessment of performance.
Reconciliation of net income attributable to The Timken Company to adjusted net income, adjusted EBITDA and adjusted EBITDA Margin:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
2025 |
2024 |
|
|
| Net Sales |
$ |
1,140.3 |
|
$ |
1,190.3 |
|
|
|
| Net Income Attributable to The Timken Company |
78.3 |
|
103.5 |
|
|
|
Net Income Attributable to The Timken Company as a Percentage of Sales |
6.9 |
% |
8.7 |
% |
|
|
| Adjustments: |
|
|
|
|
| Acquisition intangible amortization |
19.0 |
|
20.0 |
|
|
|
Impairment, restructuring and reorganization charges (1) |
3.2 |
|
4.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition-related charges (2) |
— |
|
4.7 |
|
|
|
|
|
|
|
|
Gain on sale of certain assets (3) |
(1.2) |
|
(0.7) |
|
|
|
|
|
|
|
|
CEO succession expenses (4) |
8.6 |
|
— |
|
|
|
| Noncontrolling interest of above adjustments |
3.8 |
|
(0.1) |
|
|
|
Provision for income taxes (7) |
(13.1) |
|
(6.5) |
|
|
|
| Adjusted Net Income |
$ |
98.6 |
|
$ |
125.7 |
|
|
|
| Net income attributable to noncontrolling interest |
13.1 |
|
7.1 |
|
|
|
| Provision for income taxes (as reported) |
26.9 |
|
42.7 |
|
|
|
| Interest expense |
26.5 |
|
32.2 |
|
|
|
| Interest income |
(2.3) |
|
(2.8) |
|
|
|
Depreciation and amortization expense (5) |
55.0 |
|
54.9 |
|
|
|
| Less: Acquisition intangible amortization |
19.0 |
|
20.0 |
|
|
|
Less: Noncontrolling interest (6) |
3.8 |
|
(0.1) |
|
|
|
Less: Provision for income taxes (7) |
(13.1) |
|
(6.5) |
|
|
|
| Adjusted EBITDA |
$ |
208.1 |
|
$ |
246.4 |
|
|
|
| Adjusted EBITDA Margin (% of net sales) |
18.2 |
% |
20.7 |
% |
|
|
(1) Impairment, restructuring and reorganization charges (including items recorded in cost of products sold) relate to: (i) plant closures; (ii) the rationalization of certain plants; (iii) severance related to cost reduction initiatives; and (iv) impairment of assets. The Company re-assesses its operating footprint and cost structure periodically, and makes adjustments as needed that result in restructuring charges. However, management believes these actions are not representative of the Company’s core operations.
(2) Acquisition-related charges represent deal-related expenses associated with completed transactions and any resulting inventory step-up impact.
(3) Represents the net gain resulting from the sale of certain assets.
(4) On March 31, 2025, the Company announced that Tarak B. Mehta, President and CEO of the Company would be departing from the Company, effective immediately, and Richard G. Kyle will be serving as interim President and CEO. CEO succession expenses primarily relate to the cost of the settlement agreement with Mr. Mehta in connection with his departure, net of stock compensation expense for stock awards forfeited. During 2024, the Company announced that Mr. Kyle, President and CEO of the Company would be retiring from his position as CEO as of February 15, 2025 and that Mr. Mehta would be appointed CEO on September 5, 2024. CEO succession expenses also include the acceleration of certain stock compensation awards for Mr. Kyle and other one-time costs associated with the transition in 2024.
(5) Depreciation and amortization shown excludes depreciation recognized in reorganization charges, if any.
(6) Represents the noncontrolling interest impact of the adjustments listed above, as well as the reversal of uncertain tax positions related to Timken India Limited.
(7) Provision for income taxes includes the net tax impact on pre-tax adjustments (listed above), the impact of discrete tax items recorded during the respective periods as well as other adjustments to reflect the use of one overall effective tax rate on adjusted pre-tax income in interim periods.
Diluted earnings and adjusted earnings per share in the table below are based on net income attributable to The Timken Company and adjusted net income, respectively, in the table above.
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
2025 |
2024 |
|
|
| Diluted earnings per share (EPS) |
$ |
1.11 |
|
$ |
1.46 |
|
|
|
| Adjusted EPS |
$ |
1.40 |
|
$ |
1.77 |
|
|
|
| Diluted Shares |
70,513,937 |
|
70,880,015 |
|
|
|
Free Cash Flow:
Free cash flow represents net cash provided by operating activities less capital expenditures. Management believes free cash flow is useful to investors because it is a meaningful indicator of cash generated from operating activities available for the execution of its business strategy.
Reconciliation of net cash provided by operating activities to free cash flow:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
2025 |
2024 |
|
|
| Net cash provided by operating activities |
$ |
58.6 |
|
$ |
49.3 |
|
|
|
| Capital expenditures |
(35.2) |
|
(44.1) |
|
|
|
| Free cash flow |
$ |
23.4 |
|
$ |
5.2 |
|
|
|
Ratio of Net Debt to Adjusted EBITDA:
The ratio of net debt to adjusted EBITDA for the trailing twelve months represents total debt less cash and cash equivalents divided by adjusted EBITDA for the trailing twelve months. The Company presents net debt to adjusted EBITDA because it believes it is more representative of the Company's financial position as it is reflective of the Company's ability to cover its net debt obligations with results from its core operations. Net income for the trailing twelve months ended March 31, 2025 and December 31, 2024 was $356.1 million and $375.3 million, respectively. Net debt to adjusted EBITDA for the trailing twelve months was 2.2 and 2.0 at March 31, 2025 and December 31, 2024.
Reconciliation of Net income to Adjusted EBITDA for the trailing twelve months:
|
|
|
|
|
|
|
|
|
|
Twelve Months Ended |
|
March 31, 2025 |
December 31, 2024 |
| Net income |
$ |
356.1 |
|
$ |
375.3 |
|
| Provision for income taxes |
103.1 |
|
118.9 |
|
| Interest expense |
119.4 |
|
125.1 |
|
| Interest income |
(14.4) |
|
(14.9) |
|
| Depreciation and amortization |
221.6 |
|
221.8 |
|
| Consolidated EBITDA |
785.8 |
|
826.2 |
|
| Adjustments: |
|
|
Impairment, restructuring and reorganization charges (1) |
$ |
16.5 |
|
$ |
17.8 |
|
Corporate pension and other postretirement benefit related income (2) |
(1.3) |
|
(1.3) |
|
Acquisition-related charges (3) |
8.3 |
|
13.0 |
|
Gain on sale of certain assets (4) |
(15.2) |
|
(14.7) |
|
Property losses and related expenses (5) |
1.2 |
|
1.2 |
|
CEO succession expenses (6) |
12.3 |
|
3.7 |
|
|
|
|
|
|
|
| Total adjustments |
20.7 |
|
18.6 |
|
| Adjusted EBITDA |
$ |
806.5 |
|
$ |
844.8 |
|
| Net Debt |
$ |
1,751.0 |
|
$ |
1,689.5 |
|
| Ratio of Net Debt to Adjusted EBITDA |
2.2 |
|
2.0 |
|
(1) Impairment, restructuring and reorganization charges (including items recorded in cost of products sold) relate to: (i) plant closures; (ii) the rationalization of certain plants; (iii) severance related to cost reduction initiatives; and (iv) impairment of assets. The Company re-assesses its operating footprint and cost structure periodically, and makes adjustments as needed that result in restructuring charges. However, management believes these actions are not representative of the Company’s core operations.
(2) Corporate pension and other postretirement benefit related income represents actuarial gains that resulted from the remeasurement of plan assets and obligations as a result of changes in assumptions or experience. The Company recognizes actuarial gains and losses in connection with the annual remeasurement in the fourth quarter, or if specific events trigger a remeasurement.
(3) Acquisition-related charges represent deal-related expenses associated with completed transactions and any resulting inventory step-up impact.
(4) Represents the net gain resulting from sale of certain assets. Gain on sale of certain assets for the third quarter of 2024 included $13.8 million gain related to the sale of the Gaffney, South Carolina plant.
(5) Represents property loss and related expenses incurred during the periods presented resulting from property loss that occurred during the second quarter of 2024 at one of the Company's plants in Slovakia.
(6) On March 31, 2025, the Company announced that Tarak B. Mehta, President and CEO of the Company would be departing from the Company, effective immediately, and Richard G. Kyle will be serving as interim President and CEO. During 2024, the Company announced that Mr. Kyle, President and CEO of the Company would be retiring from his position as CEO as of February 15, 2025 and that Mr. Mehta would be appointed CEO on September 5, 2024. CEO succession expenses for the twelve months ended March 31, 2025 relate to the cost of the settlement agreement with Mr. Mehta in connection with his departure, net of stock compensation expense for stock awards forfeited, plus the acceleration of certain stock compensation awards for Mr. Kyle in connection with his retirement, and other one-time costs associated with the transition in 2024.
FORWARD-LOOKING STATEMENTS
Certain statements set forth in this Form 10-Q and in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 that are not historical in nature (including the Company's forecasts, beliefs and expectations) are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, Management’s Discussion and Analysis contains numerous forward-looking statements. Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “outlook,” “intend,” “may,” “possible,” “potential,” “predict,” “project” or other similar words, phrases or expressions. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this Annual Report on Form 10-K. The Company cautions readers that actual results may differ materially from those expressed or implied in forward-looking statements made by or on behalf of the Company due to a variety of factors, such as:
•deterioration in world economic conditions, or in economic conditions in any of the geographic regions in which the Company or its customers or suppliers conduct business, including adverse effects from a global economic slowdown or recession, pandemics, epidemics or other public health concerns, terrorism, or hostilities. This includes: political risks associated with the potential instability of governments and legal systems in countries in which the Company or its customers or suppliers conduct business, changes in currency valuations, additional costs, taxes and restrictions related to repatriation of cash in international jurisdictions, strained geopolitical relations between countries in which we have significant operations, and recent world events that have increased macroeconomic risks posed by international trade disputes, tariffs and sanctions;
•negative impacts to the Company's business, results of operations, financial position or liquidity, disruption to the Company's supply chains, and negative impacts to operations;
•the effects of fluctuations in customer demand on sales, product mix and prices in the industries in which the Company operates. This includes: the ability of the Company to respond to rapid changes in customer demand, disruptions to the Company's supply chain, the effects of customer or supplier bankruptcies or liquidations, the impact of changes in industrial business cycles, the ability of the Company to effectively adjust the prices for its products in response to changing dynamics, the effects of distributor inventory corrections reflecting de-stocking of the supply chain and whether conditions of fair trade continue in the Company's markets;
•competitive factors, including changes in market penetration, increasing price competition by existing or new foreign and domestic competitors, the introduction of new products or services by existing and new competitors, competition for skilled labor and new technology that may impact the way the Company’s products are produced, sold or distributed;
•changes in operating costs. This includes: the effect of changes in the Company’s manufacturing processes; changes in costs associated with varying levels of operations and manufacturing capacity; availability and cost of raw materials, energy and fuel; changes in costs associated with the effects of tariffs; disruptions to the Company's supply chain and logistical issues associated with port closures or delays or increased costs; changes in the expected costs associated with product warranty claims especially in industry segments with potential high claim values; changes in the global regulatory landscape (including with respect to climate change or other environmental regulations); changes resulting from inventory management and cost reduction initiatives; the effects of unplanned plant shutdowns; the effects of government-imposed restrictions, commercial requirements and Company goals associated with climate change and emissions or other sustainability initiatives; and changes in the cost of labor and benefits;
•the success of the Company’s operating plans, announced programs, initiatives and capital investments; the ability to integrate acquired companies and to address material issues both identified and not uncovered during the Company's due diligence review; and the ability of acquired companies to achieve satisfactory operating results, including results being accretive to earnings, realization of synergies and expected cash flow generation;
•the Company’s ability to maintain appropriate relations with unions or works councils that represent Company employees in certain locations in order to avoid disruptions of business;
•the continued attraction, retention and development of management, other key employees, and other skilled personnel, the successful development and execution of succession plans and management of other human capital matters;
•unanticipated litigation, claims, investigations, remediation or assessments. This includes: claims, investigations or problems related to intellectual property, product liability or warranty, foreign export, sanctions and trade laws, government procurement regulations, competition and anti-bribery laws, climate change, PTFE, PFAS, other environmental or health and safety issues, data privacy and taxes;
•the rapidly evolving global regulatory landscape and the corresponding heightened operational complexity and compliance risks;
•changes in worldwide financial and capital markets, including fluctuations in interest rates, impacting the availability of financing on satisfactory terms as a result of financial stress affecting the banking system or otherwise, which affect the Company’s cost of funds and/or ability to raise capital, as well as customer demand and the ability of customers to obtain financing to purchase the Company’s products or equipment that contain the Company’s products;
•the Company's ability to satisfy its obligations and comply with covenants under its debt agreements, maintain favorable credit ratings and its ability to renew or refinance borrowings on favorable terms;
•the impact on the Company's pension obligations and assets due to changes in interest rates, investment performance and other tactics designed to reduce risk; and
•those items identified under Item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 or this Form 10-Q.
Additional risks relating to the Company's business, the industries in which the Company operates, or the Company's common shares may be described from time to time in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"). All of these risk factors are difficult to predict, are subject to material uncertainties that may affect actual results and may be beyond the Company's control.
Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the above list should not be considered to be a complete list. Except as required by the federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Refer to information appearing under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q. Furthermore, a discussion of market risk exposures is included in Part II, Item 7A. Quantitative and Qualitative Disclosure about Market Risk, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. There have been no material changes in reported market risk since the inclusion of this discussion in the Company’s Annual Report on Form 10-K referenced above.
ITEM 4. CONTROLS AND PROCEDURES
(a)Disclosure Controls and Procedures
As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s principal executive officer and principal financial officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)). Based upon that evaluation, the principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures were effective as of the end of the period covered by this report.
(b)Changes in Internal Control Over Financial Reporting
During the Company’s fiscal quarter ended March 31, 2025, there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
The Company is involved in various claims and legal actions arising in the ordinary course of business. SEC regulations require us to disclose certain information about legal proceedings when a governmental authority is a party to the proceedings if we reasonably believe that such proceedings may result in monetary sanctions above a stated threshold. Pursuant to such regulations, the Company uses a threshold of $1 million or more for purposes of determining whether disclosure of any such proceedings is required. We believe matters under this threshold are not material to the Company. In the opinion of management, the ultimate disposition of open proceedings as of March 31, 2025 will not have a material adverse effect on the Company’s consolidated financial position or annual results of operations.
Item 1A. Risk Factors
The Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, included a detailed discussion of our risk factors. There have been no material changes to the risk factors included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. Investors should not interpret the disclosure of any risk factor to imply that the risk has not already materialized.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Common Shares
The following table provides information about purchases by the Company of its common shares during the quarter ended March 31, 2025.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Period |
Total number
of shares
purchased (1)
|
Average
price paid
per share (2)
|
Total number of shares purchased as part of publicly announced plans or programs |
Maximum
number of
shares that
may yet
be purchased
under the plans
or programs (3)
|
| 1/1/2025 - 1/31/2025 |
— |
|
$ |
— |
|
— |
|
2,138,990 |
|
| 2/1/2025 - 2/28/2025 |
238,210 |
|
81.87 |
|
122,730 |
|
2,016,260 |
|
| 3/1/2025 - 3/31/2025 |
173,331 |
|
75.47 |
|
173,331 |
|
1,842,929 |
|
| Total |
411,541 |
|
$ |
79.17 |
|
296,061 |
|
— |
|
(1)Of the shares purchased in February, 115,480 represent common shares of the Company that were owned and tendered by employees to exercise stock options and to satisfy withholding obligations in connection with the exercise of stock options or vesting of restricted shares.
(2)For shares tendered in connection with the vesting of restricted shares, the average price paid per share is an average calculated using the daily high and low of the Company's common shares as quoted on the New York Stock Exchange at the time of vesting. For shares tendered in connection with the exercise of stock options, the price paid is the real-time trading stock price at the time the options are exercised.
(3)On February 12, 2021, the Company's Board of Directors approved a new share purchase plan, effective March 1, 2021, pursuant to which the Company may purchase up to ten million of its common shares, in the aggregate. This share purchase plan expires on February 28, 2026. Under this plan, the Company may purchase shares from time to time in open market purchases or privately negotiated transactions, and it may make all or part of the purchases pursuant to accelerated share repurchases or Rule 10b5-1 plans.
Item 5. Other Information
During the fiscal quarter ended March 31, 2025, no director or officer (as defined in Exchange Act Rule 16a-1(f)) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as each term is defined in Regulation 408(a) of Regulation S-K).
Item 6. Exhibits
|
|
|
|
|
|
|
Separation Agreement and Release, dated as of March 31, 2025, by and between Tarak B. Mehta and The Timken Company. |
|
|
|
Performance-Based Restricted Stock Units Agreement, dated as of April 22, 2025, by and between The Timken Company and Richard G. Kyle (covering the performance period from January 1, 2023 through December 31, 2025), granted pursuant to The Timken Company 2019 Equity and Incentive Compensation Plan, as may be amended or amended and restated from time to time. |
|
|
|
Performance-Based Restricted Stock Units Agreement, dated as of April 22, 2025, by and between The Timken Company and Richard G. Kyle (covering the performance period from January 1, 2024 through December 31, 2026), granted pursuant to The Timken Company 2019 Equity and Incentive Compensation Plan, as may be amended or amended and restated from time to time. |
|
|
|
Deferred Shares Agreement, dated as of April 22, 2025, by and between The Timken Company and Richard G. Kyle, granted pursuant to The Timken Company 2019 Equity and Incentive Compensation Plan, as may be amended or amended and restated from time to time. |
|
|
|
Certification of Richard G. Kyle, President and Chief Executive Officer (principal executive officer) of The Timken Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
Certification of Philip D. Fracassa, Executive Vice President and Chief Financial Officer (principal financial officer and principal accounting officer) of The Timken Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
Certifications of Richard G. Kyle, President and Chief Executive Officer (principal executive officer) and Philip D. Fracassa, Executive Vice President and Chief Financial Officer (principal financial officer and principal accounting officer) of The Timken Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
Financial statements from the quarterly report on Form 10-Q of The Timken Company for the quarter ended March 31, 2025 filed on April 30, 2025, formatted in Inline XBRL: (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Cash Flows and (v) the Notes to the Consolidated Financial Statements. |
|
|
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
THE TIMKEN COMPANY |
|
|
|
| Date: April 30, 2025 |
|
By: /s/ Richard G. Kyle |
|
|
Richard G. Kyle President and Chief Executive Officer (Principal Executive Officer) |
|
|
|
| Date: April 30, 2025 |
|
By: /s/ Philip D. Fracassa |
|
|
Philip D. Fracassa Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
EX-10.1
2
exhibit101.htm
EX-10.1
Document
SEPARATION AGREEMENT AND RELEASE
This Separation Agreement and Release (the “Agreement”) is made by and between Tarak B. Mehta (“Employee”) and The Timken Company (the “Company”).
WHEREAS, Employee has been employed by the Company as President and Chief Executive Officer; and
WHEREAS, Employee’s employment with the Company will be terminated on the Termination Date (as defined below).
NOW THEREFORE, in exchange for and in consideration of the promises and covenants contained herein, along with other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and Employee agree as follows:
1.Separation from Employment. Employee and the Company agree that on March 31, 2025 (“Termination Date”) Employee’s employment with the Company and all of its subsidiaries and affiliates will terminate. Effective as of the Termination Date, if, or to the extent, Employee has not already resigned, Employee will further resign: (a) as a director on the Board of Directors of the Company and from all other offices of the Company to which Employee has been elected by the Board of Directors of the Company, or to which Employee has otherwise been appointed; (b) from all administrative, fiduciary or other positions Employee may hold with respect to arrangements or plans for, of or relating to the Company; and (c) from any other directorship, office, or position of any corporation, partnership, joint venture, trust or other enterprise if Employee is serving in such directorship, office, or position at the request of the Company. The Company hereby consents to and accepts such resignations. Employee shall promptly execute all necessary documents to effectuate such resignations and shall promptly complete and execute any necessary documentation requested by the Company or required to be filed with any governmental authority in furtherance of a resignation or in furtherance of operations. The Company and Employee agree that Employee’s termination of employment on the Termination Date will be deemed to be a Termination of Employment under Section 4.1(b) of (and as defined in) the Severance Agreement, dated as of September 5, 2024, between Employee and the Company (the “Severance Agreement”) and deemed not to be the type of Termination of Employment described in clauses (i), (ii), or (iii) of Section 4.1(b) of the Severance Agreement. Employee agrees that Employee waives any claim that Employee might have to reemployment with the Company, and Employee agrees not to seek future employment with the Company. Employee agrees that the Company has no obligation to employ, hire, or rehire Employee, or to consider Employee for hire, and that this right of the Company is purely contractual and is in no way discriminatory or retaliatory.
2.Benefits Following Termination Date.
2.1The Company agrees to provide to Employee the compensation and benefits set forth on Exhibit A of this Agreement (the “Separation Benefits”), subject to Employee voluntarily and knowingly executing this Agreement within fifty (50) days after the Termination Date and letting this Agreement become effective in accordance with its terms.
2.2Employee agrees that all outstanding awards granted to Employee pursuant to The Timken Company 2019 Equity and Incentive Compensation Plan, as may be amended from time to time (the “Incentive Plan”) under: (a) the Time-Based Restricted Stock Units Agreement, with a date of grant of September 5, 2024, (b) the Time-Based Restricted Stock Units Agreement, with a date of grant of February 13, 2025, (c) the Performance-Based Restricted Stock Units Agreement, with a date of grant of September 5, 2024, (d) the Performance-Based Restricted Stock Units Agreement, with a date of grant of February 13, 2025, and (e) the Deferred Shares Agreement, with a date of grant of September 5, 2024, will be terminated and forfeited as of the Termination Date without any payment or further obligation of the Company or its affiliates. Employee agrees that the Separation Benefits are in full satisfaction of all payment obligations the Company and its subsidiaries may have under the Severance Agreement, the Incentive Plan, and other compensation arrangements of the Company and its subsidiaries.
3.Confidentiality, Non-Disparagement, and Communication with Authorities.
3.1Confidentiality. Employee agrees not to at any time talk about, write about, or otherwise publicize or disclose to any third party the terms of this Agreement or any fact concerning its negotiation, execution, or implementation except with (a) an attorney, accountant, or tax advisor engaged by Employee to advise them with respect to the Agreement; (b) the Internal Revenue Service or other governmental agency upon proper request; and (c) their immediate family, provided that all such persons agree in advance to keep said information confidential and not to disclose it to others. Further, Employee will continue to comply with the confidentiality, non-disclosure and non-use covenants set forth in Section 4 of Employee’s Non-Disclosure, Restrictive Covenant, and Assignment Agreement with the Company (the “Non-Disclosure Agreement”), which remains in full force and effect after the Termination Date.
3.2Non-disparagement. Employee agrees that Employee shall not make, or cause to be made, any statement or communication regarding the Company, its subsidiaries or affiliates to any third parties that disparages the reputation or business of the Company or any of its subsidiaries or affiliates.
3.3Communication with Authorities. Nothing in this Agreement prevents Employee from providing, without prior notice to the Company, information to governmental authorities regarding possible legal violations or otherwise testifying or participating in any investigation or proceeding by any governmental authorities regarding possible legal violations.
4.Restrictive Covenants.
4.1Severance Agreement. By signing this Agreement, Employee reaffirms that Employee will continue to abide by the covenants set forth in Section 6 of the Severance Agreement, which survive Employee’s termination of employment, and Employee agrees with the Company that Section 6.2 of the Severance Agreement is hereby amended to read as follows:
“For a period of time beginning upon the Termination Date and ending upon the eighteenth-month anniversary of the Termination Date, Employee shall not (a) engage or participate, directly or indirectly, in any Competitive Activity (as defined in Section 1.7 of the Severance Agreement) or (b) solicit or cause to be solicited on behalf of a competitor any person or entity which was a customer of the Company during the term of the Severance Agreement, if Employee had any direct responsibility for such customer while employed by the Company.”
Employee and the Company agree that the business enterprises described in the definition of “Competitive Activity” under Section 1.7 of the Severance Agreement include, but are not limited to, the following entities: JTEKT Corporation, NTN Corporation, NSK Ltd., Schaeffler AG, AB SKF, RBC Bearings Incorporated, and Regal Rexnord Corporation.
4.2Non-Disclosure Agreement. By signing this Agreement, Employee also reaffirms that Employee will continue to abide by the covenants set forth in Sections 4, 5, 6, 7, 8, 9, 10 and 11 of Employee’s Non-Disclosure Agreement, which survive Employee’s termination of employment, and Employee agrees with the Company that Sections 7 and 8 of the Non-Disclosure Agreement are hereby amended so that all occurrences in Sections 7 and 8 of the Non-Disclosure Agreement of the phrase “then for one year following my Separation” will be replaced with “then for 18 months following my Separation”.
5.Employee’s Release of All Claims.
5.1Release of the Company by Employee. Employee, for themself and their heirs, administrators, executors, spouses (if any), successors, estates, representatives, agents, and assigns, does hereby voluntarily and knowingly forever release and discharge the Company, both as Employee’s employer and as sponsor and/or administrator of employee benefits plans established for the benefit of its employees, and each of their respective current and former corporate parents, related or affiliated entities, agents, servants, parents, subsidiaries, affiliates, divisions, members, trustees, partners, officers, directors, employees, successors, predecessors, administrators, insurers and assigns (the “Released Parties”) from any and all civil suits or causes of action, damages, expenses, costs, and liabilities of any kind whatsoever. Employee expressly acknowledges that the claims released by this Paragraph include:
a.Any and all claims for breach of the Company’s policies, rules, regulations, handbooks or manuals, or for breach of express or implied contracts, express or implied covenants of good faith, quasi-contracts, promissory estoppel, unjust enrichment, negligent and/or intentional misrepresentations, or fraud; and
b.Any and all claims for wrongful discharge, defamation, invasion of privacy, intentional and/or negligent infliction of emotional distress, loss of spousal consortium, violations of public policy, violations of whistleblower statutes, retaliation, intentional torts, employment intentional torts, common law torts, or any other personal injury; and
c.Any and all claims for back pay, front pay, or other wages or benefits, for any kind of compensatory, special or consequential damages, punitive or liquidated damages, lost or unpaid benefits of any kind or nature, attorneys’ fees, costs, disbursements or expenses of any kind whatsoever; and
d.Any and all claims arising under federal, state or local constitutions, statutes, laws, rules, regulations, executive orders or common law regulating employer conduct or prohibiting employment discrimination, harassment, retaliation and/or interference based upon age, race, color, sex, religion, handicap or disability, national origin, genetic information, sexual orientation, veteran or marital status, or any other protected category or characteristic, including but not limited to any and all claims arising under the Age Discrimination in Employment Act of 1967 (“ADEA”), as amended; Title VII of the Civil Rights Act of 1964, as amended; the Civil Rights Act of 1991; 42 U.S.C. §1983; the Americans with Disabilities Act (“ADA”), as amended; the Rehabilitation Act of 1973, as amended; the Equal Pay Act, as amended; the Employee Retirement Income Security Act (“ERISA”); the Family and Medical Leave Act (“FMLA”), as amended; the Genetic Information Nondiscrimination Act of 2008; the Fair Labor Standards Act (“FLSA”); the Lilly Ledbetter Fair Pay Act of 2009; Older Workers Benefit Protection Act of 1990 (“OWBPA”); 18 U.S.C.§1514(A), also known as the Sarbanes-Oxley Act; the Worker Adjustment and Retraining Notification Act (“WARN”), 29 U.S.C. Sec. 2101, et seq.; Ohio Fair Employment Practices Act – Ohio Rev. Code Ann. § 4112.01, et seq.; Ohio Whistleblower Protection Law – Ohio Rev. Code Ann. § 4113.51, et seq.; Ohio Statutory Provisions Regarding Retaliation/Discrimination for Filing Worker’s Compensation Claim – Ohio Rev. Code Ann. § 4123.90; Ohio Equal Pay Law – Ohio Rev. Code Ann. § 4111.13 et seq.; Ohio State Wage Payment and Work Hour Laws - Ohio Rev. Code Ann. § 4111.01, et seq.; Ohio Political Action of Employees Laws; Ohio Witness and Juror Leave Laws - Ohio Rev. Code Ann. § 2313.18, et seq.; Ohio Voting Leave Laws - Ohio Rev. Code Ann. § 3599.06, et seq.; Ohio Military Family Medical Leave Act - Ohio Rev. Code Ann. § 5906.01, et seq.; Ohio Whistleblower Protection Law - Ohio Rev. Code Ann. § 4113.52; and any other federal, state or local civil, labor, pension, wage-hour or human rights law, federal or state public policy, contract or tort law; any claim arising under federal or state common law, including, but not limited to, constructive or wrongful discharge or intentional or negligent infliction of emotional distress; and any claim for costs or attorney’s fees; and
e. Any and all claims arising out of or related to Employee’s service (i) as a member of the Board of Directors of the Company; (ii) in any administrative, fiduciary or other position during their employment with the Company including, without limitation, service on any charitable foundation or benefit plan committee sponsored by the Company; and (iii) in other directorship, office or position of any subsidiary or affiliate corporation, partnership, joint venture, trust or other enterprise in which service in such directorship, office, or position was at the request of the Company.
Employee specifically understands that the release of their claims under this Agreement includes, without limitation, waiver and release of all claims against the Company and Released Parties, and Employee is not waiving any rights or claims first arising after the date Employee signs this Agreement or that cannot be waived by law. Nothing in this Agreement shall waive, release, or otherwise affect Employee’s vested interest in the Company’s tax-qualified 401(k) plan or right to pursue unemployment compensation benefits.
5.2Protected Rights. Notwithstanding anything to the contrary in this Agreement (or in any other agreement, contract or arrangement with the Company or its subsidiaries or affiliates, or in any policy, procedure or practice of the Company or its subsidiaries or affiliates (collectively, the “Arrangements”)): (a) nothing in the Arrangements or otherwise limits Employee’s right to any monetary award offered by a government-administered whistleblower award program for providing information directly to a government agency (including the Securities and Exchange Commission pursuant to Section 21F of the Securities Exchange Act of 1934, as amended, the Dodd-Frank Wall Street Reform and Consumer Protection Act or The Sarbanes-Oxley Act of 2002); and (b) nothing in the Arrangements or otherwise prevents Employee from, without prior notice to the Company, providing information (including documents) to governmental authorities or agencies regarding possible legal violations or otherwise testifying or participating in any investigation or proceeding by any governmental authorities or agencies regarding possible legal violations (for purpose of clarification, Employee is not prohibited from providing information (including documents) voluntarily to the Securities and Exchange Commission pursuant to Section 21F of the Securities Exchange Act of 1934, as amended). The Company nonetheless asserts and does not waive its attorney-client privilege over any information appropriately protected by privilege. The terms of this paragraph are referred to as the “Protected Rights,” and the terms of this Agreement are subject to the Protected Rights.
5.3Affirmations. As of the date of the signing of this Agreement, Employee agrees that they: (a) have been paid for all hours worked; (b) have reported any injuries they may have received during the course of employment with the Company; (c) have not made any allegation or brought any claims and are unaware of any facts or circumstances that might give rise to a claim or charge of discrimination, harassment, retaliation, unpaid wages, overtime, or ethical violation on behalf of any of the Released Parties; and (d) are unaware of any facts or circumstances that any of the Released Parties may have violated or failed to comply with any federal, state or local law, ordinance or regulation.
5.4Compliance with Older Workers’ Benefit Protection Act and Applicable State Laws, Advice of Counsel, Consideration, Revocation Period, and Other Information. Employee specifically acknowledges that the waiver and discharge of their claims under this Agreement include, without limitation, waiver and release of all claims against the Company and the Released Parties under the Age Discrimination in Employment Act of 1967, as amended (“ADEA”). To satisfy the requirements of the Older Workers Benefit Protection Act of 1990 (“OWBPA”), if applicable, Employee acknowledges and agrees as follows:
a.Employee is over eighteen (18) years of age; they have read the Agreement; the Agreement is written in plain and understandable language; they fully understand the Agreement; and they are entering into the Agreement freely and voluntarily and without duress, coercion or undue influence of any kind;
b.This Agreement applies to any rights Employee may have under the ADEA prior to executing this Agreement, and is inapplicable to any rights they may have under the ADEA that arise after they execute this Agreement;
c.Employee waives their claims under the ADEA in exchange for the covenants made herein, and acknowledges that certain of the benefits provided herein constitute consideration of value to which Employee would not otherwise have been entitled, including Section 2 of this Agreement;
d.Employee was and hereby is advised to consult an attorney in connection with this Agreement, and prior to the execution of this Agreement and have been fully advised concerning its contents; and
e.Employee has a period of fifty (50) calendar days to consider the terms of this Agreement. Employee may execute this Agreement before expiration of the fifty (50) day period; however, they are not required to do so. If Employee signs this Agreement before the expiration of the fifty (50) day period, they agree that they are knowingly and expressly waiving the time period. After Employee signs this Agreement, Employee has seven (7) days from that date to change Employee’s mind and revoke this Agreement. This Agreement will not become effective until after the expiration of the seven- (7) day revocation period. To revoke this Agreement, Employee must clearly communicate the decision in writing to Hansal Patel, Executive Vice President, General Counsel and Secretary of The Timken Company, 4500 Mount Pleasant St. NW, PO Box 6929, North Canton, OH 44720, Mail Code WHQ-01, by the seventh (7th) day following the date Employee signs this Agreement. Employee understands and agrees that should they revoke the release and waiver as to claims under the Age Discrimination in Employment Act of 1967, as amended, the Company’s obligations under this Agreement will become null and void.
5.5Non-Admission. This Agreement and the terms hereof are not and shall not be used or construed as evidence of an admission by the Company respecting the validity of any potential claims Employee may or may not have against the Company or of the Company’s liability with respect to any such potential claims or of any wrongdoing by the Company whatsoever. This Agreement shall not be offered as evidence for any purpose in any litigation, proceeding, or otherwise other than for the purpose of enforcing the terms of this Agreement.
6.Return of Property. Employee agrees that in connection with their termination from employment, they shall immediately return to the Company all Company documents and property in their possession or control (whether in hard copy or on electronic or magnetic media), including, but not limited to, keys, price lists, supplier and customer lists, salary and benefit information, files, reports, all correspondence both internal and external (memoranda, letters, quotes, etc.), business plans, budgets, designs, laptop computer, fax, copier, printer, automobile, cell phone or other electronic devices, and any and all other property of the Company. Further, Employee agrees to fully comply with Section 5 of Employee’s Non-Disclosure Agreement, which remains in full for and effect after the Termination Date.
7.Reasonable Assistance. In order to ensure a smooth transition from Employee’s employment with the Company, for a period of one year following the Termination Date, Employee shall provide reasonable assistance to and cooperation with the Company in connection with any matter concerning which the Employee had knowledge or responsibility while employed by the Company.
8.U.S. Defend Trade Secrets Act Notice of Immunity. The U.S. Defend Trade Secrets Act of 2016 (“DTSA”) provides that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (A) is made in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, the DTSA provides that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order.
9.Knowing and Voluntary Execution. Employee states and represents that they have carefully read this Agreement and knows and understands the contents thereof, and that they have executed the same as their own free act and deed. Employee also acknowledges that they have had the opportunity to ask questions about each and every provision of this Agreement and that they fully understand the effect of the provisions contained herein upon their legal rights.
10.Tax Matters. By signing this Agreement, Employee acknowledges that Employee will be solely responsible for any taxes (other than the employer portion of payroll taxes) which may be imposed on Employee as a result of the Separation Benefits or the provisions of this Agreement, that all amounts payable to Employee under or in connection with this Agreement will be subject to applicable tax withholding by the Company or its subsidiaries or affiliates, and that the Company has not made any representations or guarantees regarding the tax result for Employee with respect to this Agreement or the Separation Benefits.
11.Section 409A. The payments and benefits under this Agreement are intended to comply with, or be exempt from, Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively “Code Section 409A”). For purposes of Code Section 409A, Employee’s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. In no event may Employee, directly or indirectly, designate the calendar year of any payment to be made under this Agreement. With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits that are deferred compensation subject to Code Section 409A, the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year, and such payments shall be made on or before the last day of Employee’s taxable year following the taxable year in which the expense occurred.
12.Entire Agreement. This Agreement and the Severance Agreement contain the entire agreement between the Company and Employee regarding Employee’s departure from the Company. Employee hereby acknowledges that the Separation Benefits are in full satisfaction of any severance benefits under the Severance Agreement, any equity award agreements, and any other compensation arrangements between Employee and the Company. Notwithstanding the foregoing, the restrictive covenants in Sections 3 and 4 of this Agreement and Section 6 of the Severance Agreement do not supersede the restrictive covenants in any other types of agreements entered into between the Company and Employee, including, without limitation, the restrictive covenants in Employee’s Non-Disclosure Agreement and those entered into in connection with grants of equity awards. Each such set of restrictive covenants remain in full force and effect and are binding on Employee pursuant to their terms.
13.Executed Counterparts. This Agreement may be executed in one or more counterparts, and any executed copy of this Agreement shall be valid and have the same force and effect as the originally executed Agreement.
14.Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Ohio.
15.Modification. No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by the Employee and the Company.
16.Severability. In the event that any provision in this Agreement is determined to be legally invalid or unenforceable by any court of competent jurisdiction, and cannot be modified to be enforceable, the affected provision shall be stricken from the Agreement, and the remaining terms of the Agreement and its enforceability shall remain unaffected.
17.Assignability. Employee’s obligations and agreements under this Agreement shall be binding on their heirs, executors, legal representatives and assigns and shall inure to the benefit of any successors and assigns of the Company. The Company may, at any time, assign this Agreement or any of its rights or obligations arising hereunder to any party.
18.Attorneys’ Fees. Each party hereto shall bear its own attorneys’ fees and costs in connection with the negotiation, preparation and closing of this Agreement.
19.Effective Date. This Agreement is effective when signed by both parties, and the revocation period described in Section 5.4(e) has expired without Employee revoking the Agreement.
[Signature page follows]
IN WITNESS WHEREOF, Employee and the Company hereby execute this Agreement on the dates indicated below.
Dated: March 31, 2025
/s/ Tarak B. Mehta
Witness EMPLOYEE
TARAK B. MEHTA
Dated: March 31, 2025 THE TIMKEN COMPANY
By: /s/ Hansal N. Patel
Hansal N. Patel
Its: Executive Vice President, General Counsel & Pursuant to Section 2.1 of this Separation Agreement, the Separation Benefits are:
Secretary
EXHIBIT A
Separation Benefits
1. The Company will pay a lump sum cash amount equal to $5,500,000 to Employee within sixty (60) days following the Termination Date.
2. The Company will pay a lump sum cash amount equal to $900,000 to Employee within sixty (60) days following September 5, 2025.
3. The Company will pay a lump sum cash amount equal to $900,000 to Employee within ten (10) days following February 13, 2026.
4. The Company will pay a lump sum cash amount equal to $1,950,000 to Employee within ten (10) days following February 13, 2027.
5. The Company will make available to Employee, at Employee’s option, outplacement services provided through a third-party outplacement services provider selected by the Company. Such services will be available for a period of twelve (12) months following the Termination Date or, if earlier, until Employee secures subsequent employment.
EX-10.2
3
exhibit102.htm
EX-10.2
Document
THE TIMKEN COMPANY
Performance-Based Restricted Stock Units Agreement
THIS PERFORMANCE-BASED RESTRICTED STOCK UNITS AGREEMENT (this “Agreement”) is made by and between The Timken Company, an Ohio corporation (the “Company”), and the undersigned Grantee pursuant to The Timken Company 2019 Equity and Incentive Compensation Plan, as may be amended or amended and restated from time to time (the “Plan”), effective as of the Date of Grant, which is provided, along with additional grant details, on the secure web portal of the third-party vendor used by the Company for the administration of the Plan (such information is referred to herein as the “Grant Summary”). All terms used in this Agreement with initial capital letters that are defined in the Plan and not otherwise defined herein shall have the meanings assigned to them in the Plan.
1.Grant and Payment of PRSUs. Subject to the terms and conditions of the Plan and this Agreement, Grantee has been granted on the Date of Grant the number of Performance-Based Restricted Stock Units specified in the Grant Summary (the “PRSUs”). Subject to the attainment of the Management Objectives described in Section 3 of this Agreement, Grantee may earn from 0% to 200% of the PRSUs. The PRSUs will become payable in accordance with the provisions of Section 6 of this Agreement if the Restriction Period, which commences on the Date of Grant and ends on the date of payment of the Vested PRSUs, lapses and Grantee’s right to receive payment for the PRSUs becomes nonforfeitable (“Vest,” “Vesting” or “Vested”) in accordance with Sections 3 and 4 of this Agreement.
2.PRSUs Not Transferrable. None of the PRSUs nor any interest therein or in any Common Shares underlying such PRSUs will be transferable other than by will or the laws of descent and distribution prior to payment.
3.Vesting of PRSUs.
(a)Subject to Sections 4 and 5 of this Agreement, the PRSUs will Vest on the basis of the relative achievement of the Management Objective or Management Objectives approved by the Committee for such PRSUs (the “Performance Metrics”) for the three-year period specified in the Grant Summary (the “Performance Period”) as follows:
(i)The applicable percentage of the PRSUs that shall be earned by Grantee for the Performance Period shall be determined by reference to the Performance Matrix for the Performance Period approved by the Committee for such PRSUs (the “Performance Matrix”);
(ii)In the event that the Company’s achievement with respect to one of the Performance Metrics is between the performance levels specified in the Performance Matrix, the applicable percentage of the PRSUs that shall be earned by Grantee for the Performance Period shall be determined by the Committee using straight-line interpolation; and
(iii)The Vesting of the PRSUs pursuant to this Section 3 or Section 4 shall be contingent upon a determination of the Committee that the Performance Metrics, as described in this Section 3, have been satisfied.
(b)If the Committee determines that a change in the business, operations, corporate structure or capital structure of the Company, the manner in which it conducts business or other events or circumstances render the Performance Metrics specified in this Section 3 to be unsuitable, the Committee may modify such Performance Metrics or any related minimum acceptable level of achievement, in whole or in part, as the Committee deems appropriate and equitable.
(c)Subject to Sections 3(a) and 3(b), the PRSUs earned with respect to the Performance Period will Vest provided that Grantee remains in the continuous employ of the Company or a Subsidiary from the Date of Grant through the earlier of (i) February 15, 2026, or (ii) the two-month anniversary of the date on which both a successor Chief Executive Officer of the Company (“Successor CEO”) is appointed or elected by the Board as a successor to Grantee after the Date of Grant and such Successor CEO commences serving in such role (the earlier of the date specified in (i) or (ii), the “Transition Date”). For purposes of this Agreement, the continuous employment of Grantee with the Company or a Subsidiary will not be deemed to have been interrupted, and Grantee will not be deemed to have ceased to be an employee of the Company or a Subsidiary, by reason of the transfer of Grantee’s employment among the Company and its Subsidiaries.
4.Alternative Vesting of PRSUs. Notwithstanding Section 3 of this Agreement, and subject to the payment provisions of Section 6 hereof, in the event of the circumstances described below, Grantee will Vest in some or all of the PRSUs as follows:
(a)Death or Disability: If Grantee dies or becomes Permanently Disabled (as defined below) while employed by the Company or any Subsidiary prior to the Transition Date, then Grantee will Vest in a number of PRSUs equal to the product of (i) the number of PRSUs in which Grantee would have Vested in accordance with the terms and conditions of Section 3 if Grantee had remained in the continuous employ of the Company or a Subsidiary from the Date of Grant until the payment date of the Vested PRSUs under Section 6(a) or the occurrence of a Change in Control to the extent a Replacement Award is not provided, whichever occurs first, multiplied by (ii) a fraction (in no case greater than 1) the numerator of which is the number of whole months from the first day of the Performance Period through the date of such death or Permanent Disability and the denominator of which is the number of whole months from the first day of the Performance Period through December 31, 2025. PRSUs that Vest in accordance with this Section 4(a) will be paid as set forth in Section 6(a) of this Agreement. For purposes of this Agreement, “Permanently Disabled” means that Grantee has qualified for long-term disability benefits under a disability plan or program of the Company or, in the absence of a disability plan or program of the Company, under a government-sponsored disability program and is “disabled” within the meaning of Section 409A(a)(2)(C) of the Code.
(b)Change in Control:
(i)Upon a Change in Control that occurs during the Restriction Period (A) while Grantee is an employee of the Company or a Subsidiary on or prior to the Transition Date, (B) after the Transition Date if Grantee remains in the continuous employ of the Company or a Subsidiary from the Date of Grant through the Transition Date, or (C) during the period that Grantee is deemed to be in the continuous employ of the Company or a Subsidiary pursuant to Section 4(a), 4(c) or 4(d), any PRSUs that remain outstanding
and have not yet Vested as of such Change in Control will Vest (except to the extent that a Replacement Award for the PRSUs is provided to Grantee) as follows: the Performance Period will terminate and the Committee as constituted immediately before the Change in Control will determine and certify the Vested PRSUs based on actual performance through the most recent date prior to the Change in Control for which achievement of the Performance Metrics can reasonably be determined. PRSUs that Vest in accordance with this Section 4(b)(i) will be paid as set forth in Section 6(b) of this Agreement.
(ii)For purposes of this Agreement, a “Replacement Award” shall mean an award (A) of performance-based restricted stock units, (B) that has a value at least equal to the value of the PRSUs, (C) that relates to publicly traded equity securities of the Company or its successor in the Change in Control (or another entity that is affiliated with the Company or its successor following the Change in Control) (the “Successor”), (D) the tax consequences of which, under the Code, if Grantee is subject to U.S. federal income tax under the Code, are not less favorable to Grantee than the tax consequences of the PRSUs, (E) that Vests upon a termination of Grantee’s employment with the Company or the Successor for Good Reason by Grantee or without Cause (as defined in Section 4(d)) by the Company or the Successor within a period of two years after the Change in Control based on actual performance through the date of such termination, and (F) the other terms and conditions of which are not less favorable to Grantee than the terms and conditions of the PRSUs (including the provisions that would apply in the event of a subsequent Change in Control). A Replacement Award may be granted only to the extent it conforms to the requirements of Treasury Regulation 1.409A-3(i)(5)(iv)(B) or otherwise does not result in the PRSUs or Replacement Award failing to comply with Section 409A of the Code. Without limiting the generality of the foregoing, the Replacement Award may take the form of a continuation of the PRSUs if the requirements of the preceding sentence are satisfied. The determination of whether the conditions of this Section 4(b)(ii) are satisfied will be made by the Committee, as constituted immediately before the Change in Control, in its sole discretion.
(iii)For purposes of Section 4(b)(ii), “Good Reason” means: a material reduction in the nature or scope of the responsibilities, authorities or duties of Grantee attached to Grantee’s position held immediately prior to the Change in Control, a change of more than 60 miles in the location of Grantee’s principal office immediately prior to the Change in Control, or a material reduction in Grantee’s remuneration upon or after the Change in Control; provided, that no later than 90 days following an event constituting Good Reason, Grantee gives notice to the Successor of the occurrence of such event and the Successor fails to cure the event within 30 days following the receipt of such notice.
(iv)If a Replacement Award is provided, (A) the terms of the Replacement Award will govern the Vesting and payment of the Replacement Award and (B) notwithstanding anything in this Agreement to the contrary, any outstanding PRSUs which at the time of the Change in Control are not subject to a “substantial risk of forfeiture” (within the meaning of Section 409A of the Code) will be deemed to be Vested at the time of such
Change in Control and will be paid as provided for in Section 6(b) of this Agreement.
(c)Divestiture: If Grantee’s employment with the Company or a Subsidiary terminates prior to the Transition Date as the result of a Divestiture (as defined below), then Grantee shall Vest in a number of PRSUs equal to the product of (i) the number of PRSUs in which Grantee would have Vested in accordance with the terms and conditions of Section 3 if Grantee had remained in the continuous employ of the Company or a Subsidiary from the Date of Grant until the payment date of the Vested PRSUs under Section 6(a) or the occurrence of a Change in Control to the extent a Replacement Award is not provided, whichever occurs first, multiplied by (ii) a fraction (in no case greater than 1) the numerator of which is the number of whole months from the first day of the Performance Period through the date of such termination and the denominator of which is the number of whole months from the first day of the Performance Period through December 31, 2025. PRSUs that Vest in accordance with this Section 4(c) will be paid as set forth in Section 6(a) of this Agreement. For the purposes of this Agreement, the term “Divestiture” means a permanent disposition to a Person other than the Company or any Subsidiary of a plant or other facility or property at which Grantee performs a majority of Grantee’s services whether such disposition is effected by means of a sale of assets, a sale of Subsidiary stock or otherwise.
(d)Termination Without Cause: Subject to Section 8 hereof, if Grantee’s employment with the Company or a Subsidiary is terminated by the Company or a Subsidiary other than for Cause prior to the Transition Date, then Grantee shall Vest in a number of PRSUs equal to the product of (i) the number of PRSUs in which Grantee would have Vested in accordance with the terms and conditions of Section 3 as if Grantee had remained in the continuous employ of the Company or a Subsidiary from the Date of Grant until the payment date of the Vested PRSUs under Section 6(a) or the occurrence of a Change in Control to the extent a Replacement Award is not provided, whichever occurs first, multiplied by (ii) a fraction (in no case greater than 1) the numerator of which is the number of whole months from the first day of the Performance Period through the date of such termination and the denominator of which is the number of whole months from the first day of the Performance Period through December 31, 2025. PRSUs that Vest in accordance with this Section 4(d) will be paid as set forth in Section 6(a) of this Agreement
For purposes of this Agreement, “Cause” means: (i) an intentional act of fraud, embezzlement or theft in connection with Grantee’s duties with the Company or a Subsidiary (or the Successor, if applicable); (ii) an intentional wrongful disclosure of secret processes or confidential information of the Company or a Subsidiary (or the Successor, if applicable); (iii) an intentional, wrongful engagement in any competitive activity that would constitute a material breach of Grantee’s duty of loyalty to the Company or a Subsidiary (or the Successor, if applicable); (iv) the willful misconduct in the performance of Grantee’s duties to the Company or a Subsidiary (or the Successor, if applicable); or (v) gross negligence in the performance of Grantee’s duties to the Company or a Subsidiary (or the Successor, if applicable). No act, or failure to act, on the part of Grantee shall be deemed “intentional” unless done or omitted to be done by Grantee not in good
faith and without reasonable belief that Grantee’s action or omission was in or not opposed to the best interest of the Company or a Subsidiary (or the Successor, if applicable); provided, that for any Grantee who is party to an individual severance or employment agreement defining Cause, “Cause” will have the meaning set forth in such agreement.
5.Forfeiture of PRSUs. The PRSUs will be forfeited automatically and without further notice (a) immediately, to the extent the PRSUs have not Vested pursuant to Section 3 or Section 4 by March 15 of the year following the year in which the Performance Period ends, or (b) upon the date Grantee ceases to be an employee of the Company or a Subsidiary for any reason (other than as described in Section 4) prior to the Transition Date.
6.Form and Time of Payment of PRSUs.
(a)General. Subject to Sections 5 and 6(b), payment for Vested PRSUs will be made in cash or Common Shares (as determined by the Committee) between January 1 and March 15 of the year following the year in which the Performance Period ends.
(b)Other Payment Event. Notwithstanding Section 6(a), to the extent that the PRSUs are Vested on the date of a Change in Control, Grantee will receive payment for Vested PRSUs in cash or Common Shares (as determined by the Committee) within 10 days of the date of the Change in Control; provided, however, that if such Change in Control would not qualify as a permissible date of distribution under Section 409A(a)(2)(A) of the Code, and the regulations thereunder, and where Section 409A of the Code applies to such distribution, Grantee is entitled to receive the corresponding payment on the date that would have otherwise applied pursuant to Section 6(a).
7.Payment of Dividend Equivalents. With respect to each of the PRSUs covered by this Agreement, Grantee shall be credited on the records of the Company with dividend equivalents in an amount equal to the amount per Common Share of any cash dividends declared by the Board on the outstanding Common Shares as if the PRSUs were issued Common Shares during the period beginning on the Date of Grant and ending either on the date on which Grantee receives payment for the PRSUs pursuant to Section 6 hereof or at the time when the PRSUs are forfeited in accordance with Section 5 of this Agreement. These dividend equivalents will accumulate without interest and, subject to the terms and conditions of this Agreement, will be paid at the same time, to the same extent and in the same manner, in cash or Common Shares (as determined by the Committee) as the PRSUs for which the dividend equivalents were credited.
8.Release Requirement. Notwithstanding any provision of this Agreement to the contrary, the PRSUs will not Vest or become payable pursuant to Section 4(d) of this Agreement as a result of a Termination Without Cause or pursuant to Section 4(b)(ii)(E) of this Agreement as a result of a termination of employment for Good Reason by Grantee or without Cause by the Company or the Successor unless, to the extent permitted by applicable law, Grantee signs, does not revoke, and agrees to be bound by a general release of claims in a form provided by the Company or the Successor which release must be signed, and any applicable revocation period shall have expired within 30 or 60 days (as specified by the Company or the Successor at the time such release is provided) of Grantee’s termination of employment (such 30 day or 60 day period, as applicable, the “Review Period”). In the event such Review Period begins in one taxable year of
Grantee, and ends in a second taxable year of Grantee, then to the extent necessary to avoid any penalties or additional taxes under Section 409A of the Code, no payment shall be made before the second taxable year.
9.Clawback; Detrimental Activity and Recapture.
(a)Notwithstanding anything in this Agreement to the contrary, Grantee acknowledges and agrees that this Agreement and the award described herein (and any settlement thereof) are subject to the terms and conditions of the Company’s clawback policy or policies (if any) as may be in effect from time to time, including specifically to implement Section 10D of the Exchange Act and any applicable rules or regulations promulgated thereunder (including applicable rules and regulations of any national securities exchange on which the Common Shares at any point may be traded) (the “Compensation Recovery Policy”), and that applicable terms of this Agreement shall be deemed superseded by and subject to the terms and conditions of the Compensation Recovery Policy from and after the effective date thereof. By accepting this award under the Plan and pursuant to this Agreement, Grantee consents to be bound by the terms of the Compensation Recovery Policy, to the extent applicable to Grantee, and agrees and acknowledges to fully cooperate with and assist the Company in connection with any of Grantee’s obligations to the Company pursuant to the Compensation Recovery Policy, and agrees that the Company may enforce its rights under the Compensation Recovery Policy through any and all reasonable means permitted under applicable law as it deems necessary or desirable under the Compensation Recovery Policy, in each case from and after the effective dates thereof. Such cooperation and assistance shall include, but is not limited to, executing, completing and submitting any documentation necessary to facilitate the recovery or recoupment by the Company from Grantee of any such amounts, including from Grantee’s accounts or from any other compensation, to the extent permissible under Section 409A of the Code.
(b)Nothing in this Agreement or otherwise (i) limits Grantee’s right to any monetary award offered by a government-administered whistleblower award program for providing information directly to a government agency (including the Securities and Exchange Commission pursuant to Section 21F of the Exchange Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or The Sarbanes-Oxley Act of 2002, or any comparable government agency pursuant to any comparable legislation in non-U.S. jurisdictions) or (ii) prevents Grantee from providing, without prior notice to the Company, information to governmental authorities regarding possible legal violations or otherwise testifying or participating in any investigation or proceeding by any governmental authorities regarding possible legal violations, and for purpose of clarity Grantee is not prohibited from providing information voluntarily to the Securities and Exchange Commission pursuant to Section 21F of the Exchange Act or to any comparable government agencies pursuant to applicable legislation in non-U.S. jurisdictions.
10.Compliance with Law. The Company shall make reasonable efforts to comply with all applicable federal and state securities laws; provided, however, notwithstanding any other provision of this Agreement, the Company shall not be obligated to issue any of the Common Shares covered by this Agreement if the issuance thereof would result in violation of any such law.
11.Adjustments. Subject to Section 12 of the Plan, the Committee shall make any adjustments in the number of PRSUs or kind of shares of stock or other securities
underlying the PRSUs covered by this Agreement, and other terms and provisions, that the Committee shall determine is equitably required to prevent any dilution or enlargement of Grantee’s rights under this Agreement that otherwise would result from any (a) extraordinary cash dividend, stock dividend, stock split, combination of shares, recapitalization or other change in the capital structure of the Company, (b) merger, consolidation, separation, reorganization, partial or complete liquidation or other distribution of assets involving the Company or (c) other transaction or event having an effect similar to any of those referred to in Sections 11(a) or 11(b) hereof. Moreover, in the event that any transaction or event described or referred to in the immediately preceding sentence, or a Change in Control, shall occur, the Committee shall provide in substitution of any or all of Grantee’s rights under this Agreement such alternative consideration (including cash), if any, as the Committee shall determine in good faith to be equitable under the circumstances.
12.Withholding Taxes. To the extent that the Company or a Subsidiary is required to withhold federal, state, local, employment, or foreign taxes or other amounts, or, to the extent permitted under Section 409A of the Code, any other applicable taxes, in connection with Grantee’s right to receive Common Shares under this Agreement (regardless of whether Grantee is entitled to the delivery of any Common Shares at that time), and the amounts available to the Company for such withholding are insufficient, it will be a condition to the receipt of any Common Shares or any other benefit provided for under this Agreement that Grantee make arrangements satisfactory to the Company for payment of the balance of such taxes or other amounts required to be withheld. Grantee may satisfy such tax obligation by paying the Company cash via personal check. Alternatively, Grantee may elect that all or any part of such tax obligation be satisfied by the Company’s retention of a portion of the Common Shares provided for under this Agreement or by Grantee’s surrender of a portion of the Common Shares that Grantee has owned. If an election is made to satisfy Grantee’s tax obligation with the release or surrender of Common Shares, the Common Shares used for tax or other withholding will be valued at an amount equal to the fair market value of such Common Shares on the date the benefit is to be included in Grantee’s income. In no event will the fair market value of the Common Shares to be withheld and delivered pursuant to this Section 12 exceed the maximum amount of taxes that could be required to be withheld.
13.Right to Terminate Employment. No provision of this Agreement will limit in any way whatsoever any right that the Company or a Subsidiary may otherwise have to terminate the employment of Grantee at any time.
14.Relation to Other Benefits. Any economic or other benefit to Grantee under this Agreement or the Plan will not be taken into account in determining any benefits to which Grantee may be entitled under any profit-sharing, retirement or other benefit or compensation plan maintained by the Company or a Subsidiary and will not affect the amount of any life insurance coverage available to any beneficiary under any life insurance plan covering employees of the Company or a Subsidiary.
15.Amendments. Any amendment to the Plan will be deemed to be an amendment to this Agreement to the extent that the amendment is applicable to this Agreement; provided, however, that, subject to the terms of the Plan, no amendment will materially impair the rights of Grantee with respect to the PRSUs without Grantee’s consent. Notwithstanding the foregoing, the limitation requiring the consent of Grantee to certain amendments will not apply to any amendment that is deemed necessary by the Company to ensure
compliance with Section 409A of the Code, Section 10D of the Exchange Act, or other applicable law.
16.Severability. In the event that one or more of the provisions of this Agreement is invalidated for any reason by a court of competent jurisdiction, any provision so invalidated will be deemed to be separable from the other provisions of this Agreement, and the remaining provisions of this Agreement will continue to be valid and fully enforceable.
17.Choice of Law. This Agreement is made under, and shall be construed in accordance with, the internal substantive laws of the State of Ohio. Grantee agrees that the state and federal courts located in the State of Ohio shall have jurisdiction in any action, suit or proceeding against Grantee based on or arising out of this Agreement and Grantee hereby: (a) submits to the personal jurisdiction of such courts; (b) consents to service of process in connection with any action, suit or proceeding against Grantee; and (c) waives any other requirement (whether imposed by statute, rule of court or otherwise) with respect to personal jurisdiction, venue or service of process.
18.Compliance with Section 409A of the Code. To the extent applicable, it is intended that this Agreement and the Plan comply with the provisions of Section 409A of the Code, so that the income inclusion provisions of Section 409A(a)(1) of the Code do not apply to Grantee. This Agreement and the Plan shall be administered in a manner consistent with this intent. Reference to Section 409A of the Code is to Section 409A of the Internal Revenue Code of 1986, as amended, and will also include any regulations or any other formal guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service.
[SIGNATURES ON THE FOLLOWING PAGE]
The undersigned Grantee hereby acknowledges receipt of an executed original of this Agreement and accepts the award of PRSUs covered hereby, subject to the terms and conditions of the Plan and the terms and conditions herein above set forth.
/s/ Richard G. Kyle
Grantee
Date: April 22, 2025
This Agreement is executed by the Company on this 22nd day of April, 2025.
The Timken Company
By /s/ Hansal N. Patel
Name: Hansal N. Patel
Title: Executive Vice President, General Counsel and Secretary
EX-10.3
4
exhibit103.htm
EX-10.3
Document
THE TIMKEN COMPANY
Performance-Based Restricted Stock Units Agreement
THIS PERFORMANCE-BASED RESTRICTED STOCK UNITS AGREEMENT (this “Agreement”) is made by and between The Timken Company, an Ohio corporation (the “Company”), and the undersigned Grantee pursuant to The Timken Company 2019 Equity and Incentive Compensation Plan, as may be amended or amended and restated from time to time (the “Plan”), effective as of the Date of Grant, which is provided, along with additional grant details, on the secure web portal of the third-party vendor used by the Company for the administration of the Plan (such information is referred to herein as the “Grant Summary”). All terms used in this Agreement with initial capital letters that are defined in the Plan and not otherwise defined herein shall have the meanings assigned to them in the Plan.
1.Grant and Payment of PRSUs. Subject to the terms and conditions of the Plan and this Agreement, Grantee has been granted on the Date of Grant the number of Performance-Based Restricted Stock Units specified in the Grant Summary (the “PRSUs”). Subject to the attainment of the Management Objectives described in Section 3 of this Agreement, Grantee may earn from 0% to 200% of the PRSUs. The PRSUs will become payable in accordance with the provisions of Section 6 of this Agreement if the Restriction Period, which commences on the Date of Grant and ends on the date of payment of the Vested PRSUs, lapses and Grantee’s right to receive payment for the PRSUs becomes nonforfeitable (“Vest,” “Vesting” or “Vested”) in accordance with Sections 3 and 4 of this Agreement.
2.PRSUs Not Transferrable. None of the PRSUs nor any interest therein or in any Common Shares underlying such PRSUs will be transferable other than by will or the laws of descent and distribution prior to payment.
3.Vesting of PRSUs.
(a)Subject to Sections 4 and 5 of this Agreement, the PRSUs will Vest on the basis of the relative achievement of the Management Objective or Management Objectives approved by the Committee for such PRSUs (the “Performance Metrics”) for the three-year period specified in the Grant Summary (the “Performance Period”) as follows:
(i)The applicable percentage of the PRSUs that shall be earned by Grantee for the Performance Period shall be determined by reference to the Performance Matrix for the Performance Period approved by the Committee for such PRSUs (the “Performance Matrix”);
(ii)In the event that the Company’s achievement with respect to one of the Performance Metrics is between the performance levels specified in the Performance Matrix, the applicable percentage of the PRSUs that shall be earned by Grantee for the Performance Period shall be determined by the Committee using straight-line interpolation; and
(iii)The Vesting of the PRSUs pursuant to this Section 3 or Section 4 shall be contingent upon a determination of the Committee that the Performance Metrics, as described in this Section 3, have been satisfied.
(b)If the Committee determines that a change in the business, operations, corporate structure or capital structure of the Company, the manner in which it conducts business or other events or circumstances render the Performance Metrics specified in this Section 3 to be unsuitable, the Committee may modify such Performance Metrics or any related minimum acceptable level of achievement, in whole or in part, as the Committee deems appropriate and equitable.
(c)Subject to Sections 3(a) and 3(b), the PRSUs earned with respect to the Performance Period will Vest provided that Grantee remains in the continuous employ of the Company or a Subsidiary from the Date of Grant through the earlier of (i) February 15, 2026, or (ii) the two-month anniversary of the date on which both a successor Chief Executive Officer of the Company (“Successor CEO”) is appointed or elected by the Board as a successor to Grantee after the Date of Grant and such Successor CEO commences serving in such role (the earlier of the date specified in (i) or (ii), the “Transition Date”). For purposes of this Agreement, the continuous employment of Grantee with the Company or a Subsidiary will not be deemed to have been interrupted, and Grantee will not be deemed to have ceased to be an employee of the Company or a Subsidiary, by reason of the transfer of Grantee’s employment among the Company and its Subsidiaries.
4.Alternative Vesting of PRSUs. Notwithstanding Section 3 of this Agreement, and subject to the payment provisions of Section 6 hereof, in the event of the circumstances described below, Grantee will Vest in some or all of the PRSUs as follows:
(a)Death or Disability: If Grantee dies or becomes Permanently Disabled (as defined below) while employed by the Company or any Subsidiary prior to the Transition Date, then Grantee will Vest in a number of PRSUs equal to the product of (i) the number of PRSUs in which Grantee would have Vested in accordance with the terms and conditions of Section 3 if Grantee had remained in the continuous employ of the Company or a Subsidiary from the Date of Grant until the payment date of the Vested PRSUs under Section 6(a) or the occurrence of a Change in Control to the extent a Replacement Award is not provided, whichever occurs first, multiplied by (ii) a fraction (in no case greater than 1) the numerator of which is the number of whole months from the first day of the Performance Period through the date of such death or Permanent Disability and the denominator of which is the number of whole months from the first day of the Performance Period through February 15, 2026. PRSUs that Vest in accordance with this Section 4(a) will be paid as set forth in Section 6(a) of this Agreement. For purposes of this Agreement, “Permanently Disabled” means that Grantee has qualified for long-term disability benefits under a disability plan or program of the Company or, in the absence of a disability plan or program of the Company, under a government-sponsored disability program and is “disabled” within the meaning of Section 409A(a)(2)(C) of the Code.
(b)Change in Control:
(i)Upon a Change in Control that occurs during the Restriction Period (A) while Grantee is an employee of the Company or a Subsidiary on or prior to the Transition Date, (B) after the Transition Date if Grantee remains in the continuous employ of the Company or a Subsidiary from the Date of Grant through the Transition Date, or (C) during the period that Grantee is deemed to be in the continuous employ of the Company or a Subsidiary pursuant to Section 4(a), 4(c) or 4(d), any PRSUs that remain outstanding
and have not yet Vested as of such Change in Control will Vest (except to the extent that a Replacement Award for the PRSUs is provided to Grantee) as follows: the Performance Period will terminate and the Committee as constituted immediately before the Change in Control will determine and certify the Vested PRSUs based on actual performance through the most recent date prior to the Change in Control for which achievement of the Performance Metrics can reasonably be determined. PRSUs that Vest in accordance with this Section 4(b)(i) will be paid as set forth in Section 6(b) of this Agreement.
(ii)For purposes of this Agreement, a “Replacement Award” shall mean an award (A) of performance-based restricted stock units, (B) that has a value at least equal to the value of the PRSUs, (C) that relates to publicly traded equity securities of the Company or its successor in the Change in Control (or another entity that is affiliated with the Company or its successor following the Change in Control) (the “Successor”), (D) the tax consequences of which, under the Code, if Grantee is subject to U.S. federal income tax under the Code, are not less favorable to Grantee than the tax consequences of the PRSUs, (E) that Vests upon a termination of Grantee’s employment with the Company or the Successor for Good Reason by Grantee or without Cause (as defined in Section 4(d)) by the Company or the Successor within a period of two years after the Change in Control based on actual performance through the date of such termination, and (F) the other terms and conditions of which are not less favorable to Grantee than the terms and conditions of the PRSUs (including the provisions that would apply in the event of a subsequent Change in Control). A Replacement Award may be granted only to the extent it conforms to the requirements of Treasury Regulation 1.409A-3(i)(5)(iv)(B) or otherwise does not result in the PRSUs or Replacement Award failing to comply with Section 409A of the Code. Without limiting the generality of the foregoing, the Replacement Award may take the form of a continuation of the PRSUs if the requirements of the preceding sentence are satisfied. The determination of whether the conditions of this Section 4(b)(ii) are satisfied will be made by the Committee, as constituted immediately before the Change in Control, in its sole discretion.
(iii)For purposes of Section 4(b)(ii), “Good Reason” means: a material reduction in the nature or scope of the responsibilities, authorities or duties of Grantee attached to Grantee’s position held immediately prior to the Change in Control, a change of more than 60 miles in the location of Grantee’s principal office immediately prior to the Change in Control, or a material reduction in Grantee’s remuneration upon or after the Change in Control; provided, that no later than 90 days following an event constituting Good Reason, Grantee gives notice to the Successor of the occurrence of such event and the Successor fails to cure the event within 30 days following the receipt of such notice.
(iv)If a Replacement Award is provided, (A) the terms of the Replacement Award will govern the Vesting and payment of the Replacement Award and (B) notwithstanding anything in this Agreement to the contrary, any outstanding PRSUs which at the time of the Change in Control are not subject to a “substantial risk of forfeiture” (within the meaning of Section 409A of the Code) will be deemed to be Vested at the time of such
Change in Control and will be paid as provided for in Section 6(b) of this Agreement.
(c)Divestiture: If Grantee’s employment with the Company or a Subsidiary terminates prior to the Transition Date as the result of a Divestiture (as defined below), then Grantee shall Vest in a number of PRSUs equal to the product of (i) the number of PRSUs in which Grantee would have Vested in accordance with the terms and conditions of Section 3 if Grantee had remained in the continuous employ of the Company or a Subsidiary from the Date of Grant until the payment date of the Vested PRSUs under Section 6(a) or the occurrence of a Change in Control to the extent a Replacement Award is not provided, whichever occurs first, multiplied by (ii) a fraction (in no case greater than 1) the numerator of which is the number of whole months from the first day of the Performance Period through the date of such termination and the denominator of which is the number of whole months from the first day of the Performance Period through February 15, 2026. PRSUs that Vest in accordance with this Section 4(c) will be paid as set forth in Section 6(a) of this Agreement. For the purposes of this Agreement, the term “Divestiture” means a permanent disposition to a Person other than the Company or any Subsidiary of a plant or other facility or property at which Grantee performs a majority of Grantee’s services whether such disposition is effected by means of a sale of assets, a sale of Subsidiary stock or otherwise.
(d)Termination Without Cause: Subject to Section 8 hereof, if Grantee’s employment with the Company or a Subsidiary is terminated by the Company or a Subsidiary other than for Cause prior to the Transition Date, then Grantee shall Vest in a number of PRSUs equal to the product of (i) the number of PRSUs in which Grantee would have Vested in accordance with the terms and conditions of Section 3 as if Grantee had remained in the continuous employ of the Company or a Subsidiary from the Date of Grant until the payment date of the Vested PRSUs under Section 6(a) or the occurrence of a Change in Control to the extent a Replacement Award is not provided, whichever occurs first, multiplied by (ii) a fraction (in no case greater than 1) the numerator of which is the number of whole months from the first day of the Performance Period through the date of such termination and the denominator of which is the number of whole months from the first day of the Performance Period through February 15, 2026. PRSUs that Vest in accordance with this Section 4(d) will be paid as set forth in Section 6(a) of this Agreement
For purposes of this Agreement, “Cause” means: (i) an intentional act of fraud, embezzlement or theft in connection with Grantee’s duties with the Company or a Subsidiary (or the Successor, if applicable); (ii) an intentional wrongful disclosure of secret processes or confidential information of the Company or a Subsidiary (or the Successor, if applicable); (iii) an intentional, wrongful engagement in any competitive activity that would constitute a material breach of Grantee’s duty of loyalty to the Company or a Subsidiary (or the Successor, if applicable); (iv) the willful misconduct in the performance of Grantee’s duties to the Company or a Subsidiary (or the Successor, if applicable); or (v) gross negligence in the performance of Grantee’s duties to the Company or a Subsidiary (or the Successor, if applicable). No act, or failure to act, on the part of Grantee shall be deemed “intentional” unless done or omitted to be done by Grantee not in good
faith and without reasonable belief that Grantee’s action or omission was in or not opposed to the best interest of the Company or a Subsidiary (or the Successor, if applicable); provided, that for any Grantee who is party to an individual severance or employment agreement defining Cause, “Cause” will have the meaning set forth in such agreement.
5.Forfeiture of PRSUs. The PRSUs will be forfeited automatically and without further notice (a) immediately, to the extent the PRSUs have not Vested pursuant to Section 3 or Section 4 by March 15 of the year following the year in which the Performance Period ends, or (b) upon the date Grantee ceases to be an employee of the Company or a Subsidiary for any reason (other than as described in Section 4) prior to the Transition Date.
6.Form and Time of Payment of PRSUs.
(a)General. Subject to Sections 5 and 6(b), payment for Vested PRSUs will be made in cash or Common Shares (as determined by the Committee) between January 1 and March 15 of the year following the year in which the Performance Period ends.
(b)Other Payment Event. Notwithstanding Section 6(a), to the extent that the PRSUs are Vested on the date of a Change in Control, Grantee will receive payment for Vested PRSUs in cash or Common Shares (as determined by the Committee) within 10 days of the date of the Change in Control; provided, however, that if such Change in Control would not qualify as a permissible date of distribution under Section 409A(a)(2)(A) of the Code, and the regulations thereunder, and where Section 409A of the Code applies to such distribution, Grantee is entitled to receive the corresponding payment on the date that would have otherwise applied pursuant to Section 6(a).
7.Payment of Dividend Equivalents. With respect to each of the PRSUs covered by this Agreement, Grantee shall be credited on the records of the Company with dividend equivalents in an amount equal to the amount per Common Share of any cash dividends declared by the Board on the outstanding Common Shares as if the PRSUs were issued Common Shares during the period beginning on the Date of Grant and ending either on the date on which Grantee receives payment for the PRSUs pursuant to Section 6 hereof or at the time when the PRSUs are forfeited in accordance with Section 5 of this Agreement. These dividend equivalents will accumulate without interest and, subject to the terms and conditions of this Agreement, will be paid at the same time, to the same extent and in the same manner, in cash or Common Shares (as determined by the Committee) as the PRSUs for which the dividend equivalents were credited.
8.Release Requirement. Notwithstanding any provision of this Agreement to the contrary, the PRSUs will not Vest or become payable pursuant to Section 4(d) of this Agreement as a result of a Termination Without Cause or pursuant to Section 4(b)(ii)(E) of this Agreement as a result of a termination of employment for Good Reason by Grantee or without Cause by the Company or the Successor unless, to the extent permitted by applicable law, Grantee signs, does not revoke, and agrees to be bound by a general release of claims in a form provided by the Company or the Successor which release must be signed, and any applicable revocation period shall have expired within 30 or 60 days (as specified by the Company or the Successor at the time such release is provided) of Grantee’s termination of employment (such 30 day or 60 day period, as applicable, the “Review Period”). In the event such Review Period begins in one taxable year of
Grantee, and ends in a second taxable year of Grantee, then to the extent necessary to avoid any penalties or additional taxes under Section 409A of the Code, no payment shall be made before the second taxable year.
9.Clawback; Detrimental Activity and Recapture.
(a)Notwithstanding anything in this Agreement to the contrary, Grantee acknowledges and agrees that this Agreement and the award described herein (and any settlement thereof) are subject to the terms and conditions of the Company’s clawback policy or policies (if any) as may be in effect from time to time, including specifically to implement Section 10D of the Exchange Act and any applicable rules or regulations promulgated thereunder (including applicable rules and regulations of any national securities exchange on which the Common Shares at any point may be traded) (the “Compensation Recovery Policy”), and that applicable terms of this Agreement shall be deemed superseded by and subject to the terms and conditions of the Compensation Recovery Policy from and after the effective date thereof. By accepting this award under the Plan and pursuant to this Agreement, Grantee consents to be bound by the terms of the Compensation Recovery Policy, to the extent applicable to Grantee, and agrees and acknowledges to fully cooperate with and assist the Company in connection with any of Grantee’s obligations to the Company pursuant to the Compensation Recovery Policy, and agrees that the Company may enforce its rights under the Compensation Recovery Policy through any and all reasonable means permitted under applicable law as it deems necessary or desirable under the Compensation Recovery Policy, in each case from and after the effective dates thereof. Such cooperation and assistance shall include, but is not limited to, executing, completing and submitting any documentation necessary to facilitate the recovery or recoupment by the Company from Grantee of any such amounts, including from Grantee’s accounts or from any other compensation, to the extent permissible under Section 409A of the Code.
(b)Nothing in this Agreement or otherwise (i) limits Grantee’s right to any monetary award offered by a government-administered whistleblower award program for providing information directly to a government agency (including the Securities and Exchange Commission pursuant to Section 21F of the Exchange Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or The Sarbanes-Oxley Act of 2002, or any comparable government agency pursuant to any comparable legislation in non-U.S. jurisdictions) or (ii) prevents Grantee from providing, without prior notice to the Company, information to governmental authorities regarding possible legal violations or otherwise testifying or participating in any investigation or proceeding by any governmental authorities regarding possible legal violations, and for purpose of clarity Grantee is not prohibited from providing information voluntarily to the Securities and Exchange Commission pursuant to Section 21F of the Exchange Act or to any comparable government agencies pursuant to applicable legislation in non-U.S. jurisdictions.
10.Compliance with Law. The Company shall make reasonable efforts to comply with all applicable federal and state securities laws; provided, however, notwithstanding any other provision of this Agreement, the Company shall not be obligated to issue any of the Common Shares covered by this Agreement if the issuance thereof would result in violation of any such law.
11.Adjustments. Subject to Section 12 of the Plan, the Committee shall make any adjustments in the number of PRSUs or kind of shares of stock or other securities
underlying the PRSUs covered by this Agreement, and other terms and provisions, that the Committee shall determine is equitably required to prevent any dilution or enlargement of Grantee’s rights under this Agreement that otherwise would result from any (a) extraordinary cash dividend, stock dividend, stock split, combination of shares, recapitalization or other change in the capital structure of the Company, (b) merger, consolidation, separation, reorganization, partial or complete liquidation or other distribution of assets involving the Company or (c) other transaction or event having an effect similar to any of those referred to in Sections 11(a) or 11(b) hereof. Moreover, in the event that any transaction or event described or referred to in the immediately preceding sentence, or a Change in Control, shall occur, the Committee shall provide in substitution of any or all of Grantee’s rights under this Agreement such alternative consideration (including cash), if any, as the Committee shall determine in good faith to be equitable under the circumstances.
12.Withholding Taxes. To the extent that the Company or a Subsidiary is required to withhold federal, state, local, employment, or foreign taxes or other amounts, or, to the extent permitted under Section 409A of the Code, any other applicable taxes, in connection with Grantee’s right to receive Common Shares under this Agreement (regardless of whether Grantee is entitled to the delivery of any Common Shares at that time), and the amounts available to the Company for such withholding are insufficient, it will be a condition to the receipt of any Common Shares or any other benefit provided for under this Agreement that Grantee make arrangements satisfactory to the Company for payment of the balance of such taxes or other amounts required to be withheld. Grantee may satisfy such tax obligation by paying the Company cash via personal check. Alternatively, Grantee may elect that all or any part of such tax obligation be satisfied by the Company’s retention of a portion of the Common Shares provided for under this Agreement or by Grantee’s surrender of a portion of the Common Shares that Grantee has owned. If an election is made to satisfy Grantee’s tax obligation with the release or surrender of Common Shares, the Common Shares used for tax or other withholding will be valued at an amount equal to the fair market value of such Common Shares on the date the benefit is to be included in Grantee’s income. In no event will the fair market value of the Common Shares to be withheld and delivered pursuant to this Section 12 exceed the maximum amount of taxes that could be required to be withheld.
13.Right to Terminate Employment. No provision of this Agreement will limit in any way whatsoever any right that the Company or a Subsidiary may otherwise have to terminate the employment of Grantee at any time.
14.Relation to Other Benefits. Any economic or other benefit to Grantee under this Agreement or the Plan will not be taken into account in determining any benefits to which Grantee may be entitled under any profit-sharing, retirement or other benefit or compensation plan maintained by the Company or a Subsidiary and will not affect the amount of any life insurance coverage available to any beneficiary under any life insurance plan covering employees of the Company or a Subsidiary.
15.Amendments. Any amendment to the Plan will be deemed to be an amendment to this Agreement to the extent that the amendment is applicable to this Agreement; provided, however, that, subject to the terms of the Plan, no amendment will materially impair the rights of Grantee with respect to the PRSUs without Grantee’s consent. Notwithstanding the foregoing, the limitation requiring the consent of Grantee to certain amendments will not apply to any amendment that is deemed necessary by the Company to ensure
compliance with Section 409A of the Code, Section 10D of the Exchange Act, or other applicable law.
16.Severability. In the event that one or more of the provisions of this Agreement is invalidated for any reason by a court of competent jurisdiction, any provision so invalidated will be deemed to be separable from the other provisions of this Agreement, and the remaining provisions of this Agreement will continue to be valid and fully enforceable.
17.Choice of Law. This Agreement is made under, and shall be construed in accordance with, the internal substantive laws of the State of Ohio. Grantee agrees that the state and federal courts located in the State of Ohio shall have jurisdiction in any action, suit or proceeding against Grantee based on or arising out of this Agreement and Grantee hereby: (a) submits to the personal jurisdiction of such courts; (b) consents to service of process in connection with any action, suit or proceeding against Grantee; and (c) waives any other requirement (whether imposed by statute, rule of court or otherwise) with respect to personal jurisdiction, venue or service of process.
18.Compliance with Section 409A of the Code. To the extent applicable, it is intended that this Agreement and the Plan comply with the provisions of Section 409A of the Code, so that the income inclusion provisions of Section 409A(a)(1) of the Code do not apply to Grantee. This Agreement and the Plan shall be administered in a manner consistent with this intent. Reference to Section 409A of the Code is to Section 409A of the Internal Revenue Code of 1986, as amended, and will also include any regulations or any other formal guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service.
[SIGNATURES ON THE FOLLOWING PAGE]
The undersigned Grantee hereby acknowledges receipt of an executed original of this Agreement and accepts the award of PRSUs covered hereby, subject to the terms and conditions of the Plan and the terms and conditions herein above set forth.
/s/ Richard G. Kyle
Grantee
Date: April 22, 2025
This Agreement is executed by the Company on this 22nd day of April, 2025.
The Timken Company
By /s/ Hansal N. Patel
Name: Hansal N. Patel
Title: Executive Vice President, General Counsel and Secretary
EX-10.4
5
exhibit104.htm
EX-10.4
Document
THE TIMKEN COMPANY
Deferred Shares Agreement
THIS DEFERRED SHARES AGREEMENT (this “Agreement”) is made by and between The Timken Company, an Ohio corporation (the “Company”), and the undersigned Grantee pursuant to The Timken Company 2019 Equity and Incentive Compensation Plan, as may be amended or amended and restated from time to time (the “Plan”), effective as of the Date of Grant, which is provided, along with additional grant details, on the secure web portal of the third-party vendor used by the Company for the administration of the Plan (such information is referred to herein as the “Grant Summary”). All terms used in this Agreement with initial capital letters that are defined in the Plan and not otherwise defined herein shall have the meanings assigned to them in the Plan.
1.Grant and Vesting of Awards. Subject to the terms and conditions of the Plan and this Agreement, Grantee has been granted on the Date of Grant the right to receive (a) the number of Common Shares specified in the Grant Summary and (b) dividend equivalents payable in cash on a deferred basis (the “Deferred Cash Dividends”) with respect to the Common Shares covered by this Agreement. Subject to Sections 2 and 3 hereof, Grantee’s right to receive the Common Shares covered by this Agreement and any related Deferred Cash Dividends that are accumulated will become nonforfeitable on the third anniversary of the Date of Grant (the “Vesting Date”), if Grantee remains in the continuous employ of the Company or a Subsidiary from the Date of Grant through the earlier of (a) February 15, 2026, or (b) the two-month anniversary of the date on which both a successor Chief Executive Officer of the Company (“Successor CEO”) is appointed or elected by the Board as a successor to Grantee after the Date of Grant and such Successor CEO commences serving in such role (the earlier of the date specified in (a) or (b), the “Transition Date”). The period that begins on the Date of Grant and ends on the Vesting Date is the “Vesting Period”. For purposes of this Agreement, Grantee’s continuous employment with the Company or a Subsidiary will not be deemed to have been interrupted, and Grantee will not be deemed to have ceased to be an employee of the Company or a Subsidiary, by reason of any transfer of employment among the Company and its Subsidiaries.
2.Alternative Vesting of Awards. Notwithstanding Section 1 of this Agreement, and subject to the payment provisions of Section 5 of this Agreement, Grantee’s right to receive the Common Shares covered by this Agreement and any related Deferred Cash Dividends then accumulated may become nonforfeitable if any of the following circumstances apply:
(a)Death or Permanent Disability: Grantee’s right to receive the Common Shares covered by this Agreement and any related Deferred Cash Dividends then accumulated will immediately become nonforfeitable if Grantee dies or becomes Permanently Disabled (as defined below) while in the employ of the Company or any Subsidiary prior to the Transition Date. If Grantee dies or becomes Permanently Disabled during the period that Grantee is deemed to be in the continuous employ of the Company or a Subsidiary pursuant to Section 2(c), then the Common Shares covered by this Agreement and any related Deferred Cash Dividends then accumulated will immediately become nonforfeitable.
For purposes of this Agreement, “Permanently Disabled” means that Grantee has qualified for long-term disability benefits under a disability plan or program of the Company, or, in the absence of a disability plan or program of the Company, under a government-sponsored disability program and is “disabled” within the meaning of Section 409A(a)(2)(C) of the Code.
(b)Change in Control:
(i)Upon a Change in Control occurring during the Vesting Period (A) while Grantee is an employee of the Company or a Subsidiary on or prior to the Transition Date, or (B) after the Transition Date if Grantee remains in the continuous employ of the Company or a Subsidiary from the Date of Grant through the Transition Date, if any Common Shares covered by this Agreement and any related Deferred Cash Dividends then accumulated remain outstanding and unvested, they will immediately become nonforfeitable (except to the extent that a Replacement Award for such Common Shares and Deferred Cash Dividends is provided to Grantee). If Grantee is deemed to be in the continuous employ of the Company or a Subsidiary pursuant to Section 2(c), then, upon a Change in Control that occurs prior to the Vesting Date, the Common Shares covered by this Agreement and any related Deferred Cash Dividends then accumulated will immediately become nonforfeitable.
(ii)For purposes of this Agreement, a “Replacement Award” shall mean an award (A) of deferred shares, (B) that has a value at least equal to the value of the Common Shares covered by this Agreement and any related Deferred Cash Dividends then accumulated, (C) that relates to publicly traded equity securities of the Company or its successor in the Change in Control (or another entity that is affiliated with the Company or its successor following the Change in Control) (the “Successor”), (D) the tax consequences of which, under the Code, if Grantee is subject to U.S. federal income tax under the Code, are not less favorable to Grantee than the tax consequences of the Common Shares covered by this Agreement and any related Deferred Cash Dividends then accumulated, (E) that becomes nonforfeitable in full upon a termination of Grantee’s employment with the Company or its Successor in the Change in Control (or another entity that is affiliated with the Company or the Successor) for Good Reason by Grantee or without Cause (as defined in Section 2(d)) by the Company or the Successor within a period of two years after the Change in Control, and (F) the other terms and conditions of which are not less favorable to Grantee than the terms and conditions of the Common Shares covered by this Agreement and any Deferred Cash Dividends then accumulated with respect thereto (including the provisions that would apply in the event of a subsequent Change in Control). A Replacement Award may be granted only to the extent it conforms to the requirements of Treasury Regulation 1.409A-3(i)(5)(iv)(B) or otherwise does not result in the Common Shares covered by this Agreement and any Deferred Cash Dividends then accumulated with respect thereto, or the Replacement Award, failing to comply with Section 409A of the Code. Without limiting the generality of the foregoing, the Replacement Award may take the form of a continuation of the Common Shares covered by this Agreement and any related Deferred Cash Dividends then accumulated if the requirements of the preceding sentence are satisfied. The determination of whether the conditions of this Section 2(b)(ii) are satisfied will be made by the Committee, as constituted immediately before the Change in Control, in its sole discretion.
(iii)For purposes of Section 2(b)(ii), “Good Reason” means: a material reduction in the nature or scope of the responsibilities, authorities or duties of Grantee attached to Grantee’s position held immediately prior to the Change in Control, a change of more than 60 miles in the location of Grantee’s principal office immediately prior to the Change in Control, or a material reduction in Grantee’s remuneration upon or after the Change in Control; provided, that no later than 90 days following an event constituting Good Reason Grantee gives notice to the Successor of the occurrence of such event and the Successor fails to cure the event within 30 days following the receipt of such notice.
(iv)If a Replacement Award is provided, (A) the terms of the Replacement Award will govern the vesting and payment of the Replacement Award and (B) notwithstanding anything in this Agreement to the contrary, any outstanding Common Shares covered by this Agreement and any related Deferred Cash Dividends then accumulated which at the time of the Change in Control are not subject to a “substantial risk of forfeiture” (within the meaning of Section 409A of the Code) will be deemed to be nonforfeitable at the time of such Change in Control.
(c)Divestiture: If Grantee’s employment with the Company or a Subsidiary terminates prior to the Transition Date as the result of a Divestiture (as defined below), then the Common Shares covered by this Agreement and any related Deferred Cash Dividends then accumulated will become nonforfeitable in accordance with the vesting schedule set forth in Section 1 as if Grantee had remained in the continuous employ of the Company or a Subsidiary from the Date of Grant through the Vesting Date or the occurrence of a circumstance referenced in Section 2(a) or 2(b), whichever occurs first. For the purposes of this Agreement, the term “Divestiture” means a permanent disposition to a Person other than the Company or any Subsidiary of a plant or other facility or property at which Grantee performs a majority of Grantee’s services whether such disposition is effected by means of a sale of assets, a sale of Subsidiary stock or otherwise.
(d)Termination Without Cause: Subject to Section 5(c) hereof, if Grantee’s employment with the Company or a Subsidiary is terminated by the Company or a Subsidiary other than for Cause (a “Termination Without Cause”) prior to the Transition Date, then Grantee’s right to receive the Common Shares covered by this Agreement will become nonforfeitable in a prorated amount determined by multiplying such total Common Shares by a fraction (in no case greater than 1), the numerator of which is the number of whole months from the Date of Grant through the date of Termination Without Cause and the denominator of which is the number of whole months from the Date of Grant through February 15, 2026.
For purposes of this Agreement, “Cause” means: (i) an intentional act of fraud, embezzlement or theft in connection with Grantee’s duties with the Company or a Subsidiary (or the Successor, if applicable); (ii) an intentional wrongful disclosure of secret processes or confidential information of the Company or a Subsidiary (or the Successor, if applicable); (iii) an intentional, wrongful engagement in any competitive activity that would constitute a material breach of Grantee’s duty of loyalty to the Company or a Subsidiary (or the Successor, if applicable); (iv) the willful misconduct in the performance of Grantee’s duties to the Company or a Subsidiary (or the Successor, if applicable); or (v) gross negligence in the performance of Grantee’s duties to the company or a Subsidiary (or the Successor, if applicable).
No act, or failure to act, on the part of Grantee shall be deemed “intentional” unless done or omitted to be done by Grantee not in good faith and without reasonable belief that Grantee’s action or omission was in or not opposed to the best interest of the Company or a Subsidiary (or the Successor, if applicable); provided that for any Grantee who is party to an individual severance or employment agreement defining Cause, “Cause” will have the meaning set forth in such agreement.
3.Forfeiture of Awards. Grantee’s right to receive the Common Shares covered by this Agreement and any related Deferred Cash Dividends then accumulated will be forfeited automatically and without further notice on the date that Grantee ceases to be an employee of the Company or a Subsidiary for any reason other than as described in Section 1 or 2 hereof prior to the Transition Date. In the event that Grantee intentionally commits an act that the Committee determines to be materially adverse to the interests of the Company or a Subsidiary, Grantee’s right to receive the Common Shares covered by this Agreement and any related Deferred Cash Dividends then accumulated will be forfeited at the time of that determination notwithstanding any other provision of this Agreement to the contrary.
4.Crediting of Deferred Cash Dividends. With respect to each of the Common Shares covered by this Agreement, Grantee will be credited on the records of the Company with Deferred Cash Dividends in an amount equal to the amount per share of any cash dividends declared by the Board on the outstanding Common Shares during the period beginning on the Date of Grant and ending on the date on which Grantee receives payment of the Common Shares covered by this Agreement pursuant to Section 5 hereof or at the time when the Common Shares covered by this Agreement are forfeited in accordance with Section 3 of this Agreement. The Deferred Cash Dividends will accumulate without interest.
5.Payment of Awards.
(a)General: Subject to Sections 3 and 5(b), payment for the Common Shares covered by this Agreement that are nonforfeitable will be paid in Common Shares, and any such Common Shares and any related Deferred Cash Dividends then accumulated will be made within 60 days following the Vesting Date.
(b)Other Payment Events: Notwithstanding Section 5(a), to the extent that the Common Shares covered by this Agreement are nonforfeitable on the dates set forth below, payment with respect to the Common Shares covered by this Agreement that have become nonforfeitable and any related Deferred Cash Dividends then accumulated will be made as follows:
(i)Change in Control. Within 10 days of a Change in Control, Grantee is entitled to receive payment for the Common Shares covered by this Agreement that are nonforfeitable and any related Deferred Cash Dividends then accumulated on the date of the Change in Control; provided, however, that if such Change in Control would not qualify as a permissible date of distribution under Section 409A(a)(2)(A) of the Code, and the regulations thereunder, and where Section 409A of the Code applies to such distribution, Grantee is entitled to receive the corresponding payment on the date that would have otherwise applied pursuant to Sections 5(a) or 5(b)(ii) as though such Change in Control had not occurred.
(ii)Death or Permanent Disability. Within 30 days of the date of Grantee’s death or the date Grantee becomes Permanently Disabled, Grantee is entitled to receive payment for the Common Shares covered by this Agreement that are nonforfeitable and any related Deferred Cash Dividends then accumulated on such date.
(c)Release Requirement: Notwithstanding any provision of this Agreement to the contrary, the Common Shares covered by this Agreement and any Deferred Cash Dividends accumulated with respect thereto will not become nonforfeitable or payable pursuant to Section 2(d) of this Agreement as a result of a Termination Without Cause or pursuant to Section 2(b)(ii)(E) of this Agreement as a result of a termination of employment for Good Reason by Grantee or without Cause by the Company or the Successor unless, to the extent permitted by applicable law, Grantee signs, does not revoke, and agrees to be bound by a general release of claims in a form provided by the Company or the Successor, which release must be signed, and any applicable revocation period shall have expired within 30 or 60 days (as specified by the Company or the Successor at the time such release is provided) of Grantee’s termination of employment (such 30 day or 60 day period, as applicable, the “Review Period”). In the event such Review Period begins in one taxable year of Grantee, and ends in a second taxable year of Grantee, then to the extent necessary to avoid any penalties or additional taxes under Section 409A of the Code, no payment shall be made before the second taxable year.
6.Compliance with Law. The Company shall make reasonable efforts to comply with all applicable federal and state securities laws; provided, however, notwithstanding any other provision of this Agreement, the Company shall not be obligated to issue any of the Common Shares covered by this Agreement or pay any Deferred Cash Dividends accumulated with respect thereto if the issuance or payment thereof would result in violation of any such law. To the extent that the Ohio Securities Act shall be applicable to this Agreement, the Company shall not be obligated to issue any of the Common Shares or other securities covered by this Agreement or pay any Deferred Cash Dividends accumulated with respect thereto unless such Common Shares and Deferred Cash Dividends are (a) exempt from registration thereunder, (b) the subject of a transaction that is exempt from compliance therewith, (c) registered by description or qualification thereunder or (d) the subject of a transaction that shall have been registered by description thereunder.
7.Transferability. Neither Grantee’s right to receive the Common Shares covered by this Agreement nor Grantee’s right to receive any Deferred Cash Dividends shall be transferable by Grantee except by will or the laws of descent and distribution. Any purported transfer in violation of this Section 7 shall be null and void, and the purported transferee shall obtain no rights with respect to such Shares.
8.Compliance with Section 409A of the Code. To the extent applicable, it is intended that this Agreement and the Plan comply with the provisions of Section 409A of the Code.
This Agreement and the Plan shall be administered in a manner consistent with this intent.
9.Adjustments. Subject to Section 12 of the Plan, the Committee shall make any adjustments in the number or kind of shares of stock or other securities covered by this Agreement, and other terms and provisions, that the Committee shall determine is equitably required to prevent any dilution or expansion of Grantee’s rights under this Agreement that otherwise would result from any (a) extraordinary cash dividend, stock dividend, stock split, combination of shares, recapitalization or other change in the capital structure of the Company, (b) merger, consolidation, separation, reorganization, partial or complete liquidation or other distribution of assets involving the Company or (c) other transaction or event having an effect similar to any of those referred to in subsection (a) or (b) herein. Moreover, in the event that any transaction or event described or referred to in the immediately preceding sentence, or a Change in Control, shall occur, the Committee shall provide in substitution of any or all of Grantee’s rights under this Agreement such alternative consideration (including cash), if any, as the Committee shall determine in good faith to be equitable under the circumstances.
10.Withholding Taxes. To the extent that the Company or a Subsidiary is required to withhold federal, state, local or foreign taxes or other amounts in connection with any delivery of Common Shares to Grantee, and the amounts available to the Company for such withholding are insufficient, it will be a condition to the receipt of such delivery of Common Shares or any other benefit provided for under this Agreement that Grantee make arrangements satisfactory to the Company for payment of the balance of such taxes or other amounts required to be withheld. To the extent permitted by applicable law, Grantee may elect that all or any part of such withholding requirement be satisfied by retention by the Company of a portion of the Common Shares delivered to Grantee. Any Common Shares so withheld shall be credited against such withholding requirements at the fair market value of such shares on the date of such withholding. Grantee may also satisfy such tax obligation by paying the Company cash via personal check or having such amounts deducted from payroll, to the extent permitted by applicable law.
11.Clawback; Detrimental Activity and Recapture.
(a)Notwithstanding anything in this Agreement to the contrary, Grantee acknowledges and agrees that this Agreement and the award described herein (and any settlement thereof) are subject to the terms and conditions of the Company’s clawback policy or policies (if any) as may be in effect from time to time, including specifically to implement Section 10D of the Exchange Act and any applicable rules or regulations promulgated thereunder (including applicable rules and regulations of any national securities exchange on which the Common Shares at any point may be traded) (the “Compensation Recovery Policy”), and that applicable terms of this Agreement shall be deemed superseded by and subject to the terms and conditions of the Compensation Recovery Policy from and after the effective date thereof. By accepting this award under the Plan and pursuant to this Agreement, Grantee consents to be bound by the terms of the Compensation Recovery Policy, to the extent applicable to Grantee, and agrees and acknowledges to fully cooperate with and assist the Company in connection with any of Grantee’s obligations to the Company pursuant to the Compensation Recovery Policy, and agrees that the Company may enforce its rights under the Compensation Recovery Policy through any and all reasonable means permitted under applicable law as it deems necessary or desirable under the Compensation Recovery Policy, in each case from and after the effective dates thereof. Such cooperation and assistance shall include, but is not limited to, executing, completing and submitting any documentation necessary to facilitate the recovery or recoupment by the Company from Grantee of any such amounts, including from Grantee’s accounts or from any other compensation, to the extent permissible under Section 409A of the Code.
(b)Nothing in this Agreement or otherwise (i) limits Grantee’s right to any monetary award offered by a government-administered whistleblower award program for providing information directly to a government agency (including the Securities and Exchange Commission pursuant to Section 21F of the Exchange Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or The Sarbanes-Oxley Act of 2002, or any comparable government agency pursuant to any comparable legislation in non-U.S. jurisdictions) or (ii) prevents Grantee from providing, without prior notice to the Company, information to governmental authorities regarding possible legal violations or otherwise testifying or participating in any investigation or proceeding by any governmental authorities regarding possible legal violations, and for purpose of clarity Grantee is not prohibited from providing information voluntarily to the Securities and Exchange Commission pursuant to Section 21F of the Exchange Act or to any comparable government agencies pursuant to applicable legislation in non-U.S. jurisdictions).
12.No Right to Future Awards or Employment. This award is a voluntary, discretionary bonus being made on a one-time basis and it does not constitute a commitment to make any future awards. This award and any payments made hereunder will not be considered salary or other compensation for purposes of any severance pay or similar allowance, except as otherwise required by law. No provision of this Agreement shall limit in any way whatsoever any right that the Company or a Subsidiary may otherwise have to terminate Grantee’s employment at any time.
13.Relation to Other Benefits. Any economic or other benefit to Grantee under this Agreement or the Plan shall not be taken into account in determining any benefits to which Grantee may be entitled under any profit-sharing, retirement or other benefit or compensation plan maintained by the Company or a Subsidiary and shall not affect the amount of any life insurance coverage available to any beneficiary under any life insurance plan covering employees of the Company or a Subsidiary.
14.Processing of Information. Information about Grantee and Grantee’s award of Common Shares and Deferred Cash Dividends may be collected, recorded and held, used and disclosed for any purpose related to the administration of the award. Grantee understands that such processing of this information may need to be carried out by the Company and its Subsidiaries and by third party administrators whether such persons are located within Grantee’s country or elsewhere, including the United States of America. Grantee consents to the processing of information relating to Grantee and Grantee’s receipt of the Common Shares and Deferred Cash Dividends in any one or more of the ways referred to above.
15.Amendments. Any amendment to the Plan shall be deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto; provided, however, that subject to the terms of the Plan and the provisions of Section 8 hereof, no amendment shall materially impair the rights of Grantee with respect to either the Common Shares or other securities covered by this Agreement or the Deferred Cash Dividends without Grantee’s consent. Notwithstanding the foregoing, the limitation requiring the consent of Grantee to certain amendments will not apply to any amendment that is deemed necessary by the Company to ensure compliance with Section 409A of the Code, Section 10D of the Exchange Act, or other applicable law.
16.Severability. If any provision of this Agreement or the application of any provision hereof to any person or circumstances is held invalid or unenforceable, the remainder of this Agreement and the application of such provision in any other person or circumstances shall not be affected, and the provisions so held to be invalid or unenforceable shall be reformed to the extent (and only to the extent) necessary to make it enforceable and valid.
17.Choice of Law. This Agreement is made under, and shall be construed in accordance with, the internal substantive laws of the State of Ohio. Grantee agrees that the state and federal courts located in the State of Ohio shall have jurisdiction in any action, suit or proceeding against Grantee based on or arising out of this Agreement and Grantee hereby: (a) submits to the personal jurisdiction of such courts; (b) consents to service of process in connection with any action, suit or proceeding against Grantee; and (c) waives any other requirement (whether imposed by statute, rule of court or otherwise) with respect to personal jurisdiction, venue or service of process.
[Signatures on the Following Page]
This Agreement is executed by the Company on this 22nd day of April, 2025.
The Timken Company
By: /s/ Hansal N. Patel
Name: Hansal N. Patel
Title: Executive Vice President, General Counsel and Secretary
The undersigned Grantee hereby acknowledges receipt of an executed original of this Agreement and accepts the right to receive the Common Shares or other securities covered hereby and any Deferred Cash Dividends accumulated with respect thereto, subject to the terms and conditions of the Plan and the terms and conditions herein above set forth.
/s/ Richard G. Kyle
Richard G. Kyle
Date: April 22, 2025
EX-31.1
6
tkr3312025exhibit311.htm
EX-31.1
Document
Exhibit 31.1
Principal Executive Officer’s Certifications
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Richard G. Kyle, certify that:
1. I have reviewed this quarterly report on Form 10-Q of The Timken Company;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting: and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 30, 2025
|
|
|
|
|
|
| By: /s/ Richard G. Kyle |
|
Richard G. Kyle President and Chief Executive Officer (Principal Executive Officer) |
|
EX-31.2
7
tkr3312025exhibit312.htm
EX-31.2
Document
Exhibit 31.2
Principal Financial Officer’s Certifications
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Philip D. Fracassa, certify that:
1.I have reviewed this quarterly report on Form 10-Q of The Timken Company;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting: and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 30, 2025
|
|
|
|
|
|
| By: /s/ Philip D. Fracassa |
|
Philip D. Fracassa Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
|
EX-32
8
tkr3312025exhibit32.htm
EX-32
Document
Exhibit 32
Certification Pursuant to
18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the quarterly report of The Timken Company (the “Company”) on Form 10-Q for the period ended March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002, that, to such officer’s knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.
Date: April 30, 2025
|
|
|
|
|
|
| By: /s/ Richard G. Kyle |
|
Richard G. Kyle President and Chief Executive Officer (Principal Executive Officer) |
|
|
|
|
|
|
|
| By: /s/ Philip D. Fracassa |
|
Philip D. Fracassa Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
|
The foregoing certification is being furnished solely pursuant to 18 U.S.C. 1350 and is not being filed as part of the Report or as a separate disclosure document.